{"keywords":[],"symbol":"NCPH","medgen_id":"C4310735","xrefs":["{\"db\":\"OMIM\",\"id\":\"617068\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"494348\"}","{\"db\":\"OMIM\",\"id\":\"617068\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Portal hypertension, noncirrhotic","id":"35831","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"HELIX","medgen_id":"C4522164","xrefs":["{\"db\":\"OMIM\",\"id\":\"617671\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"528105\"}","{\"db\":\"OMIM\",\"id\":\"617671\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOHIDROSIS, ELECTROLYTE IMBALANCE, LACRIMAL GLAND DYSFUNCTION, ICHTHYOSIS, AND XEROSTOMIA\"}","{\"db\":\"OMIM\",\"id\":\"617579.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617579.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617579.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617671\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617671\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"HELIX SYNDROME","id":"38111","alternate_symbols":[],"alternate_names":["HYPOHIDROSIS, ELECTROLYTE IMBALANCE, LACRIMAL GLAND DYSFUNCTION, ICHTHYOSIS, AND XEROSTOMIA"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C4707885","xrefs":["{\"db\":\"Orphanet\",\"id\":\"269218\"}"],"name":"Isolated unilateral hemispheric cerebellar hypoplasia","id":"41777","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Finding"}
{"keywords":[],"symbol":"EIEE39","medgen_id":"C2751855","xrefs":["{\"db\":\"OMIM\",\"id\":\"612949\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"603667.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 39\"}","{\"db\":\"OMIM\",\"id\":\"603667.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 39\"}","{\"db\":\"OMIM\",\"id\":\"612949\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 39\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypomyelination%2C+global+cerebral/8618\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612949\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hypomyelination, global cerebral","id":"6770","alternate_symbols":[],"alternate_names":["EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 39"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0017658","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000099\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000099\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Glomerular nephritis\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000099\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6516\",\"ref_field\":\"name\"}"],"name":"Glomerulonephritis","id":"21419","alternate_symbols":[],"alternate_names":["Glomerular nephritis"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"POPCHAS","medgen_id":"CN258436","xrefs":["{\"db\":\"OMIM\",\"id\":\"618428\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618428\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURODEVELOPMENTAL DISORDER WITH IMPAIRED SPEECH AND DYSMORPHIC FACIAL FEATURES\"}","{\"db\":\"OMIM\",\"id\":\"618428\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NEDISDF\"}","{\"db\":\"OMIM\",\"id\":\"601288.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601288.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601288.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601288.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601288.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618428\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618428\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"POPOV-CHANG SYNDROME","id":"41657","alternate_symbols":["NEDISDF"],"alternate_names":["NEURODEVELOPMENTAL DISORDER WITH IMPAIRED SPEECH AND DYSMORPHIC FACIAL FEATURES"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"RIDL","medgen_id":"C2677792","xrefs":["{\"db\":\"OMIM\",\"id\":\"611943\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"420741\"}","{\"db\":\"OMIM\",\"id\":\"611943\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RADIOSENSITIVITY, IMMUNODEFICIENCY, DYSMORPHIC FACIAL FEATURES, AND LEARNING DIFFICULTIES\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Riddle+syndrome/9256\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611943\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Riddle syndrome","id":"3627","alternate_symbols":[],"alternate_names":["RADIOSENSITIVITY, IMMUNODEFICIENCY, DYSMORPHIC FACIAL FEATURES, AND LEARNING DIFFICULTIES"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0206754","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100634\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"877\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100634\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neuroendocrine neoplasia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100634\",\"ref_field\":\"name\"}","{\"db\":\"MeSH\",\"id\":\"D018358\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"128928004\",\"ref_field\":\"name\"}"],"name":"Neuroendocrine neoplasm","id":"32118","alternate_symbols":[],"alternate_names":["Neuroendocrine neoplasia"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C4082169","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001768\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001840\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010217\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001840\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Forefoot varus\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001840\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Intoe\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001840\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Metatarsus adductovarsus\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001840\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Metatarsus varus\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001840\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3570\",\"ref_field\":\"name\"}"],"name":"Metatarsus adductus","id":"22644","alternate_symbols":[],"alternate_names":["Forefoot varus","Intoe","Metatarsus adductovarsus","Metatarsus varus"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0018425","xrefs":["{\"db\":\"Orphanet\",\"id\":\"414\"}"],"name":"Gyrate atrophy","id":"38426","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"PEBAS","medgen_id":"C4540059","xrefs":["{\"db\":\"OMIM\",\"id\":\"617669\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"500144\"}","{\"db\":\"OMIM\",\"id\":\"614139.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614139.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614139.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617669\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617669\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"ENCEPHALOPATHY, PROGRESSIVE, EARLY-ONSET, WITH BRAIN ATROPHY AND SPASTICITY","id":"38116","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"VRJS","medgen_id":"C3810023","xrefs":["{\"db\":\"OMIM\",\"id\":\"615583\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"508488\"}","{\"db\":\"Orphanet\",\"id\":\"508498\"}","{\"db\":\"OMIM\",\"id\":\"615583\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHROMOSOME 8q24.3 DELETION SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"615583\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Verheij syndrome","id":"18497","alternate_symbols":[],"alternate_names":["CHROMOSOME 8q24.3 DELETION SYNDROME"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"CN166718","xrefs":["{\"db\":\"Orphanet\",\"id\":\"536391\"}","{\"db\":\"GenomeConnect, ClinGen\",\"id\":\"genomeconnect_15815_622\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Noonan spectrum disorder\"}"],"name":"Rasopathy","id":"17678","alternate_symbols":[],"alternate_names":["Noonan spectrum disorder","rasopathies"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0344963","xrefs":["{\"db\":\"Orphanet\",\"id\":\"98723\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2922\",\"ref_field\":\"name\"}","{\"db\":\"Orphanet\",\"id\":\"98723\",\"ref_field\":\"name\"}"],"name":"Hypoplastic right heart syndrome","id":"38086","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0344622","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011555\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"1464\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011555\",\"ref_field\":\"name\"}"],"name":"Double inlet left ventricle","id":"29453","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Finding"}
{"keywords":[],"medgen_id":"C4014767","xrefs":["{\"db\":\"OMIM\",\"id\":\"615947\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"444490\"}","{\"db\":\"Orphanet\",\"id\":\"535458\"}"],"name":"Hyperlipoproteinemia, type ID","id":"21329","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C3695272","xrefs":["{\"db\":\"Orphanet\",\"id\":\"370097\"}"],"name":"Albinism, oculocutaneous, type VI","id":"18203","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"MRD29","medgen_id":"C4015141","xrefs":["{\"db\":\"OMIM\",\"id\":\"616078\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"436151\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"setbp1-disorder\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"setbp1-disorder\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616078\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Mental retardation, autosomal dominant 29","id":"32123","public_definition":"SETBP1 disorder is a condition that involves speech and language problems, intellectual disability, and distinctive facial features.In people with SETBP1 disorder, problems with expressive language skills (vocabulary and the production of speech) are generally more severely affected than receptive language skills (the ability to understand speech). Speech development is limited to a few words or no speech. Affected individuals often communicate using gestures or by mimicking the expressions of others.Individuals with SETBP1 disorder have intellectual disability that can range from mild to moderate. They may also have behavioral problems, such as attention-deficit/hyperactivity disorder (ADHD) or autistic behaviors that affect communication and social interaction. Affected individuals may have weak muscle tone (hypotonia); delayed development of motor skills, such as sitting, standing, and walking; or recurrent seizures (epilepsy).Distinctive facial features in people with SETBP1 disorder can include a long face, a high forehead, eyebrows that grow together in the middle (synophrys), short eye openings (short palpebral fissures), skin folds covering the inner corner of the eyes (epicanthal folds), droopy eyelids (ptosis), puffiness of the skin around the eyes (periorbital fullness), small nostrils, a high nasal bridge, a broad tip of the nose, a thin upper lip, a high arch in the roof of the mouth (high-arched palate), and a small chin.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease","ghr_links":"SETBP1 disorder"}
{"keywords":[],"symbol":"SMALED2A","medgen_id":"C3809049","xrefs":["{\"db\":\"OMIM\",\"id\":\"615290\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"363447\"}","{\"db\":\"Orphanet\",\"id\":\"363454\"}","{\"db\":\"OMIM\",\"id\":\"609797.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2A, CHILDHOOD ONSET, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"609797.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2A, CHILDHOOD ONSET, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"609797.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2A, CHILDHOOD ONSET, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"609797.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2A, CHILDHOOD ONSET, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"609797.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2A, CHILDHOOD ONSET, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"609797.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2A, CHILDHOOD ONSET, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"615290\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2A, CHILDHOOD ONSET, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"615290\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Spinal muscular atrophy, lower extremity-predominant, 2A, autosomal dominant","id":"17967","alternate_symbols":["SMALED2"],"alternate_names":["SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2A, CHILDHOOD ONSET, AUTOSOMAL DOMINANT"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"KCS2","medgen_id":"C4316787","xrefs":["{\"db\":\"OMIM\",\"id\":\"127000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2333\"}","{\"db\":\"Orphanet\",\"id\":\"93325\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"83\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"127000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"83\",\"ref_field\":\"symbol\"}"],"name":"Kenny-Caffey syndrome type 2","id":"2509","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"WS3","medgen_id":"C0079661","xrefs":["{\"db\":\"OMIM\",\"id\":\"148820\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3440\"}","{\"db\":\"Orphanet\",\"id\":\"896\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Waardenburg+syndrome+type+3/7428\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"237918004\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"148820\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5523\",\"ref_field\":\"symbol\"}"],"name":"Klein-Waardenberg's syndrome","id":"6117","alternate_symbols":["PAX3"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"IMD32B","medgen_id":"C4016741","xrefs":["{\"db\":\"OMIM\",\"id\":\"226990\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"226990\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EPSTEIN-BARR VIRUS, SUSCEPTIBILITY TO CHRONIC INFECTION BY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epstein+Barr+Virus%2C+Chronic/2626\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Epstein Barr virus, chronic\"}","{\"db\":\"OMIM\",\"id\":\"614894\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 32B, MONOCYTE AND DENDRITIC CELL DEFICIENCY, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"226990\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 32B, MONOCYTE, DENDRITIC CELL, AND NATURAL KILLER CELL DEFICIENCY, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"226990\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IRF8 DEFICIENCY, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"614894\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IRF8 DEFICIENCY, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9534\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CEBV\"}","{\"db\":\"OMIM\",\"id\":\"226990\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"OMIM\",\"id\":\"614894\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Immunodeficiency 32b","id":"1248","alternate_symbols":["CEBV"],"alternate_names":["EPSTEIN-BARR VIRUS, SUSCEPTIBILITY TO CHRONIC INFECTION BY","Epstein Barr virus, chronic","IMMUNODEFICIENCY 32B, MONOCYTE AND DENDRITIC CELL DEFICIENCY, AUTOSOMAL RECESSIVE","IMMUNODEFICIENCY 32B, MONOCYTE, DENDRITIC CELL, AND NATURAL KILLER CELL DEFICIENCY, AUTOSOMAL RECESSIVE","IRF8 DEFICIENCY, AUTOSOMAL RECESSIVE"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1332655","xrefs":["{\"db\":\"Orphanet\",\"id\":\"280133\"}"],"name":"C3 deficiency","id":"12748","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"IMD50","medgen_id":"C4310812","xrefs":["{\"db\":\"OMIM\",\"id\":\"300988\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"504530\"}","{\"db\":\"OMIM\",\"id\":\"300988\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 50, X-LINKED RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"300988\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Immunodeficiency 50","id":"36721","alternate_symbols":[],"alternate_names":["IMMUNODEFICIENCY 50, X-LINKED RECESSIVE"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"HLD10","medgen_id":"C4225332","xrefs":["{\"db\":\"OMIM\",\"id\":\"616420\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"481152\"}","{\"db\":\"OMIM\",\"id\":\"616420\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Leukodystrophy, hypomyelinating, 10","id":"33534","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SMDP2","medgen_id":"C1970470","xrefs":["{\"db\":\"OMIM\",\"id\":\"610913\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"217566\"}","{\"db\":\"Orphanet\",\"id\":\"440392\"}","{\"db\":\"OMIM\",\"id\":\"610913\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DESQUAMATIVE INTERSTITIAL PNEUMONITIS DUE TO SURFACTANT PROTEIN C DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"610913\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INTERSTITIAL LUNG DISEASE DUE TO SURFACTANT PROTEIN C DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"610913\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PULMONARY ALVEOLAR PROTEINOSIS, CONGENITAL, 2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Surfactant+metabolism+dysfunction%2C+pulmonary%2C+2/9365\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610913\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Surfactant metabolism dysfunction, pulmonary, 2","id":"4476","alternate_symbols":[],"alternate_names":["DESQUAMATIVE INTERSTITIAL PNEUMONITIS DUE TO SURFACTANT PROTEIN C DEFICIENCY","INTERSTITIAL LUNG DISEASE DUE TO SURFACTANT PROTEIN C DEFICIENCY","PULMONARY ALVEOLAR PROTEINOSIS, CONGENITAL, 2"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"MGRISCE2","medgen_id":"C4748176","xrefs":["{\"db\":\"OMIM\",\"id\":\"618097\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"508512\"}","{\"db\":\"OMIM\",\"id\":\"601243.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601243.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601243.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618097\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618097\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"MICROCEPHALY, GROWTH RESTRICTION, AND INCREASED SISTER CHROMATID EXCHANGE 2","id":"40560","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C3549485","xrefs":["{\"db\":\"OMIM\",\"id\":\"111400\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"607922.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NOR POLYAGGLUTINATION SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"603094.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"P1PK BLOOD GROUP SYSTEM, P(k) PHENOTYPE\"}","{\"db\":\"OMIM\",\"id\":\"603094.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"P1PK BLOOD GROUP SYSTEM, P(k) PHENOTYPE\"}","{\"db\":\"OMIM\",\"id\":\"603094.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"P1PK BLOOD GROUP SYSTEM, P(k) PHENOTYPE\"}","{\"db\":\"OMIM\",\"id\":\"603094.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"P1PK BLOOD GROUP SYSTEM, P(k) PHENOTYPE\"}","{\"db\":\"OMIM\",\"id\":\"607922.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"P1PK BLOOD GROUP SYSTEM, p PHENOTYPE\"}","{\"db\":\"OMIM\",\"id\":\"607922.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"P1PK BLOOD GROUP SYSTEM, p PHENOTYPE\"}","{\"db\":\"OMIM\",\"id\":\"607922.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"P1PK BLOOD GROUP SYSTEM, p PHENOTYPE\"}","{\"db\":\"OMIM\",\"id\":\"607922.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"P1PK BLOOD GROUP SYSTEM, p PHENOTYPE\"}","{\"db\":\"OMIM\",\"id\":\"607922.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"P1PK BLOOD GROUP SYSTEM, p PHENOTYPE\"}","{\"db\":\"OMIM\",\"id\":\"607922.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"P1PK BLOOD GROUP SYSTEM, p PHENOTYPE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"p+phenotype/9063\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"24403008\",\"ref_field\":\"name\"}"],"name":"p phenotype","id":"608","alternate_symbols":[],"alternate_names":["NOR POLYAGGLUTINATION SYNDROME","P1PK BLOOD GROUP SYSTEM, P(k) PHENOTYPE","P1PK BLOOD GROUP SYSTEM, p PHENOTYPE"],"attribute_content":[],"type":"BloodGroup"}
{"keywords":[],"symbol":"3MC1","medgen_id":"C0796059","xrefs":["{\"db\":\"OMIM\",\"id\":\"257920\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2506\"}","{\"db\":\"Orphanet\",\"id\":\"293843\"}","{\"db\":\"OMIM\",\"id\":\"257920\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"600521.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"600521.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"600521.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"600521.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"600521.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Michels+syndrome/4726\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4049\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"257920\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Michels syndrome","id":"5518","alternate_symbols":[],"alternate_names":["3MC SYNDROME 1"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"EOC","medgen_id":"C0677886","xrefs":["{\"db\":\"OMIM\",\"id\":\"171834.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OVARIAN CANCER, EPITHELIAL, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"171834.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OVARIAN CANCER, EPITHELIAL, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"171834.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OVARIAN CANCER, EPITHELIAL, SOMATIC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ovarian+epithelial+cancer/5509\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9362\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9362\",\"ref_field\":\"symbol\"}"],"name":"Ovarian epithelial cancer","id":"6319","alternate_symbols":[],"alternate_names":["OVARIAN CANCER, EPITHELIAL, SOMATIC"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"AYGRP","medgen_id":"C1832812","xrefs":["{\"db\":\"OMIM\",\"id\":\"601088\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"601088\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Ayme-gripp syndrome","id":"4755","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"HLASA","medgen_id":"C4310761","xrefs":["{\"db\":\"OMIM\",\"id\":\"617021\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"528091\"}","{\"db\":\"OMIM\",\"id\":\"617021\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hydrops, lactic acidosis, and sideroblastic anemia","id":"35765","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0266295","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000089\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001968\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004741\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008641\",\"type\":\"secondary\"}","{\"db\":\"Orphanet\",\"id\":\"93101\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000089\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypoplastic kidney\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000089\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypoplastic kidneys\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000089\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Small kidneys\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000089\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Underdeveloped kidneys\"}"],"name":"Renal hypoplasia","id":"17202","alternate_symbols":[],"alternate_names":["Hypoplastic kidney","Hypoplastic kidneys","Small kidneys","Underdeveloped kidneys"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"CFPD","medgen_id":"C1839454","xrefs":["{\"db\":\"OMIM\",\"id\":\"312060\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"312060\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COMPLEMENT FACTOR PROPERDIN DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"300383.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROPERDIN DEFICIENCY, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"300383.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROPERDIN DEFICIENCY, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"300383.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROPERDIN DEFICIENCY, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"312060\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PROPERDIN DEFICIENCY, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"312060\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PFD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9913\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PFD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Properdin+deficiency%2C+X-linked/5993\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9913\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"312060\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Properdin deficiency, X-linked","id":"5804","alternate_symbols":["PFD"],"alternate_names":["COMPLEMENT FACTOR PROPERDIN DEFICIENCY","PROPERDIN DEFICIENCY, TYPE I"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"BAGOS","medgen_id":"C4748715","xrefs":["{\"db\":\"OMIM\",\"id\":\"618218\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"522077\"}","{\"db\":\"OMIM\",\"id\":\"618218\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURODEVELOPMENTAL DISORDER WITH INVOLUNTARY MOVEMENT AND ABNORMAL ELECTROENCEPHALOGRAM\"}","{\"db\":\"OMIM\",\"id\":\"618218\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NEDIMAE\"}","{\"db\":\"OMIM\",\"id\":\"185605.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"185605.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"185605.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"185605.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"185605.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618218\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618218\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"BAKER-GORDON SYNDROME","id":"40872","alternate_symbols":["NEDIMAE"],"alternate_names":["NEURODEVELOPMENTAL DISORDER WITH INVOLUNTARY MOVEMENT AND ABNORMAL ELECTROENCEPHALOGRAM"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0020481","xrefs":["{\"db\":\"OMIM\",\"id\":\"144650\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"530849\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Familial+type+5+hyperlipoproteinemia/8409\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"34349009\",\"ref_field\":\"name\"}"],"name":"Familial type 5 hyperlipoproteinemia","id":"5285","alternate_symbols":[],"alternate_names":["Hyperlipoproteinemia Type V"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0033804","xrefs":["{\"db\":\"Office of Rare Diseases\",\"id\":\"7484\",\"ref_field\":\"name\"}"],"name":"Pseudohermaphroditism","id":"38551","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"MGC1","medgen_id":"C0344530","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000485\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007660\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"249300\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"309300\",\"type\":\"MIM\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000485\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Anterior megalophthalmos\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000485\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Enlarged cornea\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000485\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased corneal diameter\"}","{\"db\":\"OMIM\",\"id\":\"309300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MGCN\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000485\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Macrocornea\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000485\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"268158009\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"309300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Megalocornea","id":"15868","alternate_symbols":[],"alternate_names":["Anterior megalophthalmos","Enlarged cornea","Increased corneal diameter","MGCN","Macrocornea"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"IMD31B","medgen_id":"C3151088","xrefs":["{\"db\":\"OMIM\",\"id\":\"613796\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"600555.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 31B\"}","{\"db\":\"OMIM\",\"id\":\"600555.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 31B\"}","{\"db\":\"OMIM\",\"id\":\"600555.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 31B\"}","{\"db\":\"OMIM\",\"id\":\"600555.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 31B\"}","{\"db\":\"OMIM\",\"id\":\"613796\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 31B\"}","{\"db\":\"OMIM\",\"id\":\"613796\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 31B, MYCOBACTERIAL AND VIRAL INFECTIONS, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"613796\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"STAT1 DEFICIENCY, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mycobacterial+and+viral+infections%2C+susceptibility+to%2C+autosomal+recessive/8934\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613796\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Mycobacterial and viral infections, susceptibility to, autosomal recessive","id":"16112","alternate_symbols":[],"alternate_names":["IMMUNODEFICIENCY 31B","IMMUNODEFICIENCY 31B, MYCOBACTERIAL AND VIRAL INFECTIONS, AUTOSOMAL RECESSIVE","STAT1 DEFICIENCY, AUTOSOMAL RECESSIVE"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C4072867","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000580\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007702\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007821\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007869\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007961\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008010\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000580\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pigmentary retinal deposits\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000580\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Retinal pigment clumping\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000580\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4357\",\"ref_field\":\"name\"}"],"name":"Pigmentary retinopathy","id":"21761","alternate_symbols":[],"alternate_names":["Pigmentary retinal deposits","Rarefaction of retinal pigmentation","Retinal pigment clumping"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"CN236730","xrefs":["{\"db\":\"HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology\",\"id\":\"8:68989641:C:00207\",\"ref_field\":\"name\"}"],"name":"Intellectual disability (severe)","id":"35640","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Finding"}
{"keywords":[],"medgen_id":"C1611706","xrefs":["{\"db\":\"Orphanet\",\"id\":\"289380\"}","{\"db\":\"Illumina Clinical Services Laboratory,Illumina\",\"id\":\"624040\",\"ref_field\":\"name\"}"],"name":"Myosclerosis","id":"36658","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"ABCDS","medgen_id":"C1838099","xrefs":["{\"db\":\"OMIM\",\"id\":\"600501\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"918\"}","{\"db\":\"Genetic Alliance\",\"id\":\"ABCD+Syndrome/61\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"335\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600501\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"ABCD syndrome","id":"168","alternate_symbols":["EDNRB"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"LSS","medgen_id":"C1851100","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010689\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"135750\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2378\"}","{\"db\":\"OMIM\",\"id\":\"135750\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FIBULA AND ULNA, DUPLICATION OF, WITH ABSENCE OF TIBIA AND RADIUS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Laurin-Sandrow+syndrome/4123\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Laurin-Sandrow syndrome\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010689\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mirror image duplication of digits\"}","{\"db\":\"OMIM\",\"id\":\"135750\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MIP\"}","{\"db\":\"OMIM\",\"id\":\"135750\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TMIP\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010689\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"135750\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Mirror image polydactyly","id":"2669","alternate_symbols":["MIP","TMIP"],"alternate_names":["FIBULA AND ULNA, DUPLICATION OF, WITH ABSENCE OF TIBIA AND RADIUS","Laurin-Sandrow syndrome","Mirror image duplication of digits"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0041915","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012618\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"488\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012618\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5425\",\"ref_field\":\"name\"}"],"name":"Urachal cyst","id":"30498","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C4016403","xrefs":["{\"db\":\"Genetics Home Reference\",\"id\":\"bladder-cancer\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"bladder-cancer\",\"ref_field\":\"public_definition\"}"],"name":"Bladder cancer, transitional cell, somatic","id":"11029","public_definition":"Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply without control or order. The bladder is a hollow, muscular organ in the lower abdomen that stores urine until it is ready to be excreted from the body. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (TCC).Bladder cancer may cause blood in the urine, pain during urination, frequent urination, or the feeling that one needs to urinate without results. These signs and symptoms are not specific to bladder cancer, however. They also can be caused by noncancerous conditions such as infections.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease","ghr_links":"bladder cancer"}
{"keywords":[],"symbol":"SDDHD","medgen_id":"C4310751","xrefs":["{\"db\":\"OMIM\",\"id\":\"617044\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"488618\"}","{\"db\":\"OMIM\",\"id\":\"617044\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Short stature, developmental delay, and congenital heart defects","id":"35764","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"RAI","medgen_id":"C0175707","xrefs":["{\"db\":\"OMIM\",\"id\":\"208530\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"97548\"}","{\"db\":\"OMIM\",\"id\":\"208530\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RIGHT ISOMERISM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6795\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"17604001\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"208530\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Bilateral right-sidedness sequence","id":"553","alternate_symbols":[],"alternate_names":["RIGHT ISOMERISM"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0011644","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001594\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007426\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100324\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"801\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100324\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Progressive systemic scleroderma\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100324\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pseudoscleroderma\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100324\",\"ref_field\":\"name\"}"],"name":"Scleroderma","id":"31111","alternate_symbols":[],"alternate_names":["Progressive systemic scleroderma","Pseudoscleroderma"],"attribute_content":[],"type":"Finding"}
{"keywords":[],"symbol":"CRPT1","medgen_id":"C1275078","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS201000\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"65759\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"carpenter-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"PS201000 \",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"carpenter-syndrome\",\"ref_field\":\"public_definition\"}"],"name":"Carpenter syndrome","id":"33105","public_definition":"Carpenter syndrome is a condition characterized by the premature fusion of certain skull bones (craniosynostosis), abnormalities of the fingers and toes, and other developmental problems.Craniosynostosis prevents the skull from growing normally, frequently giving the head a pointed appearance (acrocephaly). In severely affected individuals, the abnormal fusion of the skull bones results in a deformity called a cloverleaf skull. Craniosynostosis can cause differences between the two sides of the head and face (craniofacial asymmetry). Early fusion of the skull bones can affect the development of the brain and lead to increased pressure within the skull (intracranial pressure). Premature fusion of the skull bones can cause several characteristic facial features in people with Carpenter syndrome. Distinctive facial features may include a flat nasal bridge, outside corners of the eyes that point downward (down-slanting palpebral fissures), low-set and abnormally shaped ears, underdeveloped upper and lower jaws, and abnormal eye shape. Some affected individuals also have dental abnormalities including small primary (baby) teeth. Vision problems also frequently occur.Abnormalities of the fingers and toes include fusion of the skin between two or more fingers or toes (cutaneous syndactyly), unusually short fingers or toes (brachydactyly), or extra fingers or toes (polydactyly). In Carpenter syndrome, cutaneous syndactyly is most common between the third (middle) and fourth (ring) fingers, and polydactyly frequently occurs next to the big or second toe or the fifth (pinky) finger.People with Carpenter syndrome often have intellectual disability, which can range from mild to profound. However, some individuals with this condition have normal intelligence. The cause of intellectual disability is unknown, as the severity of craniosynostosis does not appear to be related to the severity of intellectual disability.Other features of Carpenter syndrome include obesity that begins in childhood, a soft out-pouching around the belly-button (umbilical hernia), hearing loss, and heart defects. Additional skeletal abnormalities such as deformed hips, a rounded upper back that also curves to the side (kyphoscoliosis), and knees that are angled inward (genu valgum) frequently occur. Nearly all affected males have genital abnormalities, most frequently undescended testes (cryptorchidism).A few people with Carpenter syndrome have organs or tissues within their chest and abdomen that are in mirror-image reversed positions. This abnormal placement may affect several internal organs (situs inversus); just the heart (dextrocardia), placing the heart on the right side of the body instead of on the left; or only the major (great) arteries of the heart, altering blood flow.The signs and symptoms of this disorder vary considerably, even within the same family. The life expectancy for individuals with Carpenter syndrome is shortened but extremely variable.The signs and symptoms of Carpenter syndrome are similar to another genetic condition called Greig cephalopolysyndactyly syndrome. The overlapping features, which include craniosynostosis, polydactyly, and heart abnormalities, can cause these two conditions to be misdiagnosed; genetic testing is often required for an accurate diagnosis.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1867968","xrefs":["{\"db\":\"OMIM\",\"id\":\"176090\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101330\"}","{\"db\":\"OMIM\",\"id\":\"176090\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PCT, ''SPORADIC'' TYPE\"}","{\"db\":\"OMIM\",\"id\":\"176090\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PCT, TYPE I\"}"],"name":"Porphyria cutanea tarda, type I","id":"4010","alternate_symbols":[],"alternate_names":["PCT, ''SPORADIC'' TYPE","PCT, TYPE I"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C2678480","xrefs":["{\"db\":\"OMIM\",\"id\":\"611867\",\"type\":\"MIM\"}"],"name":"Chromosome 22q11.2 deletion syndrome, distal","id":"811","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SPENCDI","medgen_id":"C1842763","xrefs":["{\"db\":\"OMIM\",\"id\":\"607944\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"50816\"}","{\"db\":\"OMIM\",\"id\":\"607944\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COMBINED IMMUNODEFICIENCY WITH AUTOIMMUNITY AND SPONDYLOMETAPHYSEAL DYSPLASIA\"}","{\"db\":\"OMIM\",\"id\":\"607944\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ROIFMAN IMMUNOSKELETAL SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"171640.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPONDYLOENCHONDRODYSPLASIA WITH OR WITHOUT IMMUNE DYSREGULATION\"}","{\"db\":\"OMIM\",\"id\":\"171640.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPONDYLOENCHONDRODYSPLASIA WITH OR WITHOUT IMMUNE DYSREGULATION\"}","{\"db\":\"OMIM\",\"id\":\"171640.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPONDYLOENCHONDRODYSPLASIA WITH OR WITHOUT IMMUNE DYSREGULATION\"}","{\"db\":\"OMIM\",\"id\":\"607944\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SPENCD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spondyloenchondrodysplasia+with+immune+dysregulation/9349\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607944\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Spondyloenchondrodysplasia with immune dysregulation","id":"4827","alternate_symbols":["SPENCD"],"alternate_names":["COMBINED IMMUNODEFICIENCY WITH AUTOIMMUNITY AND SPONDYLOMETAPHYSEAL DYSPLASIA","ROIFMAN IMMUNOSKELETAL SYNDROME","SPONDYLOENCHONDRODYSPLASIA WITH OR WITHOUT IMMUNE DYSREGULATION"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SSMS","medgen_id":"C4225248","xrefs":["{\"db\":\"OMIM\",\"id\":\"616682\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"466926\"}","{\"db\":\"OMIM\",\"id\":\"616682\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SEIZURES, SCOLIOSIS, AND MACROCEPHALY/MICROCEPHALY SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"616682\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Seizures, scoliosis, and macrocephaly syndrome","id":"34489","alternate_symbols":[],"alternate_names":["SEIZURES, SCOLIOSIS, AND MACROCEPHALY/MICROCEPHALY SYNDROME"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"3MC2","medgen_id":"C0796279","xrefs":["{\"db\":\"OMIM\",\"id\":\"265050\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"293843\"}","{\"db\":\"Orphanet\",\"id\":\"2998\"}","{\"db\":\"OMIM\",\"id\":\"265050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 2\"}","{\"db\":\"OMIM\",\"id\":\"612502.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 2\"}","{\"db\":\"OMIM\",\"id\":\"612502.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 2\"}","{\"db\":\"OMIM\",\"id\":\"612502.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 2\"}","{\"db\":\"OMIM\",\"id\":\"612502.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 2\"}","{\"db\":\"OMIM\",\"id\":\"612502.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 2\"}","{\"db\":\"OMIM\",\"id\":\"612502.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Carnevale+Syndrome/1105\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1118\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"265050\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Carnevale syndrome","id":"724","alternate_symbols":[],"alternate_names":["3MC SYNDROME 2"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"EBMD","medgen_id":"C0521723","xrefs":["{\"db\":\"OMIM\",\"id\":\"121820\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"121820\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CORNEAL DYSTROPHY, MAP-DOT-FINGERPRINT TYPE\"}","{\"db\":\"OMIM\",\"id\":\"121820\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CORNEAL DYSTROPHY, MICROCYSTIC\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9732\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MDFD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Corneal+epithelial+dystrophy/8089\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"373426005\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"121820\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Corneal epithelial dystrophy","id":"1562","alternate_symbols":["MDFD"],"alternate_names":["CORNEAL DYSTROPHY, MAP-DOT-FINGERPRINT TYPE","CORNEAL DYSTROPHY, MICROCYSTIC"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0344490","xrefs":["{\"db\":\"Developmental Genetics Unit,King Faisal Specialist Hospital \u0026 Research Centre\",\"id\":\"12DG0975\",\"ref_field\":\"name\"}"],"name":"Sacral agenesis","id":"32923","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"JLSM","medgen_id":"C4540020","xrefs":["{\"db\":\"OMIM\",\"id\":\"617662\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"527450\"}","{\"db\":\"OMIM\",\"id\":\"613842.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613842.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617662\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617662\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"JOINT LAXITY, SHORT STATURE, AND MYOPIA","id":"38090","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C4693948","xrefs":["{\"db\":\"OMIM\",\"id\":\"618018\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"529828\"}","{\"db\":\"OMIM\",\"id\":\"601129.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618018\",\"type\":\"MIM\",\"ref_field\":\"name\"}"],"name":"DRUG METABOLISM, ALTERED, CYP2C8-RELATED","id":"40112","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C4274391","xrefs":["{\"db\":\"Orphanet\",\"id\":\"231226\"}"],"name":"Beta-thalassemia dominant","id":"12075","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"IOLOD","medgen_id":"C4310792","xrefs":["{\"db\":\"OMIM\",\"id\":\"616921\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"494526\"}","{\"db\":\"OMIM\",\"id\":\"616921\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Dyskinesia, limb and orofacial, infantile-onset","id":"35316","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0029454","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011002\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"2781\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011002\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Albers-Schonberg disease\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011002\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Marble bone disease\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011002\",\"ref_field\":\"name\"}"],"name":"Osteopetrosis","id":"28913","alternate_symbols":[],"alternate_names":["Albers-Schonberg disease","Marble bone disease"],"attribute_content":[],"type":"Finding"}
{"keywords":[],"medgen_id":"C0023787","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009125\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009125\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6909\",\"ref_field\":\"name\"}"],"name":"Lipodystrophy","id":"27161","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"LQT1/2, DIGENIC","medgen_id":"C3150944","xrefs":["{\"db\":\"OMIM\",\"id\":\"192500\",\"ref_field\":\"symbol\"}"],"name":"Long QT syndrome 1/2, digenic","id":"8576","alternate_symbols":[],"alternate_names":["Long QT syndrome 1/2"],"attribute_content":[],"type":"Disease"}
{"keywords":["Neoplasm"],"symbol":"GSD1C","medgen_id":"C0342749","xrefs":["{\"db\":\"OMIM\",\"id\":\"232240\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"364\"}","{\"db\":\"Orphanet\",\"id\":\"79259\"}","{\"db\":\"Orphanet\",\"id\":\"79260\"}","{\"db\":\"OMIM\",\"id\":\"232240\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GLYCOGEN STORAGE DISEASE Ic\"}","{\"db\":\"OMIM\",\"id\":\"602671.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GLYCOGEN STORAGE DISEASE Ic\"}","{\"db\":\"OMIM\",\"id\":\"602671.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GLYCOGEN STORAGE DISEASE Ic\"}","{\"db\":\"OMIM\",\"id\":\"602671.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GLYCOGEN STORAGE DISEASE Ic\"}","{\"db\":\"OMIM\",\"id\":\"602671.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GLYCOGEN STORAGE DISEASE Ic\"}","{\"db\":\"OMIM\",\"id\":\"602671.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GLYCOGEN STORAGE DISEASE Ic\"}","{\"db\":\"OMIM\",\"id\":\"232240\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GSD Ic\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Phosphate+transport+defect/9102\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"237965005\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"232240\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Phosphate transport defect","id":"2238","alternate_symbols":[],"alternate_names":["GLYCOGEN STORAGE DISEASE Ic","GSD Ic"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1535893","xrefs":["{\"db\":\"OMIM\",\"id\":\"604715\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"443236\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Orthostatic+intolerance/5436\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8515\",\"ref_field\":\"name\"}"],"name":"Orthostatic intolerance","id":"15842","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C2751630","xrefs":["{\"db\":\"Orphanet\",\"id\":\"178503\"}","{\"db\":\"OMIM\",\"id\":\"612541\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PULMONARY ARTERIAL HYPERTENSION, LEUKOPENIA, AND ATRIAL SEPTAL DEFECT\"}"],"name":"Dursun syndrome","id":"6692","alternate_symbols":[],"alternate_names":["PULMONARY ARTERIAL HYPERTENSION, LEUKOPENIA, AND ATRIAL SEPTAL DEFECT"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0242647","xrefs":["{\"db\":\"Orphanet\",\"id\":\"52417\"}","{\"db\":\"OMIM\",\"id\":\"603517.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MALT LYMPHOMA, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"603517.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MALT LYMPHOMA, SOMATIC\"}","{\"db\":\"OMIM\",\"id\":\"603517.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MALT LYMPHOMA, SOMATIC\"}","{\"db\":\"SNOMED CT\",\"id\":\"277622004\",\"ref_field\":\"name\"}"],"name":"Mucosa-associated lymphoma","id":"17630","alternate_symbols":[],"alternate_names":["MALT LYMPHOMA, SOMATIC","MALT lymphoma"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0678230","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000286\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000624\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007930\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"131500\",\"type\":\"MIM\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000286\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Epicanthal fold\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000286\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Epicanthal folds\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000286\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Epicanthic folds\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000286\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Epicanthus palpebralis\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000286\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Eye folds\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000286\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Palpebronasal fold\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000286\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Plica palpebronasalis\"}"],"name":"Epicanthus","id":"1158","alternate_symbols":[],"alternate_names":["Epicanthal fold","Epicanthal folds","Epicanthic folds","Epicanthus palpebralis","Eye folds","Palpebronasal fold","Plica palpebronasalis"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0002994","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100665\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100666\",\"type\":\"secondary\"}","{\"db\":\"Orphanet\",\"id\":\"658\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100665\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angioneurotic oedema\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100665\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiooedema\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100665\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Quincke edema\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100665\",\"ref_field\":\"name\"}"],"name":"Angioedema","id":"31435","alternate_symbols":[],"alternate_names":["Angioneurotic oedema","Angiooedema","Quincke edema"],"attribute_content":[],"type":"Finding"}
{"keywords":[],"symbol":"CHANDS","medgen_id":"C0406733","xrefs":["{\"db\":\"OMIM\",\"id\":\"214350\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1401\"}","{\"db\":\"SNOMED CT\",\"id\":\"239037001\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"214350\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1233\",\"ref_field\":\"symbol\"}"],"name":"Curly hair, ankyloblepharon, nail dysplasia syndrome","id":"774","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0553730","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000934\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"1416\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000934\",\"ref_field\":\"name\"}"],"name":"Chondrocalcinosis","id":"22042","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Finding"}
{"keywords":[],"symbol":"FCAS1","medgen_id":"C0343068","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS120100\",\"type\":\"Phenotypic series\"}","{\"db\":\"OMIM\",\"id\":\"PS120100\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"familial-cold-autoinflammatory-syndrome\",\"ref_field\":\"public_definition\"}"],"name":"Familial cold autoinflammatory syndrome","id":"33407","public_definition":"Familial cold autoinflammatory syndrome is a condition that causes episodes of fever, skin rash, and joint pain after exposure to cold temperatures. These episodes usually begin in infancy and occur throughout life.People with this condition usually experience symptoms after cold exposure of an hour or more, although in some individuals only a few minutes of exposure is required. Symptoms may be delayed for up to a few hours after the cold exposure. Episodes last an average of 12 hours, but may continue for up to 3 days.In people with familial cold autoinflammatory syndrome, the most common symptom that occurs during an episode is an itchy or burning rash. The rash usually begins on the face or extremities and spreads to the rest of the body. Occasionally swelling in the extremities may occur.In addition to the skin rash, episodes are characterized by fever, chills, and joint pain, most often affecting the hands, knees, and ankles. Redness in the whites of the eye (conjunctivitis), sweating, drowsiness, headache, thirst, and nausea may also occur during an episode of this disorder.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0266432","xrefs":["{\"db\":\"OMIM\",\"id\":\"238320\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"755\"}","{\"db\":\"OMIM\",\"id\":\"238320\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERGONADOTROPIC HYPOGONADISM, MALE, DUE TO LHCGR DEFECT\"}","{\"db\":\"OMIM\",\"id\":\"238320\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA WITH MALE PSEUDOHERMAPHRODITISM\"}","{\"db\":\"OMIM\",\"id\":\"238320\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, COMPLETE\"}","{\"db\":\"OMIM\",\"id\":\"152790.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"152790.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"152790.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"152790.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"152790.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"152790.0021\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"152790.0025\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"152790.0026\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"152790.0027\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"152790.0028\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"238320\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEYDIG CELL HYPOPLASIA, TYPE I\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Leydig+cells+hypoplasia/4217\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"56212008\",\"ref_field\":\"name\"}"],"name":"Leydig cell agenesis","id":"2687","alternate_symbols":[],"alternate_names":["HYPERGONADOTROPIC HYPOGONADISM, MALE, DUE TO LHCGR DEFECT","LEYDIG CELL HYPOPLASIA WITH MALE PSEUDOHERMAPHRODITISM","LEYDIG CELL HYPOPLASIA, COMPLETE","LEYDIG CELL HYPOPLASIA, TYPE I"],"attribute_content":[],"type":"Disease"}
{"keywords":["Hereditary cancer syndrome","Neoplasm"],"medgen_id":"C0342418","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002444\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"241800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2113\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002444\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypothalamic hamartoma\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypothalamic+hamartomas/3697\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"237714006\",\"ref_field\":\"name\"}"],"name":"Hamartoma of hypothalamus","id":"2282","alternate_symbols":[],"alternate_names":["Hypothalamic hamartoma"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0004158","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002305\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007167\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007316\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002305\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Athetoid movements\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002305\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Involuntary writhing movements\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002305\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5863\",\"ref_field\":\"name\"}"],"name":"Athetosis","id":"22996","alternate_symbols":[],"alternate_names":["Athetoid movements","Involuntary writhing movements"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C2931299","xrefs":[],"name":"ZAP70-Related Severe Combined Immunodeficiency","id":"17778","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"CN204945","xrefs":[],"name":"Uveal melanoma","id":"41534","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0029134","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100653\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100653\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7320\",\"ref_field\":\"name\"}"],"name":"Optic neuritis","id":"31425","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C4017065","xrefs":["{\"db\":\"Orphanet\",\"id\":\"2334\"}"],"name":"Keratitis, autosomal dominant","id":"9889","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":["Hereditary cancer syndrome"],"symbol":"HIES2","medgen_id":"C4722305","xrefs":["{\"db\":\"OMIM\",\"id\":\"243700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"217390\"}","{\"db\":\"OMIM\",\"id\":\"243700\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPER-IgE RECURRENT INFECTION SYNDROME 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"611432.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPER-IgE RECURRENT INFECTION SYNDROME 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"611432.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPER-IgE RECURRENT INFECTION SYNDROME 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"611432.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPER-IgE RECURRENT INFECTION SYNDROME 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"611432.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPER-IgE RECURRENT INFECTION SYNDROME 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2816\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AR-HIES\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"dock8-immunodeficiency-syndrome\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hyperimmunoglobulin+E+recurrent+infection+syndrome%2C+autosomal+recessive/3561\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2816\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"243700\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hyperimmunoglobulin E recurrent infection syndrome, autosomal recessive","id":"5277","alternate_symbols":["AR-HIES"],"alternate_names":["HYPER-IgE RECURRENT INFECTION SYNDROME 2, AUTOSOMAL RECESSIVE"],"attribute_content":[],"type":"Disease","ghr_links":"DOCK8 immunodeficiency syndrome"}
{"keywords":[],"symbol":"SHRF","medgen_id":"C4540367","xrefs":["{\"db\":\"OMIM\",\"id\":\"617763\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"494439\"}","{\"db\":\"OMIM\",\"id\":\"602238.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602238.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617763\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617763\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"SHORT STATURE, HEARING LOSS, RETINITIS PIGMENTOSA, AND DISTINCTIVE FACIES","id":"38338","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"PLCA3","medgen_id":"C4554421","xrefs":["{\"db\":\"OMIM\",\"id\":\"617920\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"617920\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMYLOIDOSIS CUTIS DYSCHROMICA\"}","{\"db\":\"OMIM\",\"id\":\"617920\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ACD\"}","{\"db\":\"OMIM\",\"id\":\"604368.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604368.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604368.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604368.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604368.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"604368.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617920\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617920\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"AMYLOIDOSIS, PRIMARY LOCALIZED CUTANEOUS, 3","id":"38730","alternate_symbols":["ACD"],"alternate_names":["AMYLOIDOSIS CUTIS DYSCHROMICA"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"YHFS","medgen_id":"C4310778","xrefs":["{\"db\":\"OMIM\",\"id\":\"616954\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"488642\"}","{\"db\":\"OMIM\",\"id\":\"616954\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"You-Hoover-Fong syndrome","id":"35659","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SINO","medgen_id":"C4284592","xrefs":["{\"db\":\"OMIM\",\"id\":\"617296\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"521390\"}","{\"db\":\"OMIM\",\"id\":\"617296\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Spastic paraplegia, intellectual disability, nystagmus, and obesity","id":"36797","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"GSSD","medgen_id":"C0398746","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003343\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"266130\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"32\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003343\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Glutathione synthetase deficiency\"}","{\"db\":\"Genetic Alliance\",\"id\":\"5-Oxoprolinuria/52\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"234589002\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"266130\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Gluthathione synthetase deficiency","id":"1384","alternate_symbols":[],"alternate_names":["5-Oxoprolinuria","Glutathione synthetase deficiency"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"OSFD","medgen_id":"C4085248","xrefs":["{\"db\":\"OMIM\",\"id\":\"607278\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"488265\"}","{\"db\":\"OMIM\",\"id\":\"607278\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OFD\"}","{\"db\":\"OMIM\",\"id\":\"607278\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Osteofibrous dysplasia","id":"3676","alternate_symbols":["OFD"],"alternate_names":["Tibia, bowing of, with pseudarthrosis and pectus excavatum"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"ASPGX2","medgen_id":"C1845334","xrefs":["{\"db\":\"OMIM\",\"id\":\"300497\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"300497\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Asperger+syndrome+X-linked+2/7716\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300497\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Asperger syndrome X-linked 2","id":"340","alternate_symbols":[],"alternate_names":["ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 2","Asperger syndrome susceptibility, X-linked 2"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"BLAUS","medgen_id":"C1861303","xrefs":["{\"db\":\"OMIM\",\"id\":\"186580\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90340\"}","{\"db\":\"OMIM\",\"id\":\"186580\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SARCOIDOSIS, EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"186580\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ACUG\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"304\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ACUG\"}","{\"db\":\"OMIM\",\"id\":\"186580\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EOS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Synovitis+granulomatous+with+uveitis+and+cranial+neuropathies/6974\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"blau-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"304\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"186580\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Blau syndrome","id":"4676","alternate_symbols":["ACUG","EOS"],"alternate_names":["SARCOIDOSIS, EARLY-ONSET"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0038454","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001297\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002452\",\"type\":\"secondary\"}","{\"db\":\"MeSH\",\"id\":\"D020521\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001297\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cerebral vascular events\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001297\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cerebrovascular accident\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001297\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cerebrovascular accidents\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001297\",\"ref_field\":\"name\"}"],"name":"Stroke","id":"35588","alternate_symbols":[],"alternate_names":["Cerebral vascular events","Cerebrovascular accident","Cerebrovascular accidents"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C2676285","xrefs":["{\"db\":\"OMIM\",\"id\":\"612394\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"612394\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LH3 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"603066.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LYSYL HYDROXYLASE 3 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"603066.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LYSYL HYDROXYLASE 3 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"612394\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LYSYL HYDROXYLASE 3 DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bone+fragility+with+contractures%2C+arterial+rupture%2C+and+deafness/7852\",\"ref_field\":\"name\"}"],"name":"Bone fragility with contractures, arterial rupture, and deafness","id":"507","alternate_symbols":[],"alternate_names":["LH3 DEFICIENCY","LYSYL HYDROXYLASE 3 DEFICIENCY"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"AIPDS","medgen_id":"C4310614","xrefs":["{\"db\":\"OMIM\",\"id\":\"617099\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"500062\"}","{\"db\":\"OMIM\",\"id\":\"617099\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OTULIN-RELATED AUTOINFLAMMATORY SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"617099\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OTULIPENIA\"}","{\"db\":\"OMIM\",\"id\":\"617099\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ORAS\"}","{\"db\":\"OMIM\",\"id\":\"617099\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Autoinflammation, panniculitis, and dermatosis syndrome","id":"36126","alternate_symbols":["ORAS"],"alternate_names":["OTULIN-RELATED AUTOINFLAMMATORY SYNDROME","OTULIPENIA"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"DFNX7","medgen_id":"C4746975","xrefs":["{\"db\":\"OMIM\",\"id\":\"301018\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"500188\"}","{\"db\":\"OMIM\",\"id\":\"301018\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"301018\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"DEAFNESS, X-LINKED 7","id":"40822","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0344697","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011566\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"99098\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011566\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cor triatriatum dextrum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011566\",\"ref_field\":\"name\"}"],"name":"Cor triatriatum dexter","id":"29464","alternate_symbols":[],"alternate_names":["Cor triatriatum dextrum"],"attribute_content":[],"type":"Finding"}
{"keywords":[],"medgen_id":"C0023269","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100243\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"64720\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100243\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6880\",\"ref_field\":\"name\"}"],"name":"Leiomyosarcoma","id":"31035","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":["Neoplasm"],"medgen_id":"C0279606","xrefs":["{\"db\":\"Orphanet\",\"id\":\"33402\"}"],"name":"Childhood hepatocellular carcinoma","id":"14305","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"PFIC1","medgen_id":"C0268312","xrefs":["{\"db\":\"Orphanet\",\"id\":\"284385\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"progressive-familial-intrahepatic-cholestasis\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Illumina Clinical Services Laboratory,Illumina\",\"id\":\"21987\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"progressive-familial-intrahepatic-cholestasis\",\"ref_field\":\"public_definition\"}"],"name":"Familial Intrahepatic Cholestasis","id":"36535","public_definition":"Progressive familial intrahepatic cholestasis (PFIC) is a disorder that causes progressive liver disease, which typically leads to liver failure. In people with PFIC, liver cells are less able to secrete a digestive fluid called bile. The buildup of bile in liver cells causes liver disease in affected individuals.Signs and symptoms of PFIC typically begin in infancy and are related to bile buildup and liver disease. Specifically, affected individuals experience severe itching, yellowing of the skin and whites of the eyes (jaundice), failure to gain weight and grow at the expected rate (failure to thrive), high blood pressure in the vein that supplies blood to the liver (portal hypertension), and an enlarged liver and spleen (hepatosplenomegaly).There are three known types of PFIC: PFIC1, PFIC2, and PFIC3. The types are also sometimes described as shortages of particular proteins needed for normal liver function. Each type has a different genetic cause.In addition to signs and symptoms related to liver disease, people with PFIC1 may have short stature, deafness, diarrhea, inflammation of the pancreas (pancreatitis), and low levels of fat-soluble vitamins (vitamins A, D, E, and K) in the blood. Affected individuals typically develop liver failure before adulthood.The signs and symptoms of PFIC2 are typically related to liver disease only; however, these signs and symptoms tend to be more severe than those experienced by people with PFIC1. People with PFIC2 often develop liver failure within the first few years of life. Additionally, affected individuals are at increased risk of developing a type of liver cancer called hepatocellular carcinoma.Most people with PFIC3 have signs and symptoms related to liver disease only. Signs and symptoms of PFIC3 usually do not appear until later in infancy or early childhood; rarely, people are diagnosed in early adulthood. Liver failure can occur in childhood or adulthood in people with PFIC3.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease","ghr_links":"progressive familial intrahepatic cholestasis"}
{"keywords":[],"symbol":"MDCDC","medgen_id":"C4310736","xrefs":["{\"db\":\"OMIM\",\"id\":\"617066\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"486815\"}","{\"db\":\"OMIM\",\"id\":\"617066\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Muscular dystrophy, congenital, davignon-chauveau type","id":"35834","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0403554","xrefs":["{\"db\":\"OMIM\",\"id\":\"267300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93611\"}","{\"db\":\"OMIM\",\"id\":\"267300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, AUTOSOMAL RECESSIVE, WITH PROGRESSIVE NERVE DEAFNESS\"}","{\"db\":\"OMIM\",\"id\":\"267300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, WITH PROGRESSIVE NERVE DEAFNESS\"}","{\"db\":\"OMIM\",\"id\":\"267300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RTA WITH PROGRESSIVE NERVE DEAFNESS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Renal+tubular+acidosis+progressive+nerve+deafness/6212\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"236532003\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"renal-tubular-acidosis-with-deafness\",\"ref_field\":\"public_definition\"}"],"name":"Renal tubular acidosis with progressive nerve deafness","id":"5857","public_definition":"Renal tubular acidosis with deafness is a disorder characterized by kidney (renal) problems and hearing loss. The kidneys normally filter fluid and waste products from the body and remove them in urine; however, in people with this disorder, the kidneys do not remove enough acidic compounds from the body. Instead, the acids are absorbed back into the bloodstream, and the blood becomes too acidic. This chemical imbalance, called metabolic acidosis, can result in a range of signs and symptoms that vary in severity. Metabolic acidosis often causes nausea, vomiting, and dehydration; affected infants tend to have problems feeding and gaining weight (failure to thrive). Most children and adults with renal tubular acidosis with deafness have short stature, and many develop kidney stones.The metabolic acidosis that occurs in renal tubular acidosis with deafness may also lead to softening and weakening of the bones, called rickets in children and osteomalacia in adults. This bone disorder is characterized by bone pain, bowed legs, and difficulty walking. Rarely, people with renal tubular acidosis with deafness have episodes of hypokalemic paralysis, a condition that causes extreme muscle weakness associated with low levels of potassium in the blood (hypokalemia).In people with renal tubular acidosis with deafness, hearing loss caused by changes in the inner ear (sensorineural hearing loss) usually begins between childhood and young adulthood, and gradually gets worse. An inner ear abnormality affecting both ears occurs in most people with this disorder. This feature, which is called enlarged vestibular aqueduct, can be seen with medical imaging. The vestibular aqueduct is a bony canal that runs from the inner ear into the temporal bone of the skull and toward the brain. The relationship between enlarged vestibular aqueduct and hearing loss is unclear. In renal tubular acidosis with deafness, enlarged vestibular aqueduct typically occurs in individuals whose hearing loss begins in childhood.","alternate_symbols":[],"alternate_names":["Distal Renal Tubular Acidosis with Progressive Sensorineural Deafness","RENAL TUBULAR ACIDOSIS, AUTOSOMAL RECESSIVE, WITH PROGRESSIVE NERVE DEAFNESS","RENAL TUBULAR ACIDOSIS, DISTAL, WITH PROGRESSIVE NERVE DEAFNESS","RTA WITH PROGRESSIVE NERVE DEAFNESS"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"ARS","medgen_id":"C4085595","xrefs":["{\"db\":\"OMIM\",\"id\":\"616459\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"610534.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610534.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610534.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610534.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"616459\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"616459\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"AL-RAQAD SYNDROME","id":"33579","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"ASPGX1","medgen_id":"C1845341","xrefs":["{\"db\":\"OMIM\",\"id\":\"300494\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"300494\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Asperger+syndrome+X-linked+1/7715\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300494\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Asperger syndrome X-linked 1","id":"552","alternate_symbols":[],"alternate_names":["ASPERGER SYNDROME, X-LINKED, SUSCEPTIBILITY TO, 1","Asperger syndrome susceptibility, X-linked 1"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"PHASK","medgen_id":"C4747922","xrefs":["{\"db\":\"OMIM\",\"id\":\"618019\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"448267\"}","{\"db\":\"OMIM\",\"id\":\"618019\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"REGRESSIVE SPONDYLOMETAPHYSEAL DYSPLASIA\"}","{\"db\":\"OMIM\",\"id\":\"600024.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600024.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600024.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600024.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600024.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618019\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618019\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"PELGER-HUET ANOMALY WITH MILD SKELETAL ANOMALIES","id":"40117","alternate_symbols":[],"alternate_names":["REGRESSIVE SPONDYLOMETAPHYSEAL DYSPLASIA"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0014761","xrefs":["{\"db\":\"Orphanet\",\"id\":\"275938\"}","{\"db\":\"SNOMED CT\",\"id\":\"387705004\",\"ref_field\":\"name\"}"],"name":"Hemolytic disease of fetus OR newborn due to isoimmunization","id":"17390","alternate_symbols":[],"alternate_names":["Fetal Erythroblastosis","Hemolytic Disease of the Newborn"],"attribute_content":[],"type":"Disease"}
{"keywords":["Neoplasm"],"symbol":"XMEN","medgen_id":"C3275445","xrefs":["{\"db\":\"OMIM\",\"id\":\"300853\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"317476\"}","{\"db\":\"Genetic Alliance\",\"id\":\"IMMUNODEFICIENCY%2C+X-LINKED%2C+WITH+MAGNESIUM+DEFECT%2C+EPSTEIN-BARR+VIRUS+INFECTION%2C+AND+NEOPLASIA/8651\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300853\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Immunodeficiency, X-Linked, with magnesium defect, Epstein-Barr virus infection, and neoplasia","id":"16366","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0221013","xrefs":["{\"db\":\"MeSH\",\"id\":\"D034721\"}","{\"db\":\"Orphanet\",\"id\":\"2467\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"systemic-mastocytosis\",\"ref_field\":\"public_definition\"}"],"name":"Mast cell disease, systemic","id":"11266","public_definition":"Systemic mastocytosis is a blood disorder that can affect many different body systems. Individuals with the condition can develop signs and symptoms at any age, but it usually appears after adolescence.Signs and symptoms of systemic mastocytosis often include extreme tiredness (fatigue), skin redness and warmth (flushing), nausea, abdominal pain, bloating, diarrhea, the backflow of stomach acids into the esophagus (gastroesophageal reflux), nasal congestion, shortness of breath, low blood pressure (hypotension), lightheadedness, and headache. Some affected individuals have attention or memory problems, anxiety, or depression. Many individuals with systemic mastocytosis develop a skin condition called urticaria pigmentosa, which is characterized by raised patches of brownish skin that sting or itch with contact or changes in temperature. Nearly half of individuals with systemic mastocytosis will experience severe allergic reactions (anaphylaxis).There are five subtypes of systemic mastocytosis, which are differentiated by their severity and the signs and symptoms. The mildest forms of systemic mastocytosis are the indolent and smoldering types. Individuals with these types tend to have only the general signs and symptoms of systemic mastocytosis described above. Individuals with smoldering mastocytosis may have more organs affected and more severe features than those with indolent mastocytosis. The indolent type is the most common type of systemic mastocytosis.The severe types include aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia. These types are associated with a reduced life span, which varies among the types and affected individuals. In addition to the general signs and symptoms of systemic mastocytosis, these types typically involve impaired function of an organ, such as the liver, spleen, or lymph nodes. The organ dysfunction can result in an abnormal buildup of fluid in the abdominal cavity (ascites). Aggressive systemic mastocytosis is associated with a loss of bone tissue (osteoporosis and osteopenia) and multiple bone fractures. Systemic mastocytosis with an associated hematologic neoplasm and mast cell leukemia both involve blood cell disorders or blood cell cancer (leukemia). Mast cell leukemia is the rarest and most severe type of systemic mastocytosis.Individuals with the milder forms of the condition generally have a normal or near normal life expectancy, while those with the more severe forms typically survive months or a few years after diagnosis.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":["Hereditary cancer syndrome"],"symbol":"AIMAH1","medgen_id":"C1857451","xrefs":["{\"db\":\"OMIM\",\"id\":\"219080\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"189427\"}","{\"db\":\"Orphanet\",\"id\":\"99893\"}","{\"db\":\"OMIM\",\"id\":\"219080\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA\"}","{\"db\":\"OMIM\",\"id\":\"219080\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ACTH-INDEPENDENT MACRONODULAR ADRENOCORTICAL HYPERPLASIA\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cushing%27s+Syndrome/2039\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6224\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"219080\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Cushing's syndrome","id":"177","alternate_symbols":[],"alternate_names":["ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA","ACTH-INDEPENDENT MACRONODULAR ADRENOCORTICAL HYPERPLASIA","ACTH-independent macronodular adrenal hyperplasia, somatic"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SRTD7","medgen_id":"C3279792","xrefs":["{\"db\":\"OMIM\",\"id\":\"614091\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"498497\"}","{\"db\":\"Orphanet\",\"id\":\"93271\"}","{\"db\":\"OMIM\",\"id\":\"614091\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT-RIB THORACIC DYSPLASIA 7 WITH OR WITHOUT POLYDACTYLY\"}","{\"db\":\"OMIM\",\"id\":\"613602.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT-RIB THORACIC DYSPLASIA 7 WITH POLYDACTYLY\"}","{\"db\":\"OMIM\",\"id\":\"613602.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT-RIB THORACIC DYSPLASIA 7 WITH POLYDACTYLY\"}","{\"db\":\"OMIM\",\"id\":\"613602.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT-RIB THORACIC DYSPLASIA 7 WITH POLYDACTYLY\"}","{\"db\":\"OMIM\",\"id\":\"613602.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT-RIB THORACIC DYSPLASIA 7 WITH POLYDACTYLY\"}","{\"db\":\"OMIM\",\"id\":\"614091\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SRPS5\"}","{\"db\":\"OMIM\",\"id\":\"614091\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Short rib polydactyly syndrome 5","id":"16087","alternate_symbols":["SRPS5"],"alternate_names":["SHORT-RIB THORACIC DYSPLASIA 7 WITH OR WITHOUT POLYDACTYLY","SHORT-RIB THORACIC DYSPLASIA 7 WITH POLYDACTYLY"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1962971","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012819\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012819\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7137\",\"ref_field\":\"name\"}"],"name":"Myocarditis","id":"30699","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0751093","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002451\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002451\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3253\",\"ref_field\":\"name\"}"],"name":"Limb dystonia","id":"23084","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1720983","xrefs":[],"name":"Channelopathies","id":"32688","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1867146","xrefs":["{\"db\":\"OMIM\",\"id\":\"180750\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3106\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Robinow+Sorauf+syndrome/6344\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4730\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"saethre-chotzen-syndrome\",\"ref_field\":\"public_definition\"}"],"name":"Robinow Sorauf syndrome","id":"4114","public_definition":"Saethre-Chotzen syndrome is a genetic condition characterized by the premature fusion of certain skull bones (craniosynostosis). This early fusion prevents the skull from growing normally and affects the shape of the head and face.Most people with Saethre-Chotzen syndrome have prematurely fused skull bones along the coronal suture, the growth line that goes over the head from ear to ear. Other parts of the skull may be malformed as well. These changes can result in an abnormally shaped head, a high forehead, a low frontal hairline, droopy eyelids (ptosis), widely spaced eyes, and a broad nasal bridge. One side of the face may appear noticeably different from the other (facial asymmetry). Most people with Saethre-Chotzen syndrome also have small, unusually shaped ears.The signs and symptoms of Saethre-Chotzen syndrome vary widely, even among affected individuals in the same family. This condition can cause mild abnormalities of the hands and feet, such as fusion of the skin between the second and third fingers on each hand and a broad or duplicated first (big) toe. Delayed development and learning difficulties have been reported, although most people with this condition are of normal intelligence. Less common signs and symptoms of Saethre-Chotzen syndrome include short stature, abnormalities of the bones of the spine (the vertebra), hearing loss, and heart defects.Robinow-Sorauf syndrome is a condition with features similar to those of Saethre-Chotzen syndrome, including craniosynostosis and broad or duplicated great toes. It was once considered a separate disorder, but was found to result from mutations in the same gene and is now thought to be a mild variant of Saethre-Chotzen syndrome.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0344760","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011560\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"1205\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011560\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mitral valve atresia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011560\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3685\",\"ref_field\":\"name\"}"],"name":"Mitral atresia","id":"17962","alternate_symbols":[],"alternate_names":["Mitral valve atresia"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C4016054","xrefs":["{\"db\":\"Orphanet\",\"id\":\"284979\"}"],"name":"Marfan syndrome, neonatal","id":"12613","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"POF","medgen_id":"C0085215","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS311360\",\"type\":\"Phenotypic series\"}","{\"db\":\"OMIM\",\"id\":\"311360\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRAGILE X PREMATURE OVARIAN FAILURE\"}","{\"db\":\"OMIM\",\"id\":\"311360\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PRIMARY OVARIAN INSUFFICIENCY, FRAGILE X-ASSOCIATED\"}","{\"db\":\"Genetic Alliance\",\"id\":\"premature+ovarian+failure/5929\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"237788002\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"311360\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Premature ovarian failure","id":"16835","alternate_symbols":[],"alternate_names":["FRAGILE X PREMATURE OVARIAN FAILURE","PRIMARY OVARIAN INSUFFICIENCY, FRAGILE X-ASSOCIATED","Primary ovarian insufficiency"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"MRD41","medgen_id":"C4310784","xrefs":["{\"db\":\"OMIM\",\"id\":\"616944\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2823\"}","{\"db\":\"OMIM\",\"id\":\"616944\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Mental retardation, autosomal dominant 41","id":"35339","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"TCMGLY","medgen_id":"C0854699","xrefs":["{\"db\":\"OMIM\",\"id\":\"190330\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"190330\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EYELASHES, LONG\"}","{\"db\":\"OMIM\",\"id\":\"190330\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Trichomegaly","id":"6077","alternate_symbols":[],"alternate_names":["EYELASHES, LONG"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"NDMSBA","medgen_id":"C4479631","xrefs":["{\"db\":\"OMIM\",\"id\":\"617527\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"521426\"}","{\"db\":\"OMIM\",\"id\":\"603873.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603873.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603873.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617527\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617527\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"NEURODEVELOPMENTAL DISORDER WITH PROGRESSIVE MICROCEPHALY, SPASTICITY, AND BRAIN ANOMALIES","id":"37870","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"WMS4","medgen_id":"C2750787","xrefs":["{\"db\":\"OMIM\",\"id\":\"613195\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"363992\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Weill-Marchesani-like+syndrome/9474\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Weill-Marchesani-like syndrome\"}","{\"db\":\"OMIM\",\"id\":\"613195\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WMSL\"}","{\"db\":\"OMIM\",\"id\":\"613195\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Weill-Marchesani syndrome 4","id":"6868","alternate_symbols":["WMSL"],"alternate_names":["Weill-Marchesani 4 syndrome, recessive","Weill-Marchesani-like syndrome"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1855498","xrefs":["{\"db\":\"OMIM\",\"id\":\"246650\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"535453\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Lipase+deficiency+combined/4254\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10244\",\"ref_field\":\"name\"}"],"name":"Lipase deficiency combined","id":"2692","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0268285","xrefs":["{\"db\":\"OMIM\",\"id\":\"202110\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90793\"}","{\"db\":\"Orphanet\",\"id\":\"90796\"}","{\"db\":\"OMIM\",\"id\":\"202110\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA V\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Deficiency+of+steroid+17-alpha-monooxygenase/8205\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"124220008\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"17-alpha-hydroxylase-17-20-lyase-deficiency\",\"ref_field\":\"public_definition\"}"],"name":"Deficiency of steroid 17-alpha-monooxygenase","id":"185","public_definition":"17 alpha(a)-hydroxylase/17,20-lyase deficiency is a condition that affects the function of certain hormone-producing glands called the gonads (ovaries in females and testes in males) and the adrenal glands. The gonads direct sexual development before birth and during puberty and are important for reproduction. The adrenal glands, which are located on top of the kidneys, regulate the production of certain hormones, including those that control salt levels in the body. People with 17a-hydroxylase/17,20-lyase deficiency have an imbalance of many of the hormones that are made in these glands. 17a-hydroxylase/17,20-lyase deficiency is one of a group of disorders, known as congenital adrenal hyperplasias, that impair hormone production and disrupt sexual development and maturation.Hormone imbalances lead to the characteristic signs and symptoms of 17a-hydroxylase/17,20-lyase deficiency, which include high blood pressure (hypertension), low levels of potassium in the blood (hypokalemia), and abnormal sexual development. The severity of the features varies. Two forms of the condition are recognized: complete 17a-hydroxylase/17,20-lyase deficiency, which is more severe, and partial 17a-hydroxylase/17,20-lyase deficiency, which is typically less so.Males and females are affected by disruptions to sexual development differently. Females (who have two X chromosomes) with 17a-hydroxylase/17,20-lyase deficiency are born with normal external female genitalia; however, the internal reproductive organs, including the uterus and ovaries, may be underdeveloped. Women with complete 17a-hydroxylase/17,20-lyase deficiency do not develop secondary sex characteristics, such as breasts and pubic hair, and do not menstruate (amenorrhea). Women with partial 17a-hydroxylase/17,20-lyase deficiency may develop some secondary sex characteristics; menstruation is typically irregular or absent. Either form of the disorder results in an inability to conceive a baby (infertility).In affected individuals who are chromosomally male (having an X and a Y chromosome), problems with sexual development lead to abnormalities of the external genitalia. The most severely affected are born with characteristically female external genitalia and are generally raised as females. However, because they do not have female internal reproductive organs, these individuals have amenorrhea and do not develop female secondary sex characteristics. These individuals have testes, but they are abnormally located in the abdomen (undescended). Sometimes, complete 17a-hydroxylase/17,20-lyase deficiency leads to external genitalia that do not look clearly male or clearly female (ambiguous genitalia). Males with partial 17a-hydroxylase/17,20-lyase deficiency usually have abnormal male genitalia, such as a small penis (micropenis), the opening of the urethra on the underside of the penis (hypospadias), or a scrotum divided into two lobes (bifid scrotum). Males with either complete or partial 17a-hydroxylase/17,20-lyase deficiency are also infertile.","alternate_symbols":[],"alternate_names":["17-alpha-hydroxylase/17,20-lyase deficiency","ADRENAL HYPERPLASIA V"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"M/SCHAD","medgen_id":"C1291230","xrefs":["{\"db\":\"OMIM\",\"id\":\"231530\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"309127\"}","{\"db\":\"Orphanet\",\"id\":\"71212\"}","{\"db\":\"Genetic Alliance\",\"id\":\"3-Alpha+Hydroxyacyl-CoA+Dehydrogenase+Deficiency/29\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"124122005\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"3-hydroxyacyl-coa-dehydrogenase-deficiency\",\"ref_field\":\"public_definition\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9870\",\"ref_field\":\"symbol\"}"],"name":"Deficiency of 3-hydroxyacyl-CoA dehydrogenase","id":"3","public_definition":"3-hydroxyacyl-CoA dehydrogenase deficiency is an inherited condition that prevents the body from converting certain fats to energy, particularly during prolonged periods without food (fasting).Initial signs and symptoms of this disorder typically occur during infancy or early childhood and can include poor appetite, vomiting, diarrhea, and lack of energy (lethargy). Affected individuals can also have muscle weakness (hypotonia), liver problems, low blood sugar (hypoglycemia), and abnormally high levels of insulin (hyperinsulinism). Insulin controls the amount of sugar that moves from the blood into cells for conversion to energy. Individuals with 3-hydroxyacyl-CoA dehydrogenase deficiency are also at risk for complications such as seizures, life-threatening heart and breathing problems, coma, and sudden death. This condition may explain some cases of sudden infant death syndrome (SIDS), which is defined as unexplained death in babies younger than 1 year.Problems related to 3-hydroxyacyl-CoA dehydrogenase deficiency can be triggered by periods of fasting or by illnesses such as viral infections. This disorder is sometimes mistaken for Reye syndrome, a severe disorder that may develop in children while they appear to be recovering from viral infections such as chicken pox or flu. Most cases of Reye syndrome are associated with the use of aspirin during these viral infections.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"DYT16","medgen_id":"C2677567","xrefs":["{\"db\":\"OMIM\",\"id\":\"612067\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"210571\"}","{\"db\":\"GeneTests\",\"id\":\"313728\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dystonia+16/2412\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10539\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"dystonia-16\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612067\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10539\",\"ref_field\":\"symbol\"}"],"name":"Dystonia 16","id":"1518","public_definition":"Dystonia 16 is one of many forms of dystonia, which is a group of conditions characterized by involuntary movements, twisting (torsion) and tensing of various muscles, and unusual positioning of affected body parts. Dystonia 16 can appear at any age from infancy through adulthood, although it most often begins in childhood.The signs and symptoms of dystonia 16 vary among people with the condition. In many affected individuals, the disorder first affects muscles in one or both arms or legs. Tensing (contraction) of the muscles often sets the affected limb in an abnormal position, which may be painful and can lead to difficulty performing tasks, such as walking. In others, muscles in the neck are affected first, causing the head to be pulled backward and positioned with the chin in the air (retrocollis).In dystonia 16, muscles of the jaw, lips, and tongue are also commonly affected (oromandibular dystonia), causing difficulty opening and closing the mouth and problems with swallowing and speech. Speech can also be affected by involuntary tensing of the muscles that control the vocal cords (laryngeal dystonia), resulting in a quiet, breathy voice or an inability to speak clearly. Dystonia 16 gradually gets worse, eventually involving muscles in most parts of the body.Some people with dystonia 16 develop a pattern of movement abnormalities known as parkinsonism. These abnormalities include unusually slow movement (bradykinesia), muscle rigidity, tremors, and an inability to hold the body upright and balanced (postural instability). In dystonia 16, parkinsonism is relatively mild if it develops at all.The signs and symptoms of dystonia 16 usually do not get better when treated with drugs that are typically used for movement disorders.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"CANVAS","medgen_id":"C3281223","xrefs":["{\"db\":\"OMIM\",\"id\":\"614575\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"504476\"}","{\"db\":\"OMIM\",\"id\":\"614575\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome","id":"16879","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"VBU","medgen_id":"C0157743","xrefs":["{\"db\":\"Gene\",\"id\":\"29764\"}","{\"db\":\"OMIM\",\"id\":\"125630\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"493342\"}","{\"db\":\"OMIM\",\"id\":\"125630\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VIBRATORY ANGIOEDEMA\"}","{\"db\":\"OMIM\",\"id\":\"125630\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DDU\"}","{\"db\":\"OMIM\",\"id\":\"125630\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Vibratory urticaria","id":"1959","alternate_symbols":["DDU"],"alternate_names":["VIBRATORY ANGIOEDEMA"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"PAPA1","medgen_id":"C4282400","xrefs":["{\"db\":\"OMIM\",\"id\":\"174200\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Postaxial+polydactyly+type+A1/9139\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"174200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Postaxial polydactyly type A1","id":"15916","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"MRCS","medgen_id":"C2674009","xrefs":["{\"db\":\"OMIM\",\"id\":\"193220\",\"ref_field\":\"symbol\"}"],"name":"Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma","id":"9810","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C4274322","xrefs":["{\"db\":\"Orphanet\",\"id\":\"98769\"}"],"name":"Spinocerebellar ataxia type 15/16","id":"39808","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SMALED2B","medgen_id":"C4749003","xrefs":["{\"db\":\"OMIM\",\"id\":\"618291\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"609797.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"609797.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"609797.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618291\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618291\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"SPINAL MUSCULAR ATROPHY, LOWER EXTREMITY-PREDOMINANT, 2B, PRENATAL ONSET, AUTOSOMAL DOMINANT","id":"41333","alternate_symbols":[],"alternate_names":["Spinal muscular atrophy, lower extremity-predominant, 2B, autosomal dominant"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"IMD17","medgen_id":"C3810107","xrefs":["{\"db\":\"OMIM\",\"id\":\"615607\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"615607\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CD3-GAMMA DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"615607\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SCID-LIKE IMMUNODEFICIENCY, T CELL-PARTIAL, B CELL-POSITIVE, NK CELL-POSITIVE\"}","{\"db\":\"OMIM\",\"id\":\"615607\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Immunodeficiency 17","id":"18548","alternate_symbols":[],"alternate_names":["CD3-GAMMA DEFICIENCY","SCID-LIKE IMMUNODEFICIENCY, T CELL-PARTIAL, B CELL-POSITIVE, NK CELL-POSITIVE"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0002881","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004804\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004811\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004824\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004804\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenital haemolytic anemia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004804\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neonatal hemolytic anemia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004804\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6167\",\"ref_field\":\"name\"}"],"name":"Congenital hemolytic anemia","id":"24638","alternate_symbols":[],"alternate_names":["Congenital haemolytic anemia","Neonatal hemolytic anemia"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0728895","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001180\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001180\",\"ref_field\":\"name\"}"],"name":"Hand oligodactyly","id":"22228","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Finding"}
{"keywords":[],"medgen_id":"C3151466","xrefs":["{\"db\":\"OMIM\",\"id\":\"614025\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"140905\"}","{\"db\":\"OMIM\",\"id\":\"614025\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HL DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"614025\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LIPC DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hepatic+lipase+deficiency/8508\",\"ref_field\":\"name\"}"],"name":"Hepatic lipase deficiency","id":"11357","alternate_symbols":[],"alternate_names":["HL DEFICIENCY","LIPC DEFICIENCY"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"NEPPK","medgen_id":"C1833030","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007404\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"600962\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"530838\"}","{\"db\":\"OMIM\",\"id\":\"600962\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PPKNE\"}","{\"db\":\"OMIM\",\"id\":\"600962\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TYLOSIS\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007404\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"600962\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Nonepidermolytic palmoplantar keratoderma","id":"3754","alternate_symbols":["PPKNE","TYLOSIS"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"HPANBH4","medgen_id":"C4479270","xrefs":["{\"db\":\"OMIM\",\"id\":\"617384\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"508523\"}","{\"db\":\"OMIM\",\"id\":\"617384\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hyperphenylalaninemia, mild, non-bh4-deficient","id":"37047","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"PILBOS","medgen_id":"C4540131","xrefs":["{\"db\":\"OMIM\",\"id\":\"617682\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"529965\"}","{\"db\":\"OMIM\",\"id\":\"617682\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL DELAY AND SPEECH APRAXIA WITH OR WITHOUT SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"602118.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602118.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602118.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602118.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617682\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617682\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"PILAROWSKI-BJORNSSON SYNDROME","id":"38128","alternate_symbols":[],"alternate_names":["DEVELOPMENTAL DELAY AND SPEECH APRAXIA WITH OR WITHOUT SEIZURES"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"RHNR","medgen_id":"C1849387","xrefs":["{\"db\":\"OMIM\",\"id\":\"268150\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"268150\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RH-NULL DISEASE, REGULATOR TYPE\"}","{\"db\":\"OMIM\",\"id\":\"268150\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RH-NULL HEMOLYTIC ANEMIA, REGULATOR TYPE\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509191\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RHN\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Rh-null%2C+regulator+type/9250\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"268150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Rh-null, regulator type","id":"4103","alternate_symbols":["RHN"],"alternate_names":["RH-NULL DISEASE, REGULATOR TYPE","RH-NULL HEMOLYTIC ANEMIA, REGULATOR TYPE"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0028077","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000662\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007653\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007725\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007865\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007895\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000662\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Difficulties with night vision\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000662\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Night-blindness\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000662\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Poor night vision\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000662\",\"ref_field\":\"name\"}"],"name":"Nyctalopia","id":"21832","alternate_symbols":[],"alternate_names":["Difficulties with night vision","Night-blindness","Poor night vision"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0265255","xrefs":["{\"db\":\"Orphanet\",\"id\":\"324764\"}","{\"db\":\"Illumina Clinical Services Laboratory,Illumina\",\"id\":\"648970\",\"ref_field\":\"name\"}"],"name":"Trichorhinophalangeal Syndrome","id":"36667","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"3MC3","medgen_id":"C0796032","xrefs":["{\"db\":\"OMIM\",\"id\":\"248340\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2453\"}","{\"db\":\"Orphanet\",\"id\":\"293843\"}","{\"db\":\"OMIM\",\"id\":\"248340\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 3\"}","{\"db\":\"OMIM\",\"id\":\"607620.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 3\"}","{\"db\":\"OMIM\",\"id\":\"607620.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 3\"}","{\"db\":\"OMIM\",\"id\":\"607620.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3MC SYNDROME 3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Malpuech+facial+clefting+syndrome/4441\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8531\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"248340\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Malpuech facial clefting syndrome","id":"5446","alternate_symbols":[],"alternate_names":["3MC SYNDROME 3"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"LAMSHF","medgen_id":"C4225202","xrefs":["{\"db\":\"OMIM\",\"id\":\"616803\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"313884\"}","{\"db\":\"Orphanet\",\"id\":\"313892\"}","{\"db\":\"Orphanet\",\"id\":\"530983\"}","{\"db\":\"OMIM\",\"id\":\"616803\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Lamb-shaffer syndrome","id":"34618","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"LCCS3","medgen_id":"C1969655","xrefs":["{\"db\":\"OMIM\",\"id\":\"611369\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"606102.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LETHAL CONGENITAL CONTRACTURE SYNDROME 3\"}","{\"db\":\"OMIM\",\"id\":\"611369\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LETHAL CONGENITAL CONTRACTURE SYNDROME 3\"}","{\"db\":\"OMIM\",\"id\":\"611369\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE CONTRACTURE SYNDROME, ISRAELI BEDOUIN TYPE B\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Lethal+congenital+contractural+syndrome+3/8738\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611369\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Lethal congenital contractural syndrome 3","id":"2470","alternate_symbols":[],"alternate_names":["LETHAL CONGENITAL CONTRACTURE SYNDROME 3","MULTIPLE CONTRACTURE SYNDROME, ISRAELI BEDOUIN TYPE B"],"attribute_content":[],"type":"Disease"}
{"keywords":["Neoplasm"],"symbol":"GLM1","medgen_id":"C2750850","xrefs":["{\"db\":\"OMIM\",\"id\":\"137800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"301\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Glioma+susceptibility+1/8468\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Glioma susceptibility 1","id":"1926","alternate_symbols":[],"alternate_names":["Glioblastoma, somatic"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SCAR21","medgen_id":"C4225236","xrefs":["{\"db\":\"OMIM\",\"id\":\"616719\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"466794\"}","{\"db\":\"OMIM\",\"id\":\"616719\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHOLESTASIS, LOW GGT, ACUTE LIVER FAILURE, AND NEURODEGENERATION SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"616719\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 21, WITH HEPATOPATHY\"}","{\"db\":\"OMIM\",\"id\":\"616719\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CALFAN\"}","{\"db\":\"OMIM\",\"id\":\"616719\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Spinocerebellar ataxia, autosomal recessive 21","id":"34494","alternate_symbols":["CALFAN"],"alternate_names":["CHOLESTASIS, LOW GGT, ACUTE LIVER FAILURE, AND NEURODEGENERATION SYNDROME","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 21, WITH HEPATOPATHY"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"MCCPD","medgen_id":"C4225189","xrefs":["{\"db\":\"OMIM\",\"id\":\"616834\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"488168\"}","{\"db\":\"OMIM\",\"id\":\"616834\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SC4MOL DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"616834\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Microcephaly, congenital cataract, and psoriasiform dermatitis","id":"34736","alternate_symbols":[],"alternate_names":["SC4MOL DEFICIENCY"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"THMA","medgen_id":"C1864761","xrefs":["{\"db\":\"OMIM\",\"id\":\"609698\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"171706\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thyroid+hormone+metabolism%2C+abnormal/9403\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"609698\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Thyroid hormone metabolism, abnormal","id":"4271","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"NPHS14","medgen_id":"C4540559","xrefs":["{\"db\":\"OMIM\",\"id\":\"617575\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"506334\"}","{\"db\":\"OMIM\",\"id\":\"617575\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Nephrotic syndrome type 14","id":"37939","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0039538","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009792\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009792\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10646\",\"ref_field\":\"name\"}"],"name":"Teratoma","id":"27778","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"MFM7","medgen_id":"C4310711","xrefs":["{\"db\":\"OMIM\",\"id\":\"617114\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"496686\"}","{\"db\":\"OMIM\",\"id\":\"617114\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Myopathy, myofibrillar, 7","id":"36143","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C4331262","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0025171\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"251975\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0025171\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Rosette-forming glioneuronal neoplasm\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0025171\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Rosette-forming glioneuronal tumor of the fourth ventricle\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0025171\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Rosette-forming glioneuronal tumour\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0025171\",\"ref_field\":\"name\"}"],"name":"Rosette-forming glioneuronal tumor","id":"37238","alternate_symbols":[],"alternate_names":["Rosette-forming glioneuronal neoplasm","Rosette-forming glioneuronal tumor of the fourth ventricle","Rosette-forming glioneuronal tumour"],"attribute_content":[],"type":"Finding"}
{"keywords":[],"symbol":"GPIBD15","medgen_id":"C4540520","xrefs":["{\"db\":\"OMIM\",\"id\":\"617810\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"529665\"}","{\"db\":\"OMIM\",\"id\":\"617810\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL DELAY, EPILEPSY, CEREBELLAR ATROPHY, AND OSTEOPENIA\"}","{\"db\":\"OMIM\",\"id\":\"603048.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603048.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603048.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603048.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603048.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603048.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603048.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617810\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617810\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 15","id":"38419","alternate_symbols":[],"alternate_names":["DEVELOPMENTAL DELAY, EPILEPSY, CEREBELLAR ATROPHY, AND OSTEOPENIA"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0024421","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000158\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000203\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"153630\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"156207\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000158\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abnormally large tongue\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000158\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Glossal hypertrophy\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000158\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hyperplasia of the tongue\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000158\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypertrophy of the tongue\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000158\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Increased size of tongue\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000158\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Large tongue\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000158\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Lingual hyperplasia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000158\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Lingual hypertrophy\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000158\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Tongue hypertrophy\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Macroglossia/4396\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3342\",\"ref_field\":\"name\"}"],"name":"Macroglossia","id":"2628","alternate_symbols":[],"alternate_names":["Abnormally large tongue","Glossal hypertrophy","Hyperplasia of the tongue","Hypertrophy of the tongue","Increased size of tongue","Large tongue","Lingual hyperplasia","Lingual hypertrophy","Tongue hypertrophy"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1848916","xrefs":["{\"db\":\"Orphanet\",\"id\":\"309239\"}"],"name":"Tay-Sachs disease, B1 variant","id":"9325","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SPGF16","medgen_id":"C4310674","xrefs":["{\"db\":\"OMIM\",\"id\":\"617187\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"529970\"}","{\"db\":\"OMIM\",\"id\":\"617187\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ACEPHALIC SPERMATOZOA SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"617187\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Spermatogenic failure 16","id":"36307","alternate_symbols":[],"alternate_names":["ACEPHALIC SPERMATOZOA SYNDROME"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"MMYAT","medgen_id":"C4540096","xrefs":["{\"db\":\"OMIM\",\"id\":\"617675\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"502423\"}","{\"db\":\"OMIM\",\"id\":\"617675\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617675\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"MYOPATHY, MITOCHONDRIAL, AND ATAXIA","id":"38131","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"ADHD7","medgen_id":"C2751802","xrefs":["{\"db\":\"OMIM\",\"id\":\"613003\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"607478.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 7\"}","{\"db\":\"OMIM\",\"id\":\"613003\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 7\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"attention-deficit-hyperactivity-disorder\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Attention+deficit-hyperactivity+disorder+7/7752\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"attention-deficit-hyperactivity-disorder\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613003\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Attention deficit-hyperactivity disorder 7","id":"6637","public_definition":"Attention-deficit/hyperactivity disorder (ADHD) is a behavioral disorder that typically begins in childhood and is characterized by a short attention span (inattention), an inability to be calm and stay still (hyperactivity), and poor impulse control (impulsivity). Some people with ADHD have problems with only inattention or with hyperactivity and impulsivity, but most have problems related to all three features.In people with ADHD, the characteristic behaviors are frequent and severe enough to interfere with the activities of daily living such as school, work, and relationships with others. Because of an inability to stay focused on tasks, people with inattention may be easily distracted, forgetful, avoid tasks that require sustained attention, have difficulty organizing tasks, or frequently lose items.Hyperactivity is usually shown by frequent movement. Individuals with this feature often fidget or tap their foot when seated, leave their seat when it is inappropriate to do so (such as in the classroom), or talk a lot and interrupt others.Impulsivity can result in hasty actions without thought for the consequences. Individuals with poor impulse control may have difficulty waiting for their turn, deferring to others, or considering their actions before acting.More than two-thirds of all individuals with ADHD have additional conditions, including insomnia, mood or anxiety disorders, learning disorders, or substance use disorders. Affected individuals may also have autism spectrum disorder, which is characterized by impaired communication and social interaction, or Tourette syndrome, which is a disorder characterized by repetitive and involuntary movements or noises called tics.In most affected individuals, ADHD continues throughout life, but in about one-third of individuals, signs and symptoms of ADHD go away by adulthood.","alternate_symbols":[],"alternate_names":["ATTENTION DEFICIT-HYPERACTIVITY DISORDER, SUSCEPTIBILITY TO, 7"],"attribute_content":[],"type":"Disease","ghr_links":"attention-deficit/hyperactivity disorder"}
{"keywords":[],"symbol":"NDNC3","medgen_id":"C0544855","xrefs":["{\"db\":\"OMIM\",\"id\":\"151600\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"151600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEUKONYCHIA TOTALIS AND/OR PARTIALIS\"}","{\"db\":\"OMIM\",\"id\":\"151600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3\"}","{\"db\":\"OMIM\",\"id\":\"602142.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3\"}","{\"db\":\"OMIM\",\"id\":\"602142.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3\"}","{\"db\":\"OMIM\",\"id\":\"602142.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3\"}","{\"db\":\"OMIM\",\"id\":\"602142.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Leukonychia+totalis/4208\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9759\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"151600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Leukonychia totalis","id":"2685","alternate_symbols":[],"alternate_names":["LEUKONYCHIA TOTALIS AND/OR PARTIALIS","NAIL DISORDER, NONSYNDROMIC CONGENITAL, 3"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"LCCS1","medgen_id":"C1854664","xrefs":["{\"db\":\"OMIM\",\"id\":\"253310\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1486\"}","{\"db\":\"OMIM\",\"id\":\"253310\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LCCS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3227\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LCCS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Lethal+congenital+contracture+syndrome+1/4185\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3227\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"253310\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Lethal congenital contracture syndrome 1","id":"2551","alternate_symbols":["LCCS"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C4510897","xrefs":["{\"db\":\"Orphanet\",\"id\":\"2733\"}","{\"db\":\"Illumina Clinical Services Laboratory,Illumina\",\"id\":\"12476\",\"ref_field\":\"name\"}"],"name":"Omodysplasia","id":"36685","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Finding"}
{"keywords":[],"medgen_id":"C4551488","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000173\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000193\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"192100\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99771\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000193\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Bifid palatine uvula\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000193\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Forked uvula\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000193\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Split uvula\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000193\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Uvula bifida\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000193\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"18910001\",\"ref_field\":\"name\"}"],"name":"Cleft uvula","id":"3940","alternate_symbols":[],"alternate_names":["Bifid palatine uvula","Forked uvula","Split uvula","Uvula bifida","Uvula, bifid"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"DIDOD","medgen_id":"C4693860","xrefs":["{\"db\":\"OMIM\",\"id\":\"617991\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"612870.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612870.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612870.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612870.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612870.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612870.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612870.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617991\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617991\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"DEVELOPMENTAL DELAY, INTELLECTUAL DISABILITY, OBESITY, AND DYSMORPHISM","id":"40064","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1865371","xrefs":["{\"db\":\"Orphanet\",\"id\":\"275\"}"],"name":"Severe combined immunodeficiency, athabascan-type","id":"10090","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SOTOS","medgen_id":"C0175695","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS117550\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"821\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Sotos+syndrome/6665\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Sotos' syndrome\"}","{\"db\":\"SNOMED CT\",\"id\":\"75968004\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Sotos' syndrome\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525320\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SOTOS1\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"sotos-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10091\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"sotos-syndrome\",\"ref_field\":\"public_definition\"}"],"name":"Sotos syndrome","id":"36672","public_definition":"Sotos syndrome is a disorder characterized by a distinctive facial appearance, overgrowth in childhood, and learning disabilities or delayed development of mental and movement abilities. Characteristic facial features include a long, narrow face; a high forehead; flushed (reddened) cheeks; and a small, pointed chin. In addition, the outside corners of the eyes may point downward (down-slanting palpebral fissures). This facial appearance is most notable in early childhood. Affected infants and children tend to grow quickly; they are significantly taller than their siblings and peers and have an unusually large head. However, adult height is usually in the normal range.People with Sotos syndrome often have intellectual disability, and most also have behavioral problems. Frequent behavioral issues include attention-deficit/hyperactivity disorder (ADHD), phobias, obsessions and compulsions, tantrums, and impulsive behaviors. Problems with speech and language are also common. Affected individuals often have a stutter, a monotone voice, and problems with sound production. Additionally, weak muscle tone (hypotonia) may delay other aspects of early development, particularly motor skills such as sitting and crawling.Other signs and symptoms of Sotos syndrome can include an abnormal side-to-side curvature of the spine (scoliosis), seizures, heart or kidney defects, hearing loss, and problems with vision. Some infants with this disorder experience yellowing of the skin and whites of the eyes (jaundice) and poor feeding.A small percentage of people with Sotos syndrome have developed cancer, most often in childhood, but no single form of cancer occurs most frequently with this condition. It remains uncertain whether Sotos syndrome increases the risk of specific types of cancer. If people with this disorder have an increased cancer risk, it is only slightly greater than that of the general population.","alternate_symbols":["SOTOS1"],"alternate_names":["Sotos' syndrome"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"CMT2T","medgen_id":"C4015635","xrefs":["{\"db\":\"OMIM\",\"id\":\"617017\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"443950\"}","{\"db\":\"Orphanet\",\"id\":\"495274\"}","{\"db\":\"Orphanet\",\"id\":\"497757\"}","{\"db\":\"Orphanet\",\"id\":\"497764\"}","{\"db\":\"OMIM\",\"id\":\"617017\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Charcot-Marie-Tooth disease, axonal, type 2T","id":"32742","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"CMT2DD","medgen_id":"C4747974","xrefs":["{\"db\":\"OMIM\",\"id\":\"618036\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"521414\"}","{\"db\":\"OMIM\",\"id\":\"618036\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2DD\"}","{\"db\":\"OMIM\",\"id\":\"182310.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"182310.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"182310.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"182310.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"182310.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618036\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618036\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2DD","id":"40155","alternate_symbols":[],"alternate_names":["CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2DD"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SLSN","medgen_id":"C0403553","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS266900\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"3156\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"322\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Senior-Loken syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Senior+Loken+Syndrome/6501\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"236531005\",\"ref_field\":\"name\"}"],"name":"Renal dysplasia and retinal aplasia","id":"16589","alternate_symbols":["SLSN1"],"alternate_names":["Senior-Loken syndrome"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"MARCH","medgen_id":"C1856053","xrefs":["{\"db\":\"OMIM\",\"id\":\"236500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"500135\"}","{\"db\":\"OMIM\",\"id\":\"236500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hydranencephaly with renal aplasia-dysplasia","id":"2343","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1851936","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002351\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007098\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"1431\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007098\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Choreoathetosis, episodic\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007098\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Choreoathetosis, intermittent\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007098\",\"ref_field\":\"name\"}"],"name":"Paroxysmal choreoathetosis","id":"25997","alternate_symbols":[],"alternate_names":["Choreoathetosis, episodic","Choreoathetosis, intermittent"],"attribute_content":[],"type":"Finding"}
{"keywords":[],"medgen_id":"C0040761","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001669\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"PS608808\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"216694\"}","{\"db\":\"Orphanet\",\"id\":\"216694\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenitally corrected transposition of the great arteries\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001669\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Transposition of great vessels\"}","{\"db\":\"OMIM\",\"id\":\"PS608808 \",\"type\":\"Phenotypic series\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Transposition of the great arteries, dextro-looped\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"critical-congenital-heart-disease\",\"ref_field\":\"public_definition\"}"],"name":"Transposition of the great arteries","id":"17177","public_definition":"Critical congenital heart disease (CCHD) is a term that refers to a group of serious heart defects that are present from birth. These abnormalities result from problems with the formation of one or more parts of the heart during the early stages of embryonic development. CCHD prevents the heart from pumping blood effectively or reduces the amount of oxygen in the blood. As a result, organs and tissues throughout the body do not receive enough oxygen, which can lead to organ damage and life-threatening complications. Individuals with CCHD usually require surgery soon after birth.Although babies with CCHD may appear healthy for the first few hours or days of life, signs and symptoms soon become apparent. These can include an abnormal heart sound during a heartbeat (heart murmur), rapid breathing (tachypnea), low blood pressure (hypotension), low levels of oxygen in the blood (hypoxemia), and a blue or purple tint to the skin caused by a shortage of oxygen (cyanosis). If untreated, CCHD can lead to shock, coma, and death. However, most people with CCHD now survive past infancy due to improvements in early detection, diagnosis, and treatment.Some people with treated CCHD have few related health problems later in life. However, long-term effects of CCHD can include delayed development and reduced stamina during exercise. Adults with these heart defects have an increased risk of abnormal heart rhythms, heart failure, sudden cardiac arrest, stroke, and premature death.Each of the heart defects associated with CCHD affects the flow of blood into, out of, or through the heart. Some of the heart defects involve structures within the heart itself, such as the two lower chambers of the heart (the ventricles) or the valves that control blood flow through the heart. Others affect the structure of the large blood vessels leading into and out of the heart (including the aorta and pulmonary artery). Still others involve a combination of these structural abnormalities.People with CCHD have one or more specific heart defects. The heart defects classified as CCHD include coarctation of the aorta, double-outlet right ventricle, D-transposition of the great arteries, Ebstein anomaly, hypoplastic left heart syndrome, interrupted aortic arch, pulmonary atresia with intact septum, single ventricle, total anomalous pulmonary venous connection, tetralogy of Fallot, tricuspid atresia, and truncus arteriosus.","alternate_symbols":[],"alternate_names":["Congenitally corrected transposition of the great arteries","Transposition of great vessels","Transposition of the great arteries, dextro-looped"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0021670","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012197\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"97279\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012197\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3010\",\"ref_field\":\"name\"}"],"name":"Insulinoma","id":"30081","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"DFNY2","medgen_id":"CN258289","xrefs":["{\"db\":\"OMIM\",\"id\":\"400047\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"400047\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Deafness, Y-linked 2","id":"41584","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"GHDP","medgen_id":"C1858656","xrefs":["{\"db\":\"OMIM\",\"id\":\"604271\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"615925\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"314802\"}","{\"db\":\"Orphanet\",\"id\":\"314811\"}","{\"db\":\"OMIM\",\"id\":\"601898.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"601898.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"601898.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"615925\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"600946.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"600946.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"600946.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"600946.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"600946.0020\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"604271\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GROWTH HORMONE INSENSITIVITY, PARTIAL\"}","{\"db\":\"OMIM\",\"id\":\"604271\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"GHIP\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Short+stature%2C+idiopathic%2C+autosomal/9295\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615925\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Short stature, idiopathic, autosomal","id":"4141","alternate_symbols":["GHIP","SS"],"alternate_names":["GROWTH HORMONE DEFICIENCY, ISOLATED PARTIAL","GROWTH HORMONE INSENSITIVITY, PARTIAL","Short Stature"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"ADSD2","medgen_id":"C4310791","xrefs":["{\"db\":\"OMIM\",\"id\":\"616922\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"494541\"}","{\"db\":\"OMIM\",\"id\":\"616922\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Striatal degeneration, autosomal dominant 2","id":"35317","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"CPEO","medgen_id":"C0162674","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000562\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000590\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"PS157640\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"520820\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000590\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4503\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"46252003\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"progressive-external-ophthalmoplegia\",\"ref_field\":\"public_definition\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4503\",\"ref_field\":\"symbol\"}"],"name":"Progressive external ophthalmoplegia","id":"6479","public_definition":"Progressive external ophthalmoplegia is a condition characterized by weakness of the eye muscles. The condition typically appears in adults between ages 18 and 40 and slowly worsens over time. The first sign of progressive external ophthalmoplegia is typically drooping eyelids (ptosis), which can affect one or both eyelids. As ptosis worsens, affected individuals may use the forehead muscles to try to lift the eyelids, or they may lift up their chin in order to see. Another characteristic feature of progressive external ophthalmoplegia is weakness or paralysis of the muscles that move the eye (ophthalmoplegia). Affected individuals have to turn their head to see in different directions, especially as the ophthalmoplegia worsens. People with progressive external ophthalmoplegia may also have general weakness of the muscles used for movement (myopathy), particularly those in the neck, arms, or legs. The weakness may be especially noticeable during exercise (exercise intolerance). Muscle weakness may also cause difficulty swallowing (dysphagia).When the muscle cells of affected individuals are stained and viewed under a microscope, these cells usually appear abnormal. These abnormal muscle cells contain an excess of cell structures called mitochondria and are known as ragged-red fibers.Although muscle weakness is the primary symptom of progressive external ophthalmoplegia, this condition can be accompanied by other signs and symptoms. In these instances, the condition is referred to as progressive external ophthalmoplegia plus (PEO+). Additional signs and symptoms can include hearing loss caused by nerve damage in the inner ear (sensorineural hearing loss), weakness and loss of sensation in the limbs due to nerve damage (neuropathy), impaired muscle coordination (ataxia), a pattern of movement abnormalities known as parkinsonism, and depression.Progressive external ophthalmoplegia is part of a spectrum of disorders with overlapping signs and symptoms. Similar disorders include ataxia neuropathy spectrum and Kearns-Sayre syndrome. Like progressive external ophthalmoplegia, the other conditions in this spectrum can involve weakness of the eye muscles. However, these conditions have many additional features not shared by most people with progressive external ophthalmoplegia.","alternate_symbols":["PEO"],"alternate_names":["Ophthalmoplegia, Chronic Progressive External"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0544008","xrefs":["{\"db\":\"Orphanet\",\"id\":\"98979\"}","{\"db\":\"OMIM\",\"id\":\"121700\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CHED\"}","{\"db\":\"OMIM\",\"id\":\"PS121700\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}"],"name":"Corneal endothelial dystrophy","id":"34501","alternate_symbols":["CHED"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0206660","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100620\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"182127\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100620\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2005\",\"ref_field\":\"name\"}"],"name":"Germinoma","id":"31394","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0011436","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000703\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"167762\"}","{\"db\":\"Orphanet\",\"id\":\"49042\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000703\",\"ref_field\":\"name\"}"],"name":"Dentinogenesis imperfecta","id":"21860","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Finding"}
{"keywords":[],"symbol":"MCSKS","medgen_id":"C4014540","xrefs":["{\"db\":\"OMIM\",\"id\":\"615877\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"424099\"}","{\"db\":\"OMIM\",\"id\":\"615877\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MICROPHTHALMIA AND/OR COLOBOMA WITH OR WITHOUT RHIZOMELIC SKELETAL DYSPLASIA\"}","{\"db\":\"OMIM\",\"id\":\"615877\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MCOPS14\"}","{\"db\":\"OMIM\",\"id\":\"615877\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Microphthalmia/coloboma and skeletal dysplasia syndrome","id":"21245","alternate_symbols":["MCOPS14"],"alternate_names":["MICROPHTHALMIA AND/OR COLOBOMA WITH OR WITHOUT RHIZOMELIC SKELETAL DYSPLASIA"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"KHRZ","medgen_id":"C2675185","xrefs":["{\"db\":\"OMIM\",\"id\":\"612713\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"168972\"}","{\"db\":\"OMIM\",\"id\":\"612713\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, CATARACT, COLOBOMA, AND KYPHOSIS, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Kahrizi+syndrome/8702\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612713\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Kahrizi syndrome","id":"2503","alternate_symbols":[],"alternate_names":["MENTAL RETARDATION, CATARACT, COLOBOMA, AND KYPHOSIS, AUTOSOMAL RECESSIVE"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SPG18","medgen_id":"C2749936","xrefs":["{\"db\":\"OMIM\",\"id\":\"611225\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"209951\"}","{\"db\":\"Orphanet\",\"id\":\"280384\"}","{\"db\":\"OMIM\",\"id\":\"611225\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INTELLECTUAL DISABILITY, MOTOR DYSFUNCTION, AND JOINT CONTRACTURES\"}","{\"db\":\"OMIM\",\"id\":\"611225\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"611605.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"611605.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"611225\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IDMDC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spastic+paraplegia+18/6684\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4922\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"611225\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4922\",\"ref_field\":\"symbol\"}"],"name":"Spastic paraplegia 18","id":"6839","alternate_symbols":["IDMDC"],"alternate_names":["INTELLECTUAL DISABILITY, MOTOR DYSFUNCTION, AND JOINT CONTRACTURES","SPASTIC PARAPLEGIA 18, AUTOSOMAL RECESSIVE"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"PAP","medgen_id":"C1863340","xrefs":["{\"db\":\"OMIM\",\"id\":\"102200\",\"ref_field\":\"symbol\"}"],"name":"Pituitary adenoma predisposition","id":"8799","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"SWILS","medgen_id":"C1300285","xrefs":["{\"db\":\"OMIM\",\"id\":\"618150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"85172\"}","{\"db\":\"OMIM\",\"id\":\"618150\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MICROCEPHALIC OSTEODYSPLASTIC DYSPLASIA\"}","{\"db\":\"GeneTests\",\"id\":\"320633\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606976.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606976.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618150\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"SAUL-WILSON SYNDROME","id":"40720","alternate_symbols":[],"alternate_names":["MICROCEPHALIC OSTEODYSPLASTIC DYSPLASIA"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"NEDDFL","medgen_id":"C4540327","xrefs":["{\"db\":\"OMIM\",\"id\":\"617755\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"528084\"}","{\"db\":\"OMIM\",\"id\":\"601819.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601819.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601819.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601819.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601819.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617755\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617755\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"NEURODEVELOPMENTAL DISORDER WITH DYSMORPHIC FACIES AND DISTAL LIMB ANOMALIES","id":"38332","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"MRXS35","medgen_id":"C4478383","xrefs":["{\"db\":\"OMIM\",\"id\":\"300998\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"435938\"}","{\"db\":\"Orphanet\",\"id\":\"459070\"}","{\"db\":\"OMIM\",\"id\":\"300998\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300998\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"MENTAL RETARDATION, X-LINKED, SYNDROMIC, 35","id":"37904","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"COXPD29","medgen_id":"C4225200","xrefs":["{\"db\":\"OMIM\",\"id\":\"616811\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"478029\"}","{\"db\":\"OMIM\",\"id\":\"616811\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Combined oxidative phosphorylation deficiency 29","id":"34620","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"ESTRR","medgen_id":"C3809250","xrefs":["{\"db\":\"OMIM\",\"id\":\"615363\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"615363\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ESTROGEN INSENSITIVITY\"}","{\"db\":\"OMIM\",\"id\":\"615363\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Estrogen resistance","id":"12638","alternate_symbols":[],"alternate_names":["ESTROGEN INSENSITIVITY"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"ILLD","medgen_id":"C4225400","xrefs":["{\"db\":\"OMIM\",\"id\":\"615486\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"440427\"}","{\"db\":\"OMIM\",\"id\":\"615486\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PULMONARY ALVEOLAR PROTEINOSIS, REUNION ISLAND\"}","{\"db\":\"OMIM\",\"id\":\"615486\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Interstitial lung and liver disease","id":"18331","alternate_symbols":[],"alternate_names":["PULMONARY ALVEOLAR PROTEINOSIS, REUNION ISLAND"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0026975","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012486\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012486\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Inflammation of spinal cord\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012486\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7130\",\"ref_field\":\"name\"}"],"name":"Myelitis","id":"30366","alternate_symbols":[],"alternate_names":["Inflammation of spinal cord"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1706762","xrefs":["{\"db\":\"Genetics Home Reference\",\"id\":\"aldosterone-producing-adenoma\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"aldosterone-producing-adenoma\",\"ref_field\":\"public_definition\"}"],"name":"Aldosterone Producing Adrenal Cortex Adenoma","id":"32597","public_definition":"An aldosterone-producing adenoma is a noncancerous (benign) tumor that develops in an adrenal gland, which is a small hormone-producing gland located on top of each kidney. In most cases, individuals develop a single tumor in one of the adrenal glands. The adrenal tumor produces too much of the hormone aldosterone, which is a condition known as primary hyperaldosteronism. Aldosterone helps regulate the body's fluid levels and blood pressure by controlling the amount of salt retained by the kidneys. Excess aldosterone causes the kidneys to retain more salt than normal, which increases the body's fluid levels and blood pressure. People with an aldosterone-producing adenoma may develop severe high blood pressure (hypertension), and they have an increased risk of heart attack, stroke, or an irregular heart beat (atrial fibrillation).","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease","ghr_links":"aldosterone-producing adenoma"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301366\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1187\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301384\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1205\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"symbol":"CMT1F","medgen_id":"C1843164","xrefs":["{\"db\":\"OMIM\",\"id\":\"607734\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101085\"}","{\"db\":\"OMIM\",\"id\":\"607734\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1F\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+1F/1289\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Charcot-Marie-Tooth disease, type 1F\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"charcot-marie-tooth-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607734\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Charcot-Marie-Tooth disease, demyelinating, type 1f","id":"881","public_definition":"Charcot-Marie-Tooth disease encompasses a group of disorders called hereditary sensory and motor neuropathies that damage the peripheral nerves. Peripheral nerves connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, heat, and sound. Damage to the peripheral nerves that worsens over time can result in alteration or loss of sensation and wasting (atrophy) of muscles in the feet, legs, and hands.Charcot-Marie-Tooth disease usually becomes apparent in adolescence or early adulthood, but onset may occur anytime from early childhood through late adulthood. Symptoms of Charcot-Marie-Tooth disease vary in severity and age of onset even among members of the same family. Some people never realize they have the disorder because their symptoms are so mild, but most have a moderate amount of physical disability. A small percentage of people experience severe weakness or other problems which, in very rare cases, can be life-threatening. In most affected individuals, however, Charcot-Marie-Tooth disease does not affect life expectancy.Typically, the earliest symptoms of Charcot-Marie-Tooth disease result from muscle atrophy in the feet. Affected individuals may have foot abnormalities such as high arches (pes cavus), flat feet (pes planus), or curled toes (hammer toes). They often have difficulty flexing the foot or walking on the heel of the foot. These difficulties may cause a higher than normal step (steppage gait) and increase the risk of ankle injuries and tripping. As the disease worsens, muscles in the lower legs usually weaken, but leg and foot problems rarely require the use of a wheelchair.Affected individuals may also develop weakness in the hands, causing difficulty with daily activities such as writing, fastening buttons, and turning doorknobs. People with Charcot-Marie-Tooth disease typically experience a decreased sensitivity to touch, heat, and cold in the feet and lower legs, but occasionally feel aching or burning sensations. In rare cases, affected individuals have loss of vision or gradual hearing loss that sometimes leads to deafness.There are several types of Charcot-Marie-Tooth disease, which are differentiated by their effects on nerve cells and patterns of inheritance. Type 1 (CMT1) is characterized by abnormalities in myelin, the fatty substance that covers nerve cells, protecting them and helping to transmit nerve impulses. These abnormalities slow the transmission of nerve impulses and can affect the health of the nerve fiber. Type 2 (CMT2) is characterized by abnormalities in the fiber, or axon, that extends from a nerve cell body to muscles or to sense organs. These abnormalities reduce the strength of the nerve impulse. In forms of Charcot-Marie-Tooth disease classified as intermediate type, the nerve impulses are both slowed and reduced in strength, probably due to abnormalities in both myelin and axons. Type 4 (CMT4) is distinguished from the other types by its pattern of inheritance; it can affect either the axons or the myelin. Type X Charcot-Marie-Tooth disease (CMTX) is caused by mutations in genes on the X chromosome, one of the two sex chromosomes. Within the various types of Charcot-Marie-Tooth disease, subtypes (such as CMT1A, CMT1B, CMT2A, CMT4A, and CMTX1) indicate different genetic causes.Sometimes other, historical names are used to refer to particular forms of Charcot-Marie-Tooth disease. For example, Roussy-Levy syndrome is a form of CMT11 with the additional feature of rhythmic shaking (tremors). Dejerine-Sottas syndrome is a term sometimes used to describe a severe, early childhood form of Charcot-Marie-Tooth disease; it is also sometimes called type 3 (CMT3). Depending on the specific gene that is altered, this severe, early-onset form of the disorder may also be classified as CMT1 or CMT4. CMTX5 is also known as Rosenberg-Chutorian syndrome.","alternate_symbols":[],"alternate_names":["CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1F","Charcot-Marie-Tooth disease, type 1F"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301471\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1294\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301652\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1479\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"symbol":"SOTOS1","medgen_id":"C4551477","xrefs":["{\"db\":\"OMIM\",\"id\":\"117550\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"821\"}","{\"db\":\"OMIM\",\"id\":\"117550\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHROMOSOME 5q35 DELETION SYNDROME\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1479\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"117550\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Sotos syndrome 1","id":"6324","public_definition":"Sotos syndrome is characterized by a distinctive facial appearance (broad and prominent forehead with a dolichocephalic head shape, sparse frontotemporal hair, downslanting palpebral fissures, malar flushing, long and narrow face, long chin); learning disability (early developmental delay, mild-to-severe intellectual impairment); and overgrowth (height and/or head circumference 2 SD above the mean). These three clinical features are considered the cardinal features of Sotos syndrome. Major features of Sotos syndrome include behavioral problems (most notably autistic spectrum disorder), advanced bone age, cardiac anomalies, cranial MRI/CT abnormalities, joint hyperlaxity with or without pes planus, maternal preeclampsia, neonatal complications, renal anomalies, scoliosis, and seizures.","alternate_symbols":["NSD1"],"alternate_names":["CHROMOSOME 5q35 DELETION SYNDROME","Distinctive facial appearance, overgrowth in childhood, and learning disabilities or delayed development"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301607\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1434\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301750\",\"@Source\":\"PubMed\"},{\"$\":\"NBK4144\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"symbol":"WFS1","medgen_id":"C0043207","xrefs":["{\"db\":\"Genetics Home Reference\",\"id\":\"wolfram-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK4144\",\"ref_field\":\"public_definition\"}"],"name":"Wolfram syndrome","id":"18587","public_definition":"WFS1-related disorders range from Wolfram syndrome (WFS) to WFS1-related low-frequency sensory hearing loss (also known as DFNA6/14/38 low-frequency sensorineural hearing loss [LFSNHL]). WFS is a progressive neurodegenerative disorder characterized by onset of diabetes mellitus and optic atrophy before age 16 years, and typically associated with sensorineural hearing loss, progressive neurologic abnormalities (cerebellar ataxia, peripheral neuropathy, dementia, psychiatric illness, and urinary tract atony), and other endocrine abnormalities. Median age at death is 30 years. WFS-like disease is characterized by sensorineural hearing loss, diabetes mellitus, psychiatric illness, and variable optic atrophy. WFS1-related LFSNHL is characterized by congenital, nonsyndromic, slowly progressive, low-frequency (\u003c2000 Hz) sensorineural hearing loss.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301728\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1828\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301730\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1875\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"symbol":"ML3","medgen_id":"C0033788","xrefs":["{\"db\":\"OMIM\",\"id\":\"252600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"423461\"}","{\"db\":\"Orphanet\",\"id\":\"577\"}","{\"db\":\"OMIM\",\"id\":\"252600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ML III\"}","{\"db\":\"OMIM\",\"id\":\"252600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ML III ALPHA/BETA\"}","{\"db\":\"OMIM\",\"id\":\"252600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ML IIIA\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1875\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mucolipidosis III Alpha/Beta\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mucolipidosis+type+3A/4909\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3806\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"65764006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1875\",\"ref_field\":\"public_definition\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3806\",\"ref_field\":\"symbol\"}"],"name":"Pseudo-Hurler polydystrophy","id":"3039","public_definition":"Mucolipidosis alpha/beta (ML III alpha/beta; pseudo-Hurler polydystrophy), a slowly progressive disorder with clinical onset at approximately age three years, is characterized by slow growth rate and subnormal stature; radiographic evidence of mild to moderate dysostosis multiplex; joint stiffness and pain initially in the shoulders, hips, and fingers; gradual mild coarsening of facial features; and normal to mildly impaired cognitive development. If present, organomegaly is mild. Pain from osteoporosis that is clinically and radiologically apparent in childhood becomes more severe from adolescence. Cardiorespiratory complications (restrictive lung disease, thickening and insufficiency of the mitral and aortic valves, left and/or right ventricular hypertrophy) are common causes of death, typically in early to middle adulthood.","alternate_symbols":[],"alternate_names":["ML III","ML III ALPHA/BETA","ML IIIA","Mucolipidosis III Alpha/Beta","Type III Mucolipidosis"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"28796472\",\"@Source\":\"PubMed\"},{\"$\":\"NBK447258\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"symbol":"PARK17","medgen_id":"C3280133","xrefs":["{\"db\":\"OMIM\",\"id\":\"614203\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"411602\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+17/9084\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK447258\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614203\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Parkinson disease 17","id":"16525","public_definition":"VPS35-related Parkinson disease (VPS35-PD) is defined as Parkinson disease caused by heterozygous VPS35 pathogenic variants. Currently, the only known VPS35 variant with confirmed pathogenicity is c.1858G\u003eA (p.Asp620Asn). Except for a younger age of onset, VPS35-PD is clinically indistinguishable from Parkinson disease of unknown cause (so-called sporadic Parkinson disease). Variability among 50 individuals reported with molecularly confirmed VPS35-PD includes age of onset (mean: 51.08.7 years; range: 34-68 years), Parkinson subtype (tremor, akinetic rigid, mixed), first motor symptom, course of the disease (unilateral onset and slow disease progression are typical; dyskinesia and motor fluctuations may occur), and presence/absence of neuropsychiatric manifestations (including depression, schizophrenia, learning difficulties, mild cognitive impairment, and dementia).","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301582\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1408\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23193613\",\"@Source\":\"PubMed\"},{\"$\":\"NBK114459\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"symbol":"MMD3","medgen_id":"C2750076","xrefs":["{\"db\":\"OMIM\",\"id\":\"613319\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"399096\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Miyoshi+muscular+dystrophy+3/8905\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK114459\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613319\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Miyoshi muscular dystrophy 3","id":"6803","public_definition":"The spectrum of ANO5 muscle disease is a continuum that ranges from asymptomatic hyperCKemia and exercise-induced myalgia to proximal and/or distal muscle weakness. The most typical presentation is limb-girdle muscular dystrophy type 2L (LGMD2L) with late-onset proximal lower-limb weakness in the fourth or fifth decade (range 15-70 years). Less common is Miyoshi-like disease (Miyoshi muscular dystrophy 3) with early-adult-onset calf distal myopathy (around age 20 years). Incidental hyperCKemia may be present even earlier. Initial symptoms are walking difficulties, reduced sports performance, and difficulties in standing on toes as well as nonspecific exercise myalgia and/or burning sensation in the calf muscles. Muscle weakness and atrophy are frequently asymmetric. Cardiac findings can include cardiomyopathy and arrhythmias and/or left ventricular dysfunction. Bulbar or respiratory symptoms have not been reported. Females have milder disease manifestations than males. Disease progression is slow in both the LGMD and distal forms; ambulation is preserved until very late in the disease course. Life span is normal.","alternate_symbols":[],"alternate_names":["Miyoshi myopathy 3"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27929632\",\"@Source\":\"PubMed\"},{\"$\":\"NBK401562\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29792621\",\"@Source\":\"PubMed\"},{\"$\":\"NBK500456\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"symbol":"RCAD","medgen_id":"C0431693","xrefs":["{\"db\":\"OMIM\",\"id\":\"137920\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93111\"}","{\"db\":\"OMIM\",\"id\":\"137920\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MODY5\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10221\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MODY5\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Maturity-onset+diabetes+of+the+young%2C+type+5/4510\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"253864004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK401562\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"137920\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10221\",\"ref_field\":\"symbol\"}"],"name":"Familial hypoplastic, glomerulocystic kidney","id":"4321","public_definition":"The 17q12 recurrent deletion syndrome is characterized by variable combinations of the three following findings: structural or functional abnormalities of the kidney and urinary tract, maturity-onset diabetes of the young type 5 (MODY5), and neurodevelopmental or neuropsychiatric disorders (e.g., developmental delay, intellectual disability, autism spectrum disorder, schizophrenia, anxiety, and bipolar disorder). Using a method of data analysis that avoids ascertainment bias, the authors determined that multicystic kidneys and other structural renal anomalies occur in 80% to 85% of affected individuals, MODY5 in approximately 40%, and some degree of developmental delay or learning disability in approximately 50%. MODY5 is most often diagnosed before age 25 years (range: age 10-50 years).","alternate_symbols":["MODY5"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301434\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1257\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Brandi et al., 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11739416\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ATA, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19469690\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21863057\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Int'l RET Mutation Consortium, 1996\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"8918855\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ES, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24893135\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NANETS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3419007\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","keywords":["Hereditary cancer syndrome","Neoplasm"],"symbol":"MEN2B","medgen_id":"C0025269","xrefs":["{\"db\":\"MeSH\",\"id\":\"D018814\"}","{\"db\":\"OMIM\",\"id\":\"162300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"247709\"}","{\"db\":\"Orphanet\",\"id\":\"653\"}","{\"db\":\"OMIM\",\"id\":\"162300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MEN IIB\"}","{\"db\":\"OMIM\",\"id\":\"162300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB\"}","{\"db\":\"OMIM\",\"id\":\"164761.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB\"}","{\"db\":\"OMIM\",\"id\":\"164761.0043\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB\"}","{\"db\":\"OMIM\",\"id\":\"162300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE III\"}","{\"db\":\"SNOMED CT\",\"id\":\"61530001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Multiple endocrine neoplasia, type 3\"}","{\"db\":\"OMIM\",\"id\":\"162300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS\"}","{\"db\":\"OMIM\",\"id\":\"162300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MEN3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Multiple+endocrine+neoplasia%2C+type+2B/4958\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"6153000\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1257\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"162300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Multiple endocrine neoplasia, type 2b","id":"3226","public_definition":"Multiple endocrine neoplasia type 2 (MEN 2) includes the following phenotypes: MEN 2A, FMTC (familial medullary thyroid carcinoma, which may be a variant of MEN 2A), and MEN 2B. All three phenotypes involve high risk for development of medullary carcinoma of the thyroid (MTC); MEN 2A and MEN 2B involve an increased risk for pheochromocytoma; MEN 2A involves an increased risk for parathyroid adenoma or hyperplasia. Additional features in MEN 2B include mucosal neuromas of the lips and tongue, distinctive facies with enlarged lips, ganglioneuromatosis of the gastrointestinal tract, and a marfanoid habitus. MTC typically occurs in early childhood in MEN 2B, early adulthood in MEN 2A, and middle age in FMTC.","alternate_symbols":["MEN3","RET"],"alternate_names":["MEN IIB","MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB","MULTIPLE ENDOCRINE NEOPLASIA, TYPE III","Multiple endocrine neoplasia, type 3","NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301434\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1257\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Brandi et al., 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11739416\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ATA, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19469690\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21863057\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Int'l RET Mutation Consortium, 1996\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"8918855\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NANETS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3419007\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","keywords":["Neoplasm"],"symbol":"MTC","medgen_id":"C1833921","xrefs":["{\"db\":\"OMIM\",\"id\":\"155240\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"653\"}","{\"db\":\"Orphanet\",\"id\":\"99361\"}","{\"db\":\"OMIM\",\"id\":\"155240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FMTC\"}","{\"db\":\"OMIM\",\"id\":\"155240\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MTC1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thyroid+cancer%2C+familial+medullary/7104\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9427\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1257\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"155240\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Familial medullary thyroid carcinoma","id":"4268","public_definition":"Multiple endocrine neoplasia type 2 (MEN 2) includes the following phenotypes: MEN 2A, FMTC (familial medullary thyroid carcinoma, which may be a variant of MEN 2A), and MEN 2B. All three phenotypes involve high risk for development of medullary carcinoma of the thyroid (MTC); MEN 2A and MEN 2B involve an increased risk for pheochromocytoma; MEN 2A involves an increased risk for parathyroid adenoma or hyperplasia. Additional features in MEN 2B include mucosal neuromas of the lips and tongue, distinctive facies with enlarged lips, ganglioneuromatosis of the gastrointestinal tract, and a marfanoid habitus. MTC typically occurs in early childhood in MEN 2B, early adulthood in MEN 2A, and middle age in FMTC.","alternate_symbols":["FMTC","MTC1"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301703\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1531\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110944\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24651602\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"WS1","medgen_id":"C1847800","xrefs":["{\"db\":\"OMIM\",\"id\":\"193500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"894\"}","{\"db\":\"OMIM\",\"id\":\"193500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"WAARDENBURG SYNDROME WITH DYSTOPIA CANTHORUM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Waardenburg+syndrome+type+1/7424\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5519\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1531\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"193500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5519\",\"ref_field\":\"symbol\"}"],"name":"Waardenburg syndrome type 1","id":"4496","public_definition":"Waardenburg syndrome type I (WS1) is an auditory-pigmentary disorder comprising congenital sensorineural hearing loss and pigmentary disturbances of the iris, hair, and skin, along with dystopia canthorum (lateral displacement of the inner canthi). The hearing loss in WS1, observed in approximately 60% of affected individuals, is congenital, typically non-progressive, either unilateral or bilateral, and sensorineural. Most commonly, hearing loss in WS1 is bilateral and profound (\u003e100 dB). The majority of individuals with WS1 have either a white forelock or early graying of the scalp hair before age 30 years. The classic white forelock observed in approximately 45% of individuals is the most common hair pigmentation anomaly seen in WS1. Affected individuals may have complete heterochromia iridium, partial/segmental heterochromia, or hypoplastic or brilliant blue irides. Congenital leukoderma is frequently seen on the face, trunk, or limbs.","alternate_symbols":["PAX3"],"alternate_names":["WAARDENBURG SYNDROME WITH DYSTOPIA CANTHORUM"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301541\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1367\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"NEJM, 2009\",\"@Type\":\"review\",\"ID\":{\"$\":\"19846853\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Brit Cmt Stand Hematol/BTS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19821824\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"AHUS3","medgen_id":"C2752039","xrefs":["{\"db\":\"OMIM\",\"id\":\"612923\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2134\"}","{\"db\":\"Orphanet\",\"id\":\"93580\"}","{\"db\":\"OMIM\",\"id\":\"612923\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AHUS, SUSCEPTIBILITY TO, 3\"}","{\"db\":\"OMIM\",\"id\":\"217030.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3\"}","{\"db\":\"OMIM\",\"id\":\"217030.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3\"}","{\"db\":\"OMIM\",\"id\":\"217030.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3\"}","{\"db\":\"OMIM\",\"id\":\"217030.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3\"}","{\"db\":\"OMIM\",\"id\":\"217030.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3\"}","{\"db\":\"OMIM\",\"id\":\"217030.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3\"}","{\"db\":\"OMIM\",\"id\":\"612923\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Atypical+hemolytic-uremic+syndrome+3/7755\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1367\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612923\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Atypical hemolytic-uremic syndrome 3","id":"6747","public_definition":"Hemolytic-uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs. The onset of atypical HUS (aHUS) ranges from the neonatal period to adulthood. Genetic aHUS accounts for an estimated 60% of all aHUS. Individuals with genetic aHUS frequently experience relapse even after complete recovery following the presenting episode; 60% of genetic aHUS progresses to end-stage renal disease (ESRD).","alternate_symbols":[],"alternate_names":["AHUS, SUSCEPTIBILITY TO, 3","HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301690\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1517\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"AHRQ, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"NBK248310\",\"@Source\":\"BookShelf\"}},{\"@Abbrev\":\"HRS/EHRA/APHRS, 2013\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"23994779\",\"@Source\":\"PubMed\"}}]}","keywords":[],"medgen_id":"C1142166","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS601144\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"130\"}","{\"db\":\"MeSH\",\"id\":\"D053840\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Sudden Unexplained Death Syndrome\"}","{\"db\":\"MeSH\",\"id\":\"D053840\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Sudden Unexplained Nocturnal Death Syndrome (SUNDS)\"}","{\"db\":\"OMIM\",\"id\":\"601144\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SUNDS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Brugada+Syndrome/982\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"brugada-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1030\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"418818005\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1517\",\"ref_field\":\"public_definition\"}"],"name":"Brugada syndrome","id":"16748","public_definition":"Brugada syndrome is characterized by cardiac conduction abnormalities (ST-segment abnormalities in leads V1-V3 on ECG and a high risk for ventricular arrhythmias) that can result in sudden death. Brugada syndrome presents primarily during adulthood although age at diagnosis may range from infancy to late adulthood. The mean age of sudden death is approximately 40 years. Clinical presentations may also include sudden infant death syndrome (SIDS; death of a child during the first year of life without an identifiable cause) and the sudden unexpected nocturnal death syndrome (SUNDS), a typical presentation in individuals from Southeast Asia. Other conduction defects can include first-degree AV block, intraventricular conduction delay, right bundle branch block, and sick sinus syndrome.","alternate_symbols":["BrS","SUNDS"],"alternate_names":["Sudden Unexplained Death Syndrome","Sudden Unexplained Nocturnal Death Syndrome (SUNDS)","Sudden unexplained nocturnal death syndrome"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301578\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1404\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21654722\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"UKHCDO, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23157203\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"HEMA","medgen_id":"C0019069","xrefs":["{\"db\":\"OMIM\",\"id\":\"306700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"169805\"}","{\"db\":\"Orphanet\",\"id\":\"177926\"}","{\"db\":\"Orphanet\",\"id\":\"98878\"}","{\"db\":\"OMIM\",\"id\":\"300841.0067\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOPHILIA A, SEVERE\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1404\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hemophilia A\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+factor+VIII+deficiency+disease/8517\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"28293008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1404\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"306700\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hereditary factor VIII deficiency disease","id":"2126","public_definition":"Hemophilia A is characterized by deficiency in factor VIII clotting activity that results in prolonged oozing after injuries, tooth extractions, or surgery, and delayed or recurrent bleeding prior to complete wound healing. The age of diagnosis and frequency of bleeding episodes are related to the level of factor VIII clotting activity. Individuals with severe hemophilia A are usually diagnosed during the first two years of life following bleeding from minor mouth injuries and large \"goose eggs\" from minor head bumps. Without prophylactic treatment, they may average up to two to five spontaneous bleeding episodes each month including spontaneous joint bleeds or deep-muscle hematomas, and prolonged bleeding or excessive pain and swelling from minor injuries, surgery, and tooth extractions. Individuals with moderate hemophilia A seldom have spontaneous bleeding; however, they do have prolonged or delayed oozing after relatively minor trauma and are usually diagnosed before age five to six years; the frequency of bleeding episodes varies, usually from once a month to once a year. Individuals with mild hemophilia A do not have spontaneous bleeding episodes; however, without pre- and postoperative treatment, abnormal bleeding occurs with surgery or tooth extractions; the frequency of bleeding episodes varies widely, typically from once a year to once every ten years. Individuals with mild hemophilia A are often not diagnosed until later in life. Approximately 30% of heterozygous females have clotting activity below 40% and are at risk for bleeding (even if the affected family member is mildly affected). After major trauma or invasive procedures, prolonged or excessive bleeding usually occurs, regardless of severity.","alternate_symbols":[],"alternate_names":["HEMOPHILIA A, SEVERE","Hemophilia A"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301691\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1518\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"CDC, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22475884\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25473725\",\"@Source\":\"PubMed\"},{\"$\":\"NBK258640\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG ACT Sheets, 2001\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"American College of Medical Genetics ACT SHEETs, Newborn Screening ACT Sheets and Confirmatory Algorithms\"},\"URL\":{\"$\":\"https://www.ncbi.nlm.nih.gov/books/NBK55827\"}}]}","keywords":[],"medgen_id":"C0268151","xrefs":["{\"db\":\"OMIM\",\"id\":\"230400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"352\"}","{\"db\":\"Orphanet\",\"id\":\"79239\"}","{\"db\":\"OMIM\",\"id\":\"230400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE DEFICIENCY\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2424\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GALT deficiency\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2424\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Galactosemia, classic\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Deficiency+of+UTP-hexose-1-phosphate+uridylyltransferase/8206\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"124354006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1518\",\"ref_field\":\"public_definition\"}"],"name":"Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase","id":"5173","public_definition":"The term \"galactosemia\" refers to disorders of galactose metabolism that include classic galactosemia, clinical variant galactosemia, and biochemical variant galactosemia. This GeneReview focuses on: Classic galactosemia, which can result in life-threatening complications including feeding problems, failure to thrive, hepatocellular damage, bleeding, and E. coli sepsis in untreated infants. If a lactose-restricted diet is provided during the first ten days of life, the neonatal signs usually quickly resolve and the complications of liver failure, sepsis, and neonatal death are prevented; however, despite adequate treatment from an early age, children with classic galactosemia remain at increased risk for developmental delays, speech problems (termed childhood apraxia of speech and dysarthria), and abnormalities of motor function. Almost all females with classic galactosemia manifest premature ovarian insufficiency (POI). Clinical variant galactosemia, which can result in life-threatening complications including feeding problems, failure to thrive, hepatocellular damage including cirrhosis, and bleeding in untreated infants. This is exemplified by the disease that occurs in African Americans and native Africans in South Africa. Persons with clinical variant galactosemia may be missed with newborn screening (NBS) as the hypergalactosemia is not as marked as in classic galactosemia and breath testing is normal. If a lactose-restricted diet is provided during the first ten days of life, the severe acute neonatal complications are usually prevented. African Americans with clinical variant galactosemia and adequate early treatment do not appear to be at risk for long-term complications including POI.","alternate_symbols":[],"alternate_names":["GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE DEFICIENCY","GALT deficiency","Galactosemia, classic","Transferase Deficiency Galactosemia"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301536\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1362\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301317\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1138\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20050888\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"SCA15","medgen_id":"C1847725","xrefs":["{\"db\":\"OMIM\",\"id\":\"606658\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98770\"}","{\"db\":\"OMIM\",\"id\":\"606658\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINOCEREBELLAR ATAXIA 16\"}","{\"db\":\"OMIM\",\"id\":\"606658\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SCA16\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spinocerebellar+ataxia+15/6749\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10477\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1362\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"606658\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10477\",\"ref_field\":\"symbol\"}"],"name":"Spinocerebellar ataxia 15","id":"5955","public_definition":"Spinocerebellar ataxia type 15 (SCA15) is characterized by slowly progressive gait and limb ataxia, often in combination with ataxic dysarthria, titubation, upper limb postural tremor, mild hyperreflexia, gaze-evoked nystagmus, and impaired vestibuloocular reflex gain. Onset is between ages seven and 72 years, usually with gait ataxia but sometimes with tremor. Affected individuals remain ambulatory for ten to 54 years after symptom onset. Mild dysphagia usually after two or more decades of symptoms has been observed in members of multiple affected families and movement-induced oscillopsia has been described in one member of an affected family.","alternate_symbols":["SCA16"],"alternate_names":["SPINOCEREBELLAR ATAXIA 16","Spinocerebellar Ataxia Type15"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301479\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1302\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22237449\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31021589\",\"@Source\":\"PubMed\"},{\"$\":\"NBK540447\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"symbol":"STL1","medgen_id":"C2020284","xrefs":["{\"db\":\"OMIM\",\"id\":\"108300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"828\"}","{\"db\":\"Orphanet\",\"id\":\"90653\"}","{\"db\":\"OMIM\",\"id\":\"108300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AOM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5018\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AOM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Stickler+syndrome+type+1/6878\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5018\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1302\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"108300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5018\",\"ref_field\":\"symbol\"}"],"name":"Stickler syndrome type 1","id":"3852","public_definition":"Stickler syndrome is a connective tissue disorder that can include ocular findings of myopia, cataract, and retinal detachment; hearing loss that is both conductive and sensorineural; midfacial underdevelopment and cleft palate (either alone or as part of the Robin sequence); and mild spondyloepiphyseal dysplasia and/or precocious arthritis. Variable phenotypic expression of Stickler syndrome occurs both within and among families; interfamilial variability is in part explained by locus and allelic heterogeneity.","alternate_symbols":["AOM","COL11A1"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"ACOG, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20027064\",\"@Source\":\"PubMed\"}}}","keywords":[],"symbol":"AT3D","medgen_id":"C0272375","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001976\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"613118\",\"type\":\"MIM\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001976\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Anti-thrombin III deficiency\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Antithrombin+III+Deficiency/526\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Antithrombin III deficiency\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001976\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Antithrombin III deficiency\"}","{\"db\":\"SNOMED CT\",\"id\":\"36351005\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Antithrombin III deficiency\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001976\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Decreased antithrombin III\"}","{\"db\":\"OMIM\",\"id\":\"613118\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"THPH7\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001976\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613118\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Reduced antithrombin III activity","id":"6634","alternate_symbols":["THPH7"],"alternate_names":["Anti-thrombin III deficiency","Antithrombin III deficiency","Decreased antithrombin III","Thrombophilia due to antithrombin III deficiency"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}}}","keywords":[],"medgen_id":"C0027809","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100008\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"252164\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100008\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neurilemmoma\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100008\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neurinoma\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100008\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neurolemmoma\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100008\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Schwann cell tumor\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100008\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Schwann cell tumour\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100008\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Schwannomas\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Schwannoma/6451\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100008\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4767\",\"ref_field\":\"name\"}"],"name":"Schwannoma","id":"6289","alternate_symbols":[],"alternate_names":["Neurilemmoma","Neurinoma","Neurolemmoma","Schwann cell tumor","Schwann cell tumour","Schwannomas"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301366\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1187\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301462\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1285\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}}]}","keywords":[],"symbol":"CMT2E","medgen_id":"C1843225","xrefs":["{\"db\":\"OMIM\",\"id\":\"607684\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99939\"}","{\"db\":\"OMIM\",\"id\":\"607684\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2E\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+2E/1296\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9193\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"charcot-marie-tooth-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607684\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Charcot-Marie-Tooth disease type 2E","id":"4779","public_definition":"Charcot-Marie-Tooth disease encompasses a group of disorders called hereditary sensory and motor neuropathies that damage the peripheral nerves. Peripheral nerves connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, heat, and sound. Damage to the peripheral nerves that worsens over time can result in alteration or loss of sensation and wasting (atrophy) of muscles in the feet, legs, and hands.Charcot-Marie-Tooth disease usually becomes apparent in adolescence or early adulthood, but onset may occur anytime from early childhood through late adulthood. Symptoms of Charcot-Marie-Tooth disease vary in severity and age of onset even among members of the same family. Some people never realize they have the disorder because their symptoms are so mild, but most have a moderate amount of physical disability. A small percentage of people experience severe weakness or other problems which, in very rare cases, can be life-threatening. In most affected individuals, however, Charcot-Marie-Tooth disease does not affect life expectancy.Typically, the earliest symptoms of Charcot-Marie-Tooth disease result from muscle atrophy in the feet. Affected individuals may have foot abnormalities such as high arches (pes cavus), flat feet (pes planus), or curled toes (hammer toes). They often have difficulty flexing the foot or walking on the heel of the foot. These difficulties may cause a higher than normal step (steppage gait) and increase the risk of ankle injuries and tripping. As the disease worsens, muscles in the lower legs usually weaken, but leg and foot problems rarely require the use of a wheelchair.Affected individuals may also develop weakness in the hands, causing difficulty with daily activities such as writing, fastening buttons, and turning doorknobs. People with Charcot-Marie-Tooth disease typically experience a decreased sensitivity to touch, heat, and cold in the feet and lower legs, but occasionally feel aching or burning sensations. In rare cases, affected individuals have loss of vision or gradual hearing loss that sometimes leads to deafness.There are several types of Charcot-Marie-Tooth disease, which are differentiated by their effects on nerve cells and patterns of inheritance. Type 1 (CMT1) is characterized by abnormalities in myelin, the fatty substance that covers nerve cells, protecting them and helping to transmit nerve impulses. These abnormalities slow the transmission of nerve impulses and can affect the health of the nerve fiber. Type 2 (CMT2) is characterized by abnormalities in the fiber, or axon, that extends from a nerve cell body to muscles or to sense organs. These abnormalities reduce the strength of the nerve impulse. In forms of Charcot-Marie-Tooth disease classified as intermediate type, the nerve impulses are both slowed and reduced in strength, probably due to abnormalities in both myelin and axons. Type 4 (CMT4) is distinguished from the other types by its pattern of inheritance; it can affect either the axons or the myelin. Type X Charcot-Marie-Tooth disease (CMTX) is caused by mutations in genes on the X chromosome, one of the two sex chromosomes. Within the various types of Charcot-Marie-Tooth disease, subtypes (such as CMT1A, CMT1B, CMT2A, CMT4A, and CMTX1) indicate different genetic causes.Sometimes other, historical names are used to refer to particular forms of Charcot-Marie-Tooth disease. For example, Roussy-Levy syndrome is a form of CMT11 with the additional feature of rhythmic shaking (tremors). Dejerine-Sottas syndrome is a term sometimes used to describe a severe, early childhood form of Charcot-Marie-Tooth disease; it is also sometimes called type 3 (CMT3). Depending on the specific gene that is altered, this severe, early-onset form of the disorder may also be classified as CMT1 or CMT4. CMTX5 is also known as Rosenberg-Chutorian syndrome.","alternate_symbols":[],"alternate_names":["CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2E","Charcot-Marie-Tooth Neuropathy Type 2"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301284\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1105\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"SCAN1","medgen_id":"C1846574","xrefs":["{\"db\":\"OMIM\",\"id\":\"607250\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"607250\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, WITH AXONAL NEUROPATHY 1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spinocerebellar+ataxia+autosomal+recessive+with+axonal+neuropathy/6776\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10000\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607250\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10000\",\"ref_field\":\"symbol\"}"],"name":"Spinocerebellar ataxia autosomal recessive with axonal neuropathy","id":"5961","alternate_symbols":[],"alternate_names":["SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE, WITH AXONAL NEUROPATHY 1"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301293\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1114\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"WMS1","medgen_id":"C4552002","xrefs":["{\"db\":\"OMIM\",\"id\":\"277600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3449\"}","{\"db\":\"OMIM\",\"id\":\"277600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL\"}","{\"db\":\"OMIM\",\"id\":\"277600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPHEROPHAKIA-BRACHYMORPHIA SYNDROME\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Weill-Marchesani+syndrome+1/9472\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1114\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"277600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Weill-Marchesani syndrome 1","id":"5119","public_definition":"Weill-Marchesani syndrome (WMS) is a connective tissue disorder characterized by abnormalities of the lens of the eye, proportionate short stature, brachydactyly, and joint stiffness. The ocular problems, typically recognized in childhood, include microspherophakia (small spherical lens), myopia secondary to the abnormal shape of the lens, ectopia lentis (abnormal position of the lens), and glaucoma, which can lead to blindness. Height of adult males is 142-169 cm; height of adult females is 130-157 cm. Autosomal recessive and autosomal dominant WMS cannot be distinguished by clinical findings alone.","alternate_symbols":[],"alternate_names":["MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL","SPHEROPHAKIA-BRACHYMORPHIA SYNDROME","Weill-Marchesani Syndrome, Autosomal Recessive","Weill-Marchesani syndrome 1, recessive"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301303\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1124\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"NS10","medgen_id":"C4225280","xrefs":["{\"db\":\"OMIM\",\"id\":\"616564\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"648\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1124\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616564\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Noonan syndrome 10","id":"34307","public_definition":"Noonan syndrome (NS) is characterized by characteristic facies, short stature, congenital heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, varied coagulation defects, lymphatic dysplasias, and ocular abnormalities. Although birth length is usually normal, final adult height approaches the lower limit of normal. Congenital heart disease occurs in 50%-80% of individuals. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or develop in infancy or childhood. Other structural defects include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Up to one fourth of affected individuals have mild intellectual disability, and language impairments in general are more common in NS than in the general population.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C1970119","xrefs":["{\"db\":\"OMIM\",\"id\":\"600919\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"OMIM\",\"id\":\"600919\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANKYRIN-B SYNDROME\"}","{\"db\":\"Genetic Alliance\",\"id\":\"CARDIAC+ARRHYTHMIA%2C+ANKYRIN-B-RELATED/7891\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}"],"name":"Cardiac arrhythmia, ankyrin B-related","id":"4726","public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","alternate_symbols":[],"alternate_names":["ANKYRIN-B SYNDROME"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"LQT14","medgen_id":"C4015671","xrefs":["{\"db\":\"OMIM\",\"id\":\"616247\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616247\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Long QT syndrome 14","id":"32764","public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"LQT12","medgen_id":"C2751830","xrefs":["{\"db\":\"OMIM\",\"id\":\"612955\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Long+QT+syndrome+12/8765\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612955\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Long QT syndrome 12","id":"6779","public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"LQT15","medgen_id":"C4015695","xrefs":["{\"db\":\"OMIM\",\"id\":\"616249\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616249\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Long QT syndrome 15","id":"32765","public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301369\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1190\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"DURS2","medgen_id":"C0751083","xrefs":["{\"db\":\"OMIM\",\"id\":\"604356\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"233\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Duane+Retraction+Syndrome+2/2335\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9966\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1190\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"604356\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9966\",\"ref_field\":\"symbol\"}"],"name":"Duane syndrome type 2","id":"1988","public_definition":"Duane syndrome is a strabismus condition clinically characterized by congenital non-progressive limited horizontal eye movement accompanied by globe retraction which results in narrowing of the palpebral fissure. The lateral movement anomaly results from failure of the abducens nucleus and nerve (cranial nerve VI) to fully innervate the lateral rectus muscle; globe retraction occurs as a result of abnormal innervation of the lateral rectus muscle by the oculomotor nerve (cranial nerve III). At birth, affected infants have restricted ability to move the affected eye(s) outward (abduction) and/or inward (adduction), though the limitations may not be recognized in early infancy. In addition, the globe retracts into the orbit with attempted adduction, accompanied by narrowing of the palpebral fissure. Many individuals with Duane syndrome have strabismus in primary gaze but can use a compensatory head turn to align the eyes, and thus can preserve binocular vision and avoid diplopia. Individuals with Duane syndrome who lack binocular vision are at risk for amblyopia. The majority of affected individuals with Duane syndrome have isolated Duane syndrome (i.e., they do not have other detected congenital anomalies). Other individuals with Duane syndrome fall into well-defined syndromic diagnoses. However, many individuals with Duane syndrome have non-ocular findings that do not fit a known syndrome; these individuals are included as part of the discussion of nonsyndromic Duane syndrome.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301369\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1190\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"DURS1","medgen_id":"C0994516","xrefs":["{\"db\":\"Gene\",\"id\":\"10674\"}","{\"db\":\"OMIM\",\"id\":\"126800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"233\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Duane+Retraction+Syndrome+1/2334\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10763\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1190\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"126800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10763\",\"ref_field\":\"symbol\"}"],"name":"Duane syndrome type 1","id":"1501","public_definition":"Duane syndrome is a strabismus condition clinically characterized by congenital non-progressive limited horizontal eye movement accompanied by globe retraction which results in narrowing of the palpebral fissure. The lateral movement anomaly results from failure of the abducens nucleus and nerve (cranial nerve VI) to fully innervate the lateral rectus muscle; globe retraction occurs as a result of abnormal innervation of the lateral rectus muscle by the oculomotor nerve (cranial nerve III). At birth, affected infants have restricted ability to move the affected eye(s) outward (abduction) and/or inward (adduction), though the limitations may not be recognized in early infancy. In addition, the globe retracts into the orbit with attempted adduction, accompanied by narrowing of the palpebral fissure. Many individuals with Duane syndrome have strabismus in primary gaze but can use a compensatory head turn to align the eyes, and thus can preserve binocular vision and avoid diplopia. Individuals with Duane syndrome who lack binocular vision are at risk for amblyopia. The majority of affected individuals with Duane syndrome have isolated Duane syndrome (i.e., they do not have other detected congenital anomalies). Other individuals with Duane syndrome fall into well-defined syndromic diagnoses. However, many individuals with Duane syndrome have non-ocular findings that do not fit a known syndrome; these individuals are included as part of the discussion of nonsyndromic Duane syndrome.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301369\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1190\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"DRS","medgen_id":"C0013261","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS126800\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"233\"}","{\"db\":\"OMIM\",\"id\":\"PS126800 \",\"type\":\"Phenotypic series\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Duane retraction syndrome\"}","{\"db\":\"Orphanet\",\"id\":\"233\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Duane retraction syndrome\"}","{\"db\":\"OMIM\",\"id\":\"126800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RETRACTION SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"126800\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DUS\"}","{\"db\":\"SNOMED CT\",\"id\":\"60318001\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1190\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"126800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6288\",\"ref_field\":\"symbol\"}"],"name":"Duane's syndrome","id":"15951","public_definition":"Duane syndrome is a strabismus condition clinically characterized by congenital non-progressive limited horizontal eye movement accompanied by globe retraction which results in narrowing of the palpebral fissure. The lateral movement anomaly results from failure of the abducens nucleus and nerve (cranial nerve VI) to fully innervate the lateral rectus muscle; globe retraction occurs as a result of abnormal innervation of the lateral rectus muscle by the oculomotor nerve (cranial nerve III). At birth, affected infants have restricted ability to move the affected eye(s) outward (abduction) and/or inward (adduction), though the limitations may not be recognized in early infancy. In addition, the globe retracts into the orbit with attempted adduction, accompanied by narrowing of the palpebral fissure. Many individuals with Duane syndrome have strabismus in primary gaze but can use a compensatory head turn to align the eyes, and thus can preserve binocular vision and avoid diplopia. Individuals with Duane syndrome who lack binocular vision are at risk for amblyopia. The majority of affected individuals with Duane syndrome have isolated Duane syndrome (i.e., they do not have other detected congenital anomalies). Other individuals with Duane syndrome fall into well-defined syndromic diagnoses. However, many individuals with Duane syndrome have non-ocular findings that do not fit a known syndrome; these individuals are included as part of the discussion of nonsyndromic Duane syndrome.","alternate_symbols":["DUS"],"alternate_names":["Duane retraction syndrome","RETRACTION SYNDROME"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"PARK11","medgen_id":"C4083045","xrefs":["{\"db\":\"OMIM\",\"id\":\"607688\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"411602\"}","{\"db\":\"OMIM\",\"id\":\"607688\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612003.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612003.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612003.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612003.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612003.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+11/9080\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"parkinson-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607688\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Parkinson disease 11","id":"3272","public_definition":"Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.Often the first symptom of Parkinson disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.Parkinson disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgment and memory.Generally, Parkinson disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson disease.","alternate_symbols":[],"alternate_names":["PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C1970035","xrefs":["{\"db\":\"OMIM\",\"id\":\"605909\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 6, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"608309.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 6, LATE-ONSET, SUSCEPTIBILITY TO\"}"],"name":"Parkinson disease 6","id":"9220","alternate_symbols":[],"alternate_names":["PARKINSON DISEASE 6, LATE-ONSET, SUSCEPTIBILITY TO"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"PARK1","medgen_id":"C1868595","xrefs":["{\"db\":\"OMIM\",\"id\":\"168601\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+1/9079\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"168601\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Parkinson disease 1","id":"3277","alternate_symbols":[],"alternate_names":["Parkinson disease 1, autosomal dominant"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C2751533","xrefs":[],"name":"Parkinson disease, autosomal recessive early-onset, digenic, PINK1/DJ1","id":"9221","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C1838867","xrefs":["{\"db\":\"OMIM\",\"id\":\"556500\",\"type\":\"MIM\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"parkinson-disease\",\"ref_field\":\"public_definition\"}"],"name":"Parkinson disease, mitochondrial","id":"5739","public_definition":"Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.Often the first symptom of Parkinson disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.Parkinson disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgment and memory.Generally, Parkinson disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson disease.","alternate_symbols":[],"alternate_names":["Parkinson disease, susceptibility to"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"PARK13","medgen_id":"C1853202","xrefs":["{\"db\":\"OMIM\",\"id\":\"610297\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2828\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+13/9081\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"parkinson-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"610297\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Parkinson disease 13","id":"3474","public_definition":"Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.Often the first symptom of Parkinson disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.Parkinson disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgment and memory.Generally, Parkinson disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson disease.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"PARK5","medgen_id":"C3150899","xrefs":["{\"db\":\"OMIM\",\"id\":\"613643\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2828\"}","{\"db\":\"OMIM\",\"id\":\"613643\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+5/9088\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"parkinson-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613643\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Parkinson disease 5","id":"10988","public_definition":"Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.Often the first symptom of Parkinson disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.Parkinson disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgment and memory.Generally, Parkinson disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson disease.","alternate_symbols":[],"alternate_names":["PARKINSON DISEASE 5, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301409\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1231\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C1855100","xrefs":["{\"db\":\"OMIM\",\"id\":\"251120\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"251120\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"METHYLMALONIC ACIDURIA III\"}","{\"db\":\"OMIM\",\"id\":\"251120\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"METHYLMALONYL-CoA RACEMASE DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Methylmalonyl-CoA+epimerase+deficiency/8868\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1231\",\"ref_field\":\"public_definition\"}"],"name":"Methylmalonyl-CoA epimerase deficiency","id":"2916","public_definition":"Isolated methylmalonic acidemia/aciduria, the topic of this GeneReview, is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut0 enzymatic subtype or mut enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Onset of the manifestations of isolated methylmalonic acidemia/aciduria ranges from the neonatal period to adulthood. All phenotypes are characterized by periods of relative health and intermittent metabolic decompensation, usually associated with intercurrent infections and stress. In the neonatal period the disease can present with lethargy, vomiting, hypotonia, hypothermia, respiratory distress, severe ketoacidosis, hyperammonemia, neutropenia, and thrombocytopenia and can result in death within the first four weeks of life. In the infantile/non-B12-responsive phenotype, infants are normal at birth, but develop lethargy, vomiting, dehydration, failure to thrive, hepatomegaly, hypotonia, and encephalopathy within a few weeks to months of age. An intermediate B12-responsive phenotype can occasionally be observed in neonates, but is usually observed in the first months or years of life; affected children exhibit anorexia, failure to thrive, hypotonia, and developmental delay, and sometimes have protein aversion and/or vomiting and lethargy after protein intake. Atypical and \"benign\"/adult methylmalonic acidemia phenotypes are associated with increased, albeit mild, urinary excretion of methylmalonate. Major secondary complications of methylmalonic acidemia include: intellectual impairment (variable); tubulointerstitial nephritis with progressive renal failure; \"metabolic stroke\" (acute and chronic basal ganglia injury) causing a disabling movement disorder with choreoathetosis, dystonia, and para/quadriparesis; pancreatitis; growth failure; functional immune impairment; and optic nerve atrophy.","alternate_symbols":[],"alternate_names":["METHYLMALONIC ACIDURIA III","METHYLMALONYL-CoA RACEMASE DEFICIENCY"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301409\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1231\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"MMA","medgen_id":"C0268583","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002912\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003123\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008295\",\"type\":\"secondary\"}","{\"db\":\"MeSH\",\"id\":\"C537358\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Methylmalonic+acidemia/4713\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002912\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7033\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"42393006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1231\",\"ref_field\":\"public_definition\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7033\",\"ref_field\":\"symbol\"}"],"name":"Methylmalonic acidemia","id":"6374","public_definition":"Isolated methylmalonic acidemia/aciduria, the topic of this GeneReview, is caused by complete or partial deficiency of the enzyme methylmalonyl-CoA mutase (mut0 enzymatic subtype or mut enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. Onset of the manifestations of isolated methylmalonic acidemia/aciduria ranges from the neonatal period to adulthood. All phenotypes are characterized by periods of relative health and intermittent metabolic decompensation, usually associated with intercurrent infections and stress. In the neonatal period the disease can present with lethargy, vomiting, hypotonia, hypothermia, respiratory distress, severe ketoacidosis, hyperammonemia, neutropenia, and thrombocytopenia and can result in death within the first four weeks of life. In the infantile/non-B12-responsive phenotype, infants are normal at birth, but develop lethargy, vomiting, dehydration, failure to thrive, hepatomegaly, hypotonia, and encephalopathy within a few weeks to months of age. An intermediate B12-responsive phenotype can occasionally be observed in neonates, but is usually observed in the first months or years of life; affected children exhibit anorexia, failure to thrive, hypotonia, and developmental delay, and sometimes have protein aversion and/or vomiting and lethargy after protein intake. Atypical and \"benign\"/adult methylmalonic acidemia phenotypes are associated with increased, albeit mild, urinary excretion of methylmalonate. Major secondary complications of methylmalonic acidemia include: intellectual impairment (variable); tubulointerstitial nephritis with progressive renal failure; \"metabolic stroke\" (acute and chronic basal ganglia injury) causing a disabling movement disorder with choreoathetosis, dystonia, and para/quadriparesis; pancreatitis; growth failure; functional immune impairment; and optic nerve atrophy.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301418\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1240\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"RRS1","medgen_id":"C1849334","xrefs":["{\"db\":\"OMIM\",\"id\":\"268310\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1507\"}","{\"db\":\"Orphanet\",\"id\":\"97360\"}","{\"db\":\"OMIM\",\"id\":\"268310\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COSTOVERTEBRAL SEGMENTATION DEFECT WITH MESOMELIA\"}","{\"db\":\"OMIM\",\"id\":\"268310\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COVESDEM SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"268310\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ROBINOW SYNDROME, AUTOSOMAL RECESSIVE 1\"}","{\"db\":\"OMIM\",\"id\":\"602337.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ROBINOW SYNDROME, AUTOSOMAL RECESSIVE 1\"}","{\"db\":\"OMIM\",\"id\":\"602337.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ROBINOW SYNDROME, AUTOSOMAL RECESSIVE 1\"}","{\"db\":\"OMIM\",\"id\":\"602337.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ROBINOW SYNDROME, AUTOSOMAL RECESSIVE 1\"}","{\"db\":\"OMIM\",\"id\":\"602337.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ROBINOW SYNDROME, AUTOSOMAL RECESSIVE 1\"}","{\"db\":\"OMIM\",\"id\":\"602337.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ROBINOW SYNDROME, AUTOSOMAL RECESSIVE 1\"}","{\"db\":\"OMIM\",\"id\":\"602337.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ROBINOW SYNDROME, AUTOSOMAL RECESSIVE 1\"}","{\"db\":\"OMIM\",\"id\":\"602337.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ROBINOW SYNDROME, AUTOSOMAL RECESSIVE 1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Robinow+syndrome+autosomal+recessive/6346\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1240\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"268310\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Robinow syndrome, autosomal recessive","id":"5880","public_definition":"ROR2-related Robinow syndrome is characterized by distinctive craniofacial features, skeletal abnormalities, and other anomalies. Craniofacial features include macrocephaly, broad prominent forehead, low-set ears, ocular hypertelorism, prominent eyes, midface hypoplasia, short upturned nose with depressed nasal bridge and flared nostrils, large and triangular mouth with exposed incisors and upper gums, gum hypertrophy, misaligned teeth, ankyloglossia, and micrognathia. Skeletal abnormalities include short stature, mesomelic or acromesomelic limb shortening, hemivertebrae with fusion of thoracic vertebrae, and brachydactyly. Other common features include micropenis with or without cryptorchidism in males and reduced clitoral size and hypoplasia of the labia majora in females, renal tract abnormalities, and nail hypoplasia or dystrophy. The disorder is recognizable at birth or in early childhood.","alternate_symbols":[],"alternate_names":["COSTOVERTEBRAL SEGMENTATION DEFECT WITH MESOMELIA","COVESDEM SYNDROME","ROBINOW SYNDROME, AUTOSOMAL RECESSIVE 1"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301423\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1245\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"CN043584","xrefs":["{\"db\":\"GeneReviews\",\"id\":\"NBK1245\",\"ref_field\":\"public_definition\"}"],"name":"Congenital stationary night blindness, X-linked","id":"9475","public_definition":"X-linked congenital stationary night blindness (CSNB) is characterized by non-progressive retinal findings of reduced visual acuity ranging from 20/30 to 20/200; defective dark adaptation; refractive error, most typically myopia ranging from low (-0.25 diopters [D] to -4.75 D) to high (-10.00 D) but occasionally hyperopia; nystagmus; strabismus; normal color vision; and normal fundus examination. Characteristic ERG findings can help distinguish between complete X-linked CSNB and incomplete X-linked CSNB.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301423\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1245\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"CSNB1A","medgen_id":"C3495587","xrefs":["{\"db\":\"OMIM\",\"id\":\"310500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"215\"}","{\"db\":\"OMIM\",\"id\":\"310500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CSNB, COMPLETE, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"310500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NBM1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+stationary+night+blindness%2C+type+1A/8081\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1245\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"310500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Congenital stationary night blindness, type 1A","id":"3641","public_definition":"X-linked congenital stationary night blindness (CSNB) is characterized by non-progressive retinal findings of reduced visual acuity ranging from 20/30 to 20/200; defective dark adaptation; refractive error, most typically myopia ranging from low (-0.25 diopters [D] to -4.75 D) to high (-10.00 D) but occasionally hyperopia; nystagmus; strabismus; normal color vision; and normal fundus examination. Characteristic ERG findings can help distinguish between complete X-linked CSNB and incomplete X-linked CSNB.","alternate_symbols":["NBM1"],"alternate_names":["CSNB, COMPLETE, X-LINKED"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301435\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1258\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"VWM","medgen_id":"C1858991","xrefs":["{\"db\":\"OMIM\",\"id\":\"603896\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"157713\"}","{\"db\":\"Orphanet\",\"id\":\"157716\"}","{\"db\":\"Orphanet\",\"id\":\"157719\"}","{\"db\":\"Orphanet\",\"id\":\"99853\"}","{\"db\":\"Orphanet\",\"id\":\"99854\"}","{\"db\":\"OMIM\",\"id\":\"603896\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHILDHOOD ATAXIA WITH CENTRAL NERVOUS SYSTEM HYPOMYELINIZATION\"}","{\"db\":\"OMIM\",\"id\":\"603945.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"603945.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"603945.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"606273.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"606454.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"603896\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CACH\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"231\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CLE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"CACH+Syndrome/1012\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"231\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1258\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"603896\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Leukoencephalopathy with vanishing white matter","id":"2596","public_definition":"Childhood ataxia with central nervous system hypomyelination / vanishing white matter (CACH/VWM) is characterized by ataxia, spasticity, and variable optic atrophy. The phenotypic range includes a prenatal/congenital form, a subacute infantile form (onset age \u003c1 year), an early childhood-onset form (onset age 1 to \u003c4 years), a late childhood-/juvenile-onset form (onset age 4 to \u003c18 years), and an adult-onset form (onset 18 years). The prenatal/congenital form is characterized by severe encephalopathy. In the later-onset forms initial motor and intellectual development is normal or mildly delayed, followed by neurologic deterioration with a chronic progressive or subacute course. While in childhood-onset forms motor deterioration dominates, in adult-onset forms cognitive decline and personality changes dominate. Chronic progressive decline can be exacerbated by rapid deterioration during febrile illnesses or following head trauma or major surgical procedures, or by acute and extreme fright.","alternate_symbols":["CACH","CLE"],"alternate_names":["CHILDHOOD ATAXIA WITH CENTRAL NERVOUS SYSTEM HYPOMYELINIZATION","LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301437\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1260\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C0234166","xrefs":["{\"db\":\"Orphanet\",\"id\":\"306773\"}","{\"db\":\"GeneTests\",\"id\":\"74148\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1260\",\"ref_field\":\"public_definition\"}"],"name":"Hyperekplexia","id":"10190","public_definition":"Hereditary hyperekplexia (HPX) is characterized by generalized stiffness immediately after birth that normalizes during the first years of life; excessive startle reflex (eye blinking and a flexor spasm of the trunk) to unexpected (particularly auditory) stimuli; and a short period of generalized stiffness following the startle response during which voluntary movements are impossible. Exaggerated head-retraction reflex (HRR) consisting of extension of the head followed by violent flexor spasms of limbs and neck muscles elicited by tapping the tip of the nose is observed in most children. Other findings include periodic limb movements in sleep (PLMS) and hypnagogic (occurring when falling asleep) myoclonus. Sudden infant death (SIDS) has been reported. Intellect is usually normal; mild intellectual disability may occur.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301464\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1287\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"HPS8","medgen_id":"C3888026","xrefs":["{\"db\":\"OMIM\",\"id\":\"614077\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"231537\"}","{\"db\":\"Orphanet\",\"id\":\"79430\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hermansky-Pudlak+syndrome+8/8542\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1287\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614077\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hermansky-Pudlak syndrome 8","id":"9717","public_definition":"Hermansky-Pudlak syndrome (HPS) is characterized by oculocutaneous albinism, a bleeding diathesis, and, in some individuals, pulmonary fibrosis, granulomatous colitis, or immunodeficiency. Ocular findings include reduced iris pigment with iris transillumination, reduced retinal pigment, foveal hypoplasia with significant reduction in visual acuity (usually in the range of 20/50 to 20/400), nystagmus, and increased crossing of the optic nerve fibers. Hair color ranges from white to brown; skin color ranges from white to olive and is usually a shade lighter than that of other family members. The bleeding diathesis can result in variable bruising, epistaxis, gingival bleeding, postpartum hemorrhage, colonic bleeding, and prolonged bleeding with menses or after tooth extraction, circumcision, and other surgeries. Pulmonary fibrosis, a restrictive lung disease, typically causes symptoms in the early thirties and can progress to death within a decade. Granulomatous colitis is severe in about 15% of affected individuals. Neutropenia and/or immune defects occur primarily in individuals with pathogenic variants in AP3B1 and AP3D1.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301479\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1302\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"OSMEDA","medgen_id":"C1861481","xrefs":["{\"db\":\"OMIM\",\"id\":\"184840\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"166100\"}","{\"db\":\"OMIM\",\"id\":\"184840\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSMED, HETEROZYGOUS\"}","{\"db\":\"OMIM\",\"id\":\"120290.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"120290.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"120290.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"120290.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"184840\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"184840\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PIERRE ROBIN SYNDROME WITH FETAL CHONDRODYSPLASIA STICKLER SYNDROME, NONOCULAR TYPE\"}","{\"db\":\"OMIM\",\"id\":\"184840\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"STICKLER SYNDROME, TYPE III\"}","{\"db\":\"OMIM\",\"id\":\"184840\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"WEISSENBACHER-ZWEYMULLER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"184840\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"STL3\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5021\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"STL3\"}","{\"db\":\"OMIM\",\"id\":\"184840\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WZS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Stickler+syndrome%2C+type+3/6880\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5021\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1302\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"184840\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Stickler syndrome, type 3","id":"5999","public_definition":"Stickler syndrome is a connective tissue disorder that can include ocular findings of myopia, cataract, and retinal detachment; hearing loss that is both conductive and sensorineural; midfacial underdevelopment and cleft palate (either alone or as part of the Robin sequence); and mild spondyloepiphyseal dysplasia and/or precocious arthritis. Variable phenotypic expression of Stickler syndrome occurs both within and among families; interfamilial variability is in part explained by locus and allelic heterogeneity.","alternate_symbols":["COL11A2","STL3","WZS"],"alternate_names":["OSMED, HETEROZYGOUS","OTOSPONDYLOMEGAEPIPHYSEAL DYSPLASIA, AUTOSOMAL DOMINANT","PIERRE ROBIN SYNDROME WITH FETAL CHONDRODYSPLASIA STICKLER SYNDROME, NONOCULAR TYPE","STICKLER SYNDROME, TYPE III","WEISSENBACHER-ZWEYMULLER SYNDROME"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301481\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1304\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"DDEB","medgen_id":"C0432322","xrefs":["{\"db\":\"OMIM\",\"id\":\"131750\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"231568\"}","{\"db\":\"OMIM\",\"id\":\"131750\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTROPHIC EPIDERMOLYSIS BULLOSA, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"131750\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EBDD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Generalized+dominant+dystrophic+epidermolysis+bullosa/8457\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2139\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1304\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"131750\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Generalized dominant dystrophic epidermolysis bullosa","id":"14025","public_definition":"Dystrophic epidermolysis bullosa (DEB) is a genetic skin disorder affecting skin and nails that usually presents at birth. DEB is divided into two major types depending on inheritance pattern: recessive dystrophic epidermolysis bullosa (RDEB) and dominant dystrophic epidermolysis bullosa (DDEB). Each type is further divided into multiple clinical subtypes. Absence of a known family history of DEB does not preclude the diagnosis. Clinical findings in severe generalized RDEB include skin fragility manifest by blistering with minimal trauma that heals with milia and scarring. Blistering and erosions affecting the whole body may be present in the neonatal period. Oral involvement may lead to mouth blistering, fusion of the tongue to the floor of the mouth, and progressive diminution of the size of the oral cavity. Esophageal erosions can lead to webs and strictures that can cause severe dysphagia. Consequently, malnutrition and vitamin and mineral deficiency may lead to growth restriction in young children. Corneal erosions can lead to scarring and loss of vision. Blistering of the hands and feet followed by scarring fuses the digits into \"mitten\" hands and feet, with contractures and pseudosyndactyly. The lifetime risk of aggressive squamous cell carcinoma is higher than 90%. In contrast, the blistering in the less severe forms of RDEB may be localized to hands, feet, knees, and elbows with or without involvement of flexural areas and the trunk, and without the mutilating scarring seen in severe generalized RDEB. In DDEB, blistering is often mild and limited to hands, feet, knees, and elbows, but nonetheless heals with scarring. Dystrophic nails, especially toenails, are common and may be the only manifestation of DDEB.","alternate_symbols":["EBDD"],"alternate_names":["DYSTROPHIC EPIDERMOLYSIS BULLOSA, AUTOSOMAL DOMINANT","Epidermolysis bullosa dystrophica, autosomal dominant"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301508\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1333\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"SMAX1","medgen_id":"C1839259","xrefs":["{\"db\":\"OMIM\",\"id\":\"313200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"206701\"}","{\"db\":\"Orphanet\",\"id\":\"481\"}","{\"db\":\"OMIM\",\"id\":\"313200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1\"}","{\"db\":\"OMIM\",\"id\":\"313700.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1\"}","{\"db\":\"OMIM\",\"id\":\"313200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"KD\"}","{\"db\":\"OMIM\",\"id\":\"313200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SBMA\"}","{\"db\":\"OMIM\",\"id\":\"313200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XBSN\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Kennedy+Disease/993\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6818\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1333\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"313200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Bulbo-spinal atrophy X-linked","id":"4172","public_definition":"Spinal and bulbar muscular atrophy (SBMA) is a gradually progressive neuromuscular disorder in which degeneration of lower motor neurons results in muscle weakness, muscle atrophy, and fasciculations. SBMA occurs only in males. Affected individuals often show gynecomastia, testicular atrophy, and reduced fertility as a result of mild androgen insensitivity.","alternate_symbols":["KD","SBMA","XBSN"],"alternate_names":["SPINAL AND BULBAR MUSCULAR ATROPHY, X-LINKED 1"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301516\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1342\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C0009207","xrefs":["{\"db\":\"Orphanet\",\"id\":\"191\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"cockayne-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6122\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"21086008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1342\",\"ref_field\":\"public_definition\"}"],"name":"Cockayne syndrome","id":"6530","public_definition":"Cockayne syndrome (referred to as CS in this GeneReview) spans a continuous phenotypic spectrum that includes: CS type I, the \"classic\" or \"moderate\" form; CS type II, a more severe form with symptoms present at birth; this form overlaps with cerebrooculofacioskeletal (COFS) syndrome; CS type III, a milder and later-onset form; COFS syndrome, a fetal form of CS. CS type I is characterized by normal prenatal growth with the onset of growth and developmental abnormalities in the first two years. By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile. Progressive impairment of vision, hearing, and central and peripheral nervous system function leads to severe disability; death typically occurs in the first or second decade. CS type II is characterized by growth failure at birth, with little or no postnatal neurologic development. Congenital cataracts or other structural anomalies of the eye may be present. Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints. Death usually occurs by age five years. CS type III is a phenotype in which major clinical features associated with CS only become apparent after age two years; growth and/or cognition exceeds the expectations for CS type I. COFS syndrome is characterized by very severe prenatal developmental anomalies (arthrogryposis and microphthalmia).","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301516\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1342\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"CSB","medgen_id":"C0751038","xrefs":["{\"db\":\"OMIM\",\"id\":\"133540\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"191\"}","{\"db\":\"Orphanet\",\"id\":\"90322\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1342\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"133540\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Cockayne syndrome B","id":"1524","public_definition":"Cockayne syndrome (referred to as CS in this GeneReview) spans a continuous phenotypic spectrum that includes: CS type I, the \"classic\" or \"moderate\" form; CS type II, a more severe form with symptoms present at birth; this form overlaps with cerebrooculofacioskeletal (COFS) syndrome; CS type III, a milder and later-onset form; COFS syndrome, a fetal form of CS. CS type I is characterized by normal prenatal growth with the onset of growth and developmental abnormalities in the first two years. By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile. Progressive impairment of vision, hearing, and central and peripheral nervous system function leads to severe disability; death typically occurs in the first or second decade. CS type II is characterized by growth failure at birth, with little or no postnatal neurologic development. Congenital cataracts or other structural anomalies of the eye may be present. Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints. Death usually occurs by age five years. CS type III is a phenotype in which major clinical features associated with CS only become apparent after age two years; growth and/or cognition exceeds the expectations for CS type I. COFS syndrome is characterized by very severe prenatal developmental anomalies (arthrogryposis and microphthalmia).","alternate_symbols":["ERCC6"],"alternate_names":["Cockayne Syndrome, Type II"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301516\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1342\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"CSA","medgen_id":"C0751039","xrefs":["{\"db\":\"OMIM\",\"id\":\"216400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"191\"}","{\"db\":\"Orphanet\",\"id\":\"90321\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1415\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cockayne syndrome  type I\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cockayne+Syndrome/1701\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1415\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1342\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"216400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Cockayne syndrome type A","id":"1523","public_definition":"Cockayne syndrome (referred to as CS in this GeneReview) spans a continuous phenotypic spectrum that includes: CS type I, the \"classic\" or \"moderate\" form; CS type II, a more severe form with symptoms present at birth; this form overlaps with cerebrooculofacioskeletal (COFS) syndrome; CS type III, a milder and later-onset form; COFS syndrome, a fetal form of CS. CS type I is characterized by normal prenatal growth with the onset of growth and developmental abnormalities in the first two years. By the time the disease has become fully manifest, height, weight, and head circumference are far below the fifth percentile. Progressive impairment of vision, hearing, and central and peripheral nervous system function leads to severe disability; death typically occurs in the first or second decade. CS type II is characterized by growth failure at birth, with little or no postnatal neurologic development. Congenital cataracts or other structural anomalies of the eye may be present. Affected children have early postnatal contractures of the spine (kyphosis, scoliosis) and joints. Death usually occurs by age five years. CS type III is a phenotype in which major clinical features associated with CS only become apparent after age two years; growth and/or cognition exceeds the expectations for CS type I. COFS syndrome is characterized by very severe prenatal developmental anomalies (arthrogryposis and microphthalmia).","alternate_symbols":["ERCC8"],"alternate_names":["Cockayne syndrome  type I"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301527\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1353\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"PBD9B","medgen_id":"CN159238","xrefs":["{\"db\":\"OMIM\",\"id\":\"614879\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"773\"}","{\"db\":\"OMIM\",\"id\":\"614879\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PEROXISOME BIOGENESIS DISORDER, PEX7-RELATED, ATYPICAL\"}","{\"db\":\"OMIM\",\"id\":\"614879\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"REFSUM DISEASE, ADULT, 2\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1353\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614879\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Peroxisome biogenesis disorder 9B","id":"17440","public_definition":"Refsum disease is characterized by anosmia and early-onset retinitis pigmentosa, which are both universal findings with variable combinations of neuropathy, deafness, ataxia, and ichthyosis. Onset of symptoms ranges from age seven months to older than age 50 years. Cardiac arrhythmia and heart failure caused by cardiomyopathy are potentially severe health problems that develop later in life.","alternate_symbols":[],"alternate_names":["PEROXISOME BIOGENESIS DISORDER, PEX7-RELATED, ATYPICAL","REFSUM DISEASE, ADULT, 2"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301530\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1356\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"MCKD2","medgen_id":"C1859040","xrefs":["{\"db\":\"OMIM\",\"id\":\"603860\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"34149\"}","{\"db\":\"Orphanet\",\"id\":\"88950\"}","{\"db\":\"OMIM\",\"id\":\"603860\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ADMCKD2\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10679\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ADMCKD2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Medullary+cystic+kidney+disease+2/4550\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10679\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1356\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"603860\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10679\",\"ref_field\":\"symbol\"}"],"name":"Medullary cystic kidney disease 2","id":"2876","public_definition":"Autosomal dominant tubulointerstitial kidney disease caused by UMOD pathogenic variants (ADTKD-UMOD) was previously known as familial juvenile hyperuricemic nephropathy type 1 (FJHN1), medullary cystic kidney disease type 2 (MCKD2), and UMOD-associated kidney disease (or uromodulin-associated kidney disease). Typical clinical findings: Urinalysis revealing minimal protein and no blood. Slowly progressive chronic kidney failure, usually first noted in the teen years and progressing to end-stage renal disease (ESRD) between the fourth and seventh decades (Age at ESRD varies among and within families.) Hyperuricemia and gout (resulting from reduced kidney excretion of uric acid) that occurs as early as the teenage years.","alternate_symbols":["ADMCKD2"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301549\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1375\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"HHF7","medgen_id":"C1864902","xrefs":["{\"db\":\"OMIM\",\"id\":\"610021\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Exercise-Induced+Hyperinsulinemic+Hypoglycemia/2669\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9932\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"congenital-hyperinsulinism\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"610021\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9932\",\"ref_field\":\"symbol\"}"],"name":"Exercise-induced hyperinsulinemic hypoglycemia","id":"2359","public_definition":"Congenital hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent episodes of low blood sugar (hypoglycemia). In infants and young children, these episodes are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.The severity of congenital hyperinsulinism varies widely among affected individuals, even among members of the same family. About 60 percent of infants with this condition experience a hypoglycemic episode within the first month of life. Other affected children develop hypoglycemia by early childhood. Unlike typical episodes of hypoglycemia, which occur most often after periods without food (fasting) or after exercising, episodes of hypoglycemia in people with congenital hyperinsulinism can also occur after eating.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301549\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1375\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"HHF3","medgen_id":"C1865290","xrefs":["{\"db\":\"OMIM\",\"id\":\"602485\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hyperinsulinemic+hypoglycemia+familial+3/3563\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9930\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"congenital-hyperinsulinism\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"602485\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9930\",\"ref_field\":\"symbol\"}"],"name":"Hyperinsulinemic hypoglycemia familial 3","id":"5280","public_definition":"Congenital hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent episodes of low blood sugar (hypoglycemia). In infants and young children, these episodes are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.The severity of congenital hyperinsulinism varies widely among affected individuals, even among members of the same family. About 60 percent of infants with this condition experience a hypoglycemic episode within the first month of life. Other affected children develop hypoglycemia by early childhood. Unlike typical episodes of hypoglycemia, which occur most often after periods without food (fasting) or after exercising, episodes of hypoglycemia in people with congenital hyperinsulinism can also occur after eating.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301556\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1382\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"SPG20","medgen_id":"C0393559","xrefs":["{\"db\":\"OMIM\",\"id\":\"275900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101000\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spastic+paraplegia+20/6687\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"troyer-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5372\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"230264003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1382\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"275900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5372\",\"ref_field\":\"symbol\"}"],"name":"Troyer syndrome","id":"5934","public_definition":"Troyer syndrome is characterized by progressive spastic paraparesis, dysarthria, pseudobulbar palsy, distal amyotrophy, short stature, and subtle skeletal abnormalities. Most affected children exhibit delays in walking and speech and difficulty in managing oral secretions, followed by increased lower-limb spasticity and slow deterioration in both gait and speech. Mild cerebellar signs are common. The most severely affected individuals have choreoathetosis. Emotional lability / difficulty in controlling emotions and affective disorders, such as inappropriate euphoria and/or crying, are frequently described. Life expectancy is normal.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301559\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1385\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"MPDT","medgen_id":"C3280443","xrefs":["{\"db\":\"OMIM\",\"id\":\"614321\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"MYOPATHY%2C+DISTAL%2C+TATEYAMA+TYPE/8953\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1385\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614321\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Distal myopathy, Tateyama type","id":"16607","public_definition":"The caveolinopathies, a group of muscle diseases, can be classified into five phenotypes, which can be seen in different members of the same family: Limb-girdle muscular dystrophy 1C (LGMD1C), characterized by onset usually in the first decade, mild-to-moderate proximal muscle weakness, calf hypertrophy, positive Gower sign, and variable muscle cramps after exercise. Isolated hyperCKemia (i.e., elevated serum concentration of creatine kinase (CK) in the absence of signs of muscle disease) (HCK). Rippling muscle disease (RMD), characterized by signs of increased muscle irritability, such as percussion-induced rapid contraction (PIRC), percussion-induced muscle mounding (PIMM), and/or electrically silent muscle contractions (rippling muscle). Distal myopathy (DM), observed in one individual only Hypertrophic cardiomyopathy (HCM), without skeletal muscle manifestations.","alternate_symbols":[],"alternate_names":["CAV3-Related Distal Myopathy"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301561\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1387\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"CHAC","medgen_id":"C0393576","xrefs":["{\"db\":\"OMIM\",\"id\":\"200150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2388\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3956\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Chorea-acanthocytosis\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Choreoacanthocytosis/1384\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3956\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1387\",\"ref_field\":\"public_definition\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501217\",\"ref_field\":\"symbol\"}","{\"db\":\"OMIM\",\"id\":\"200150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Choreoacanthocytosis","id":"805","public_definition":"Chorea-acanthocytosis (ChAc) is characterized by a progressive movement disorder, cognitive and behavior changes, a myopathy that can be subclinical, and chronic hyperCKemia in serum. Although the disorder is named for acanthocytosis of the red blood cells, this feature is variable. The movement disorder is mostly limb chorea, but some individuals present with parkinsonism. Dystonia is common and affects the oral region and especially the tongue, causing dysarthria and serious dysphagia with resultant weight loss. Habitual tongue and lip biting are characteristic, as well as tongue protrusion dystonia. Progressive cognitive and behavioral changes resemble those in a frontal lobe syndrome. Seizures are observed in almost half of affected individuals and can be the initial manifestation. Myopathy results in progressive distal muscle wasting and weakness. Mean age of onset in ChAc is about 30 years, although ChAc can develop as early as the first decade or as late as the seventh decade. It runs a chronic progressive course and may lead to major disability within a few years. Life expectancy is reduced, with age of death ranging from 28 to 61 years.","alternate_symbols":[],"alternate_names":["Chorea-acanthocytosis"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301581\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1407\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"PPS","medgen_id":"C0265259","xrefs":["{\"db\":\"OMIM\",\"id\":\"119500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1300\"}","{\"db\":\"Orphanet\",\"id\":\"294963\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Popliteal+pterygium+syndrome/5870\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3242\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"66783006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1407\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"119500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3242\",\"ref_field\":\"symbol\"}"],"name":"Popliteal pterygium syndrome","id":"4007","public_definition":"IRF6-related disorders span a spectrum from isolated cleft lip and palate and Van der Woude syndrome (VWS) at the mild end to popliteal pterygium syndrome (PPS) at the more severe end. Individuals with VWS show one or more of the following anomalies: Congenital, usually bilateral, paramedian lower-lip fistulae (pits) or sometimes small mounds with a sinus tract leading from a mucous gland of the lip. Cleft lip (CL). Cleft palate (CP). Note: Cleft lip with or without cleft palate (CLP) is observed about twice as often as CP only. Submucous cleft palate (SMCP). The PPS phenotype includes the following: CLP. Fistulae of the lower lip. Webbing of the skin extending from the ischial tuberosities to the heels. In males: bifid scrotum and cryptorchidism. In females: hypoplasia of the labia majora. Syndactyly of fingers and/or toes. Anomalies of the skin around the nails. A characteristic pyramidal fold of skin overlying the nail of the hallux (almost pathognomonic). In some non-classic forms of PPS: filiform synechiae connecting the upper and lower jaws (syngnathia) or the upper and lower eyelids (ankyloblepharon). In both VWS and PPS, growth and intelligence are normal.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301593\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1420\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"ARCI","medgen_id":"C0020758","xrefs":["{\"db\":\"Orphanet\",\"id\":\"79354\"}","{\"db\":\"SNOMED CT\",\"id\":\"13059002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1420\",\"ref_field\":\"public_definition\"}"],"name":"Congenital ichthyosis of skin","id":"9461","public_definition":"Autosomal recessive congenital ichthyosis (ARCI) encompasses several forms of nonsyndromic ichthyosis. Although most neonates with ARCI are collodion babies, the clinical presentation and severity of ARCI may vary significantly, ranging from harlequin ichthyosis, the most severe and often fatal form, to lamellar ichthyosis (LI) and (nonbullous) congenital ichthyosiform erythroderma (CIE). These phenotypes are now recognized to fall on a continuum; however, the phenotypic descriptions are clinically useful for clarification of prognosis and management. Infants with harlequin ichthyosis are usually born prematurely and are encased in thick, hard, armor-like plates of cornified skin that severely restrict movement. Life-threatening complications in the immediate postnatal period include respiratory distress, feeding problems, and systemic infection. Collodion babies are born with a taut, shiny, translucent or opaque membrane that encases the entire body and lasts for days to weeks. LI and CIE are seemingly distinct phenotypes: classic, severe LI with dark brown, plate-like scale with no erythroderma and CIE with finer whiter scale and underlying generalized redness of the skin. Affected individuals with severe involvement can have ectropion, eclabium, scarring alopecia involving the scalp and eyebrows, and palmar and plantar keratoderma. Besides these major forms of nonsyndromic ichthyosis, a few rare subtypes have been recognized, such as bathing suit ichthyosis, self-improving collodion ichthyosis, or ichthyosis-prematurity syndrome.","alternate_symbols":["LI1"],"alternate_names":["Autosomal recessive congenital ichthyosis"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301596\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1423\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"HFGS","medgen_id":"C1841679","xrefs":["{\"db\":\"OMIM\",\"id\":\"140000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2438\"}","{\"db\":\"OMIM\",\"id\":\"140000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HFG\"}","{\"db\":\"OMIM\",\"id\":\"140000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HFU\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hand+Foot+Uterus+Syndrome/3232\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2594\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1423\",\"ref_field\":\"public_definition\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2594\",\"ref_field\":\"symbol\"}"],"name":"Hand foot uterus syndrome","id":"5226","public_definition":"Hand-foot-genital syndrome (HFGS) is characterized by limb malformations and urogenital defects. Mild-to-severe bilateral shortening of the thumbs and great toes, caused primarily by shortening of the distal phalanx and/or the first metacarpal or metatarsal, is the most common limb malformation and results in impaired dexterity or apposition of the thumbs. Urogenital malformations include abnormalities of the ureters and urethra and various degrees of incomplete mllerian fusion in females, and hypospadias of variable severity with or without chordee in males. Vesicoureteral reflux, recurrent urinary tract infections, and chronic pyelonephritis may occur; fertility is normal.","alternate_symbols":["HFG","HFU"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301598\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1425\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"NPHS7","medgen_id":"C3554330","xrefs":["{\"db\":\"OMIM\",\"id\":\"615008\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"329903\"}","{\"db\":\"Orphanet\",\"id\":\"357008\"}","{\"db\":\"OMIM\",\"id\":\"615008\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEPHROTIC SYNDROME, TYPE 7, WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1425\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615008\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Nephrotic syndrome, type 7","id":"17531","public_definition":"C3 glomerulopathy (C3G) is a complex ultra-rare complement-mediated renal disease caused by uncontrolled activation of the complement alternative pathway (AP) in the fluid phase (as opposed to cell surface) that is rarely inherited in a simple mendelian fashion. C3G affects individuals of all ages, with a median age at diagnosis of 23 years. Individuals with C3G typically present with hematuria, proteinuria, hematuria and proteinuria, acute nephritic syndrome or nephrotic syndrome, and low levels of the complement component C3. Spontaneous remission of C3G is uncommon, and about half of affected individuals develop end-stage renal disease (ESRD) within ten years of diagnosis, occasionally developing the late comorbidity of impaired visual acuity.","alternate_symbols":[],"alternate_names":["NEPHROTIC SYNDROME, TYPE 7, WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301603\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1430\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"GLUT1DS1","medgen_id":"C4551966","xrefs":["{\"db\":\"OMIM\",\"id\":\"606777\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"71277\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1430\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"606777\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"GLUT1 deficiency syndrome 1","id":"1929","public_definition":"The phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS) is now known to be a continuum that includes the classic phenotype as well as paroxysmal exercise-induced dyskinesia and epilepsy (previously known as dystonia 18 [DYT18]) and paroxysmal choreoathetosis with spasticity (previously known as dystonia 9 [DYT9]), atypical childhood absence epilepsy, myoclonic astatic epilepsy, and paroxysmal non-epileptic findings including intermittent ataxia, choreoathetosis, dystonia, and alternating hemiplegia. The classic phenotype is characterized by infantile-onset seizures, delayed neurologic development, acquired microcephaly, and complex movement disorders. Seizures in classic early-onset Glut1 DS begin before age six months. Several seizure types occur: generalized tonic or clonic, focal, myoclonic, atypical absence, atonic, and unclassified. In some infants, apneic episodes and abnormal episodic eye-head movements similar to opsoclonus may precede the onset of seizures. The frequency, severity, and type of seizures vary among affected individuals and are not related to disease severity. Cognitive impairment, ranging from learning disabilities to severe intellectual disability, is typical. The complex movement disorder, characterized by ataxia, dystonia, and chorea, may occur in any combination and may be continuous, paroxysmal, or continual with fluctuations in severity influenced by environmental factors such as fasting or with infectious stress. Symptoms often improve substantially when a ketogenic diet is started.","alternate_symbols":[],"alternate_names":["GLUT1 deficiency syndrome 1, infantile onset, severe"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301603\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1430\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"GLUT1DS2","medgen_id":"C1842534","xrefs":["{\"db\":\"OMIM\",\"id\":\"612126\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98811\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dystonia+18/2414\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Dystonia 18\"}","{\"db\":\"OMIM\",\"id\":\"612126\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PAROXYSMAL EXERCISE-INDUCED DYSKINESIA WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA\"}","{\"db\":\"OMIM\",\"id\":\"612126\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PAROXYSMAL EXERTION-INDUCED DYSTONIA WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA\"}","{\"db\":\"OMIM\",\"id\":\"612126\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PED WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA\"}","{\"db\":\"OMIM\",\"id\":\"612126\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DYT18\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10541\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DYT18\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10541\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PED\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1430\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612126\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"GLUT1 deficiency syndrome 2","id":"1930","public_definition":"The phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS) is now known to be a continuum that includes the classic phenotype as well as paroxysmal exercise-induced dyskinesia and epilepsy (previously known as dystonia 18 [DYT18]) and paroxysmal choreoathetosis with spasticity (previously known as dystonia 9 [DYT9]), atypical childhood absence epilepsy, myoclonic astatic epilepsy, and paroxysmal non-epileptic findings including intermittent ataxia, choreoathetosis, dystonia, and alternating hemiplegia. The classic phenotype is characterized by infantile-onset seizures, delayed neurologic development, acquired microcephaly, and complex movement disorders. Seizures in classic early-onset Glut1 DS begin before age six months. Several seizure types occur: generalized tonic or clonic, focal, myoclonic, atypical absence, atonic, and unclassified. In some infants, apneic episodes and abnormal episodic eye-head movements similar to opsoclonus may precede the onset of seizures. The frequency, severity, and type of seizures vary among affected individuals and are not related to disease severity. Cognitive impairment, ranging from learning disabilities to severe intellectual disability, is typical. The complex movement disorder, characterized by ataxia, dystonia, and chorea, may occur in any combination and may be continuous, paroxysmal, or continual with fluctuations in severity influenced by environmental factors such as fasting or with infectious stress. Symptoms often improve substantially when a ketogenic diet is started.","alternate_symbols":["DYT18","PED"],"alternate_names":["Dystonia 18","GLUT1 deficiency syndrome 2, childhood onset","PAROXYSMAL EXERCISE-INDUCED DYSKINESIA WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA","PAROXYSMAL EXERTION-INDUCED DYSTONIA WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA","PED WITH OR WITHOUT EPILEPSY AND/OR HEMOLYTIC ANEMIA"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301604\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1431\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"GKD","medgen_id":"C0268418","xrefs":["{\"db\":\"OMIM\",\"id\":\"307030\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"284408\"}","{\"db\":\"Orphanet\",\"id\":\"284411\"}","{\"db\":\"Orphanet\",\"id\":\"284414\"}","{\"db\":\"Orphanet\",\"id\":\"408\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hyperglycerolemia/3554\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"124322002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1431\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"307030\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2807\",\"ref_field\":\"symbol\"}"],"name":"Deficiency of glycerol kinase","id":"1727","public_definition":"NR0B1-related adrenal hypoplasia congenita includes both X-linked adrenal hypoplasia congenita (X-linked AHC) and Xp21 deletion (previously called complex glycerol kinase deficiency). X-linked AHC is characterized by primary adrenal insufficiency and/or hypogonadotropic hypogonadism (HH). Adrenal insufficiency is acute infantile onset (average age 3 weeks) in approximately 60% of affected males and childhood onset (ages 1-9 years) in approximately 40%. HH typically manifests in a male with adrenal insufficiency as delayed puberty (i.e., onset age \u003e14 years) and less commonly as arrested puberty at about Tanner Stage 3. Rarely, X-linked AHC manifests initially in early adulthood as delayed-onset adrenal insufficiency, partial HH, and/or infertility. Heterozygous females very occasionally have manifestations of adrenal insufficiency or hypogonadotropic hypogonadism. Xp21 deletion includes deletion of NR0B1 (causing X-linked AHC) and GK (causing glycerol kinase deficiency), and in some cases deletion of DMD (causing Duchenne muscular dystrophy). Developmental delay has been reported in males with Xp21 deletion when the deletion extends proximally to include DMD or when larger deletions extend distally to include IL1RAPL1 and DMD.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301609\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1436\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"EDMD2","medgen_id":"C0410190","xrefs":["{\"db\":\"OMIM\",\"id\":\"181350\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"261\"}","{\"db\":\"Orphanet\",\"id\":\"98853\"}","{\"db\":\"OMIM\",\"id\":\"181350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CARDIOMYOPATHY, DILATED, WITH QUADRICEPS MYOPATHY\"}","{\"db\":\"OMIM\",\"id\":\"150330.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"150330.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"150330.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"150330.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"150330.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"150330.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"150330.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"150330.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"150330.0032\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"150330.0035\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"150330.0038\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"181350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"181350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HAUPTMANN-THANNHAUSER MUSCULAR DYSTROPHY\"}","{\"db\":\"OMIM\",\"id\":\"181350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY WITH EARLY CONTRACTURES AND CARDIOMYOPATHY, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"181350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1B\"}","{\"db\":\"OMIM\",\"id\":\"181350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, PROXIMAL, TYPE 1B\"}","{\"db\":\"OMIM\",\"id\":\"181350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SCAPULOILIOPERONEAL ATROPHY WITH CARDIOPATHY\"}","{\"db\":\"OMIM\",\"id\":\"181350\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EMD2\"}","{\"db\":\"OMIM\",\"id\":\"181350\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LGMD1B\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Benign+scapuloperoneal+muscular+dystrophy+with+cardiomyopathy/7808\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"240072005\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1436\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"181350\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Benign scapuloperoneal muscular dystrophy with cardiomyopathy","id":"1590","public_definition":"Emery-Dreifuss muscular dystrophy (EDMD) is characterized by the clinical triad of: joint contractures that begin in early childhood; slowly progressive muscle weakness and wasting initially in a humero-peroneal distribution that later extends to the scapular and pelvic girdle muscles; and cardiac involvement that may manifest as palpitations, presyncope and syncope, poor exercise tolerance, and congestive heart failure along with variable cardiac rhythm disturbances. Age of onset, severity, and progression of muscle and cardiac involvement demonstrate both inter- and intrafamilial variability. Clinical variability ranges from early onset with severe presentation in childhood to late onset with slow progression in adulthood. In general, joint contractures appear during the first two decades, followed by muscle weakness and wasting. Cardiac involvement usually occurs after the second decade and respiratory function may be impaired in some individuals.","alternate_symbols":["EMD2","LGMD1B"],"alternate_names":["Autosomal Dominant Emery-Dreifuss Muscular Dystrophy","CARDIOMYOPATHY, DILATED, WITH QUADRICEPS MYOPATHY","EMERY-DREIFUSS MUSCULAR DYSTROPHY 2, AUTOSOMAL DOMINANT","HAUPTMANN-THANNHAUSER MUSCULAR DYSTROPHY","LMNA-Related Dilated Cardiomyopathy","LMNA-Related Emery-Dreifuss Muscular Dystrophy, Autosomal","MUSCULAR DYSTROPHY WITH EARLY CONTRACTURES AND CARDIOMYOPATHY, AUTOSOMAL DOMINANT","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1B","MUSCULAR DYSTROPHY, PROXIMAL, TYPE 1B","SCAPULOILIOPERONEAL ATROPHY WITH CARDIOPATHY"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301609\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1436\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"EDMD1","medgen_id":"C0751337","xrefs":["{\"db\":\"OMIM\",\"id\":\"310300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"261\"}","{\"db\":\"Orphanet\",\"id\":\"98863\"}","{\"db\":\"OMIM\",\"id\":\"310300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EMD1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Emery-Dreifuss+Muscular+Dystrophy/2510\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1436\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"310300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2102\",\"ref_field\":\"symbol\"}"],"name":"Emery-Dreifuss muscular dystrophy 1, X-linked","id":"15903","public_definition":"Emery-Dreifuss muscular dystrophy (EDMD) is characterized by the clinical triad of: joint contractures that begin in early childhood; slowly progressive muscle weakness and wasting initially in a humero-peroneal distribution that later extends to the scapular and pelvic girdle muscles; and cardiac involvement that may manifest as palpitations, presyncope and syncope, poor exercise tolerance, and congestive heart failure along with variable cardiac rhythm disturbances. Age of onset, severity, and progression of muscle and cardiac involvement demonstrate both inter- and intrafamilial variability. Clinical variability ranges from early onset with severe presentation in childhood to late onset with slow progression in adulthood. In general, joint contractures appear during the first two decades, followed by muscle weakness and wasting. Cardiac involvement usually occurs after the second decade and respiratory function may be impaired in some individuals.","alternate_symbols":["EMD1"],"alternate_names":["EMD-Related Cardiomyopathy"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301617\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1444\",\"@Source\":\"BookShelf\"}]}}","keywords":["hereditary cancer syndrome"],"symbol":"FHL","medgen_id":"C0272199","xrefs":["{\"db\":\"Orphanet\",\"id\":\"158038\"}","{\"db\":\"Orphanet\",\"id\":\"540\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hemophagocytic+Lymphohistiocytosis+%28HLH%29/3306\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hemophagocytic lymphohistiocytosis\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6589\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"398250003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1444\",\"ref_field\":\"public_definition\"}"],"name":"Familial hemophagocytic lymphohistiocytosis","id":"14293","public_definition":"Familial hemophagocytic lymphohistiocytosis (FHL) is characterized by proliferation and infiltration of hyperactivated macrophages and T-lymphocytes manifesting as acute illness with prolonged fever, cytopenias, and hepatosplenomegaly. Onset is typically within the first months or years of life and, on occasion, in utero, although later childhood or adult onset is more common than previously suspected. Neurologic abnormalities may be present initially or may develop later; they may include increased intracranial pressure, irritability, neck stiffness, hypotonia, hypertonia, convulsions, cranial nerve palsies, ataxia, hemiplegia, quadriplegia, blindness, and coma. Rash and lymphadenopathy are less common. Other findings include liver dysfunction and bone marrow hemophagocytosis. The median survival of children with typical FHL, without treatment, is less than two months; progression of hemophagocytic lymphohistiocytosis and infection account for the majority of deaths in untreated individuals.","alternate_symbols":["HPLH"],"alternate_names":["Hemophagocytic lymphohistiocytosis"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301672\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1499\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"MFM3","medgen_id":"C3714934","xrefs":["{\"db\":\"OMIM\",\"id\":\"609200\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"609200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1\"}","{\"db\":\"OMIM\",\"id\":\"609200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1A\"}","{\"db\":\"OMIM\",\"id\":\"609200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LGMD1\"}","{\"db\":\"OMIM\",\"id\":\"609200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LGMD1A\"}","{\"db\":\"OMIM\",\"id\":\"609200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Myofibrillar myopathy 3","id":"3430","alternate_symbols":["LGMD1","LGMD1A"],"alternate_names":["MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 1A"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301699\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1526\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"RSTS1","medgen_id":"C4551859","xrefs":["{\"db\":\"OMIM\",\"id\":\"180849\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"353277\"}","{\"db\":\"Orphanet\",\"id\":\"783\"}","{\"db\":\"OMIM\",\"id\":\"600140.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RUBINSTEIN-TAYBI SYNDROME 1, INCOMPLETE\"}","{\"db\":\"OMIM\",\"id\":\"600140.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RUBINSTEIN-TAYBI SYNDROME 1, INCOMPLETE\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7593\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RTS\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1526\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"180849\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Rubinstein-Taybi syndrome 1","id":"4360","public_definition":"Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.","alternate_symbols":["CREBBP","RTS"],"alternate_names":["RUBINSTEIN-TAYBI SYNDROME 1, INCOMPLETE"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301699\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1526\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"RSTS2","medgen_id":"C3150941","xrefs":["{\"db\":\"OMIM\",\"id\":\"613684\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"353284\"}","{\"db\":\"Orphanet\",\"id\":\"783\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Rubinstein-Taybi+syndrome+2/9259\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1526\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613684\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Rubinstein-Taybi syndrome 2","id":"15794","public_definition":"Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.","alternate_symbols":["EP300"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301704\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1532\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C0242387","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005321\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"PS154500\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"861\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0005321\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mandibulofacial dysostosis\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9124\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MFD1\"}","{\"db\":\"OMIM\",\"id\":\"154500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TCOF\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9124\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TCOF\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9124\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TCS\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"treacher-collins-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9124\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"82203000\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1532\",\"ref_field\":\"public_definition\"}"],"name":"Treacher Collins syndrome","id":"6070","public_definition":"Treacher Collins syndrome (TCS) is characterized by bilateral and symmetric downslanting palpebral fissures, malar hypoplasia, micrognathia, and external ear abnormalities. Hypoplasia of the zygomatic bones and mandible can cause significant feeding and respiratory difficulties. About 40%-50% of individuals have conductive hearing loss attributed most commonly to malformation of the ossicles and hypoplasia of the middle ear cavities. Inner ear structures tend to be normal. Other, less common abnormalities include cleft palate and unilateral or bilateral choanal stenosis or atresia. Typically intellect is normal.","alternate_symbols":["MFD1","TCOF","TCS"],"alternate_names":["Mandibulofacial dysostosis"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301725\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1768\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"CMH16","medgen_id":"C3151204","xrefs":["{\"db\":\"OMIM\",\"id\":\"613838\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Familial+hypertrophic+cardiomyopathy+16/8389\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613838\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Familial hypertrophic cardiomyopathy 16","id":"16051","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301728\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1828\",\"@Source\":\"BookShelf\"}]}}","keywords":["Neoplasm"],"medgen_id":"C2673377","xrefs":["{\"db\":\"OMIM\",\"id\":\"252500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"576\"}","{\"db\":\"OMIM\",\"id\":\"252500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ML II ALPHA/BETA\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1828\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mucolipidosis II\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6749\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"GNPTA\"}","{\"db\":\"OMIM\",\"id\":\"252500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ICD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6749\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ICD\"}","{\"db\":\"OMIM\",\"id\":\"252500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ML II\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mucolipidosis+II/3706\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6749\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1828\",\"ref_field\":\"public_definition\"}"],"name":"I cell disease","id":"3038","public_definition":"GNPTAB-related disorders comprise the phenotypes mucolipidosis II (ML II) and mucolipidosis III/ (ML III/), and phenotypes intermediate between ML II and ML III/. ML II is evident at birth and slowly progressive; death most often occurs in early childhood. Orthopedic abnormalities present at birth may include thoracic deformity, kyphosis, clubfeet, deformed long bones, and/or dislocation of the hip(s). Growth often ceases in the second year of life; contractures develop in all large joints. The skin is thickened, facial features are coarse, and gingiva are hypertrophic. All children have cardiac involvement, most commonly thickening and insufficiency of the mitral valve and, less frequently, the aortic valve. Progressive mucosal thickening narrows the airways, and gradual stiffening of the thoracic cage contributes to respiratory insufficiency, the most common cause of death. ML III/ becomes evident at about age three years with slow growth rate and short stature; joint stiffness and pain initially in the shoulders, hips, and fingers; gradual mild coarsening of facial features; and normal to mildly impaired cognitive development. Pain from osteoporosis becomes more severe during adolescence. Cardiorespiratory complications (restrictive lung disease, thickening and insufficiency of the mitral and aortic valves, left and/or right ventricular hypertrophy) are common causes of death, typically in early to middle adulthood. Phenotypes intermediate between ML II and ML III/ are characterized by physical growth in infancy that resembles that of ML II and neuromotor and speech development that resemble that of ML III/.","alternate_symbols":["GNPTA","ICD","ML II"],"alternate_names":["ML II ALPHA/BETA","Mucolipidosis II","Mucolipidosis III Alpha/Beta"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301736\",\"@Source\":\"PubMed\"},{\"$\":\"NBK2534\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"BOOMD","medgen_id":"C0432201","xrefs":["{\"db\":\"OMIM\",\"id\":\"112310\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1263\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Boomerang+Dysplasia/895\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"933\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"254054000\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK2534\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"112310\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Boomerang dysplasia","id":"514","public_definition":"The FLNB-related disorders include a spectrum of phenotypes ranging from mild (spondylocarpotarsal synostosis [SCT] syndrome and Larsen syndrome) to severe (atelosteogenesis types I [AOI] and III [AOIII], boomerang dysplasia). SCT syndrome is characterized by disproportionate short stature, block vertebrae, scoliosis and lordosis, carpal and tarsal fusion, club feet, hearing loss, dental enamel hypoplasia, and mild facial dysmorphisms. Larsen syndrome is characterized by congenital dislocations of the hip, knee, and elbow; club feet (equinovarus or equinovalgus foot deformities); scoliosis and cervical kyphosis, which can be associated with a cervical myelopathy; short, broad, spatulate distal phalanges; and distinctive craniofacies (prominent forehead, depressed nasal bridge, malar flattening, and widely spaced eyes). Both can have midline cleft palate and conductive hearing loss. AOIII and AOI are characterized by severe short-limbed dwarfism; dislocated hips, knees, and elbows; and club feet. AOI is lethal in the perinatal period.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20556892\",\"@Source\":\"PubMed\"},{\"$\":\"NBK43797\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"RHS","medgen_id":"C1785148","xrefs":["{\"db\":\"OMIM\",\"id\":\"129400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3022\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Rapp-Hodgkin+syndrome/6153\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5690\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"7731005\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK43797\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"129400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5690\",\"ref_field\":\"symbol\"}"],"name":"Rapp-Hodgkin ectodermal dysplasia syndrome","id":"3593","public_definition":"The TP63-related disorders comprise six overlapping phenotypes: Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) syndrome (which includes Rapp-Hodgkin syndrome). Acro-dermo-ungual-lacrimal-tooth (ADULT) syndrome. Ectrodactyly, ectodermal dysplasia, cleft lip/palate syndrome 3 (EEC3). Limb-mammary syndrome. Split-hand/foot malformation type 4 (SHFM4). Isolated cleft lip/cleft palate (orofacial cleft 8). Individuals typically have varying combinations of ectodermal dysplasia (subjective hypohidrosis, nail dysplasia, sparse hair, tooth abnormalities), cleft lip/palate, split-hand/foot malformation/syndactyly, lacrimal duct obstruction, hypopigmentation, and hypoplastic breasts and/or nipples. Findings associated with a single phenotype include ankyloblepharon filiforme adnatum (tissue strands that completely or partially fuse the upper and lower eyelids), skin erosions especially on the scalp associated with areas of scarring and alopecia, hypospadias, trismus, and excessive freckling.","alternate_symbols":[],"alternate_names":["Orofacial Cleft 8"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"21089229\",\"@Source\":\"PubMed\"},{\"$\":\"NBK49247\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C0020072","xrefs":["{\"db\":\"Orphanet\",\"id\":\"970\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3976\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HSAN2\"}","{\"db\":\"GeneTests\",\"id\":\"319145\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK49247\",\"ref_field\":\"public_definition\"}"],"name":"Hereditary sensory and autonomic neuropathy type II","id":"14326","public_definition":"Hereditary sensory and autonomic neuropathy type II (HSAN2) is characterized by progressively reduced sensation to pain, temperature, and touch. Onset can be at birth and is often before puberty. The sensory deficit is predominantly distal with the lower limbs more severely affected than the upper limbs. Over time sensory function becomes severely reduced. Unnoticed injuries and neuropathic skin promote ulcerations and infections that result in spontaneous amputation of digits or the need for surgical amputation. Osteomyelitis is common. Painless fractures can complicate the disease. Autonomic disturbances are variable and can include hyperhidrosis, tonic pupils, and urinary incontinence in those with more advanced disease.","alternate_symbols":["HSAN2"],"alternate_names":["HSN Type II"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"22359776\",\"@Source\":\"PubMed\"},{\"$\":\"NBK84258\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"WITKOS","medgen_id":"C4310804","xrefs":["{\"db\":\"OMIM\",\"id\":\"613406\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"500166\"}","{\"db\":\"Orphanet\",\"id\":\"94065\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"15q24-microdeletion\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613406\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Witteveen-kolk syndrome","id":"6678","public_definition":"15q24 microdeletion is a chromosomal change in which a small piece of chromosome 15 is deleted in each cell. The deletion occurs on the long (q) arm of the chromosome at a position designated q24.15q24 microdeletion is associated with mild to moderate intellectual disability and delayed speech development. Other common signs and symptoms include short stature, weak muscle tone (hypotonia), and skeletal abnormalities including loose (lax) joints. Affected males may have genital abnormalities, which can include an unusually small penis (micropenis) and the opening of the urethra on the underside of the penis (hypospadias). Affected individuals also have distinctive facial features such as a high front hairline, broad eyebrows, widely set eyes (hypertelorism), outside corners of the eyes that point downward (downslanting palpebral fissures), a broad nasal bridge, a full lower lip, and a long, smooth space between the upper lip and nose (philtrum).","alternate_symbols":[],"alternate_names":["15q24 Microdeletion Syndrome"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"22420014\",\"@Source\":\"PubMed\"},{\"$\":\"NBK84550\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"MDWH","medgen_id":"C1834821","xrefs":["{\"db\":\"OMIM\",\"id\":\"250460\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1838\"}","{\"db\":\"OMIM\",\"id\":\"250460\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CHHV\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10622\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CHHV\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Metaphyseal+dysplasia+without+hypotrichosis/4702\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10622\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK84550\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"250460\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Metaphyseal dysplasia without hypotrichosis","id":"2910","public_definition":"The cartilage-hair hypoplasia  anauxetic dysplasia (CHH-AD) spectrum disorders are a continuum that includes the following phenotypes: Metaphyseal dysplasia without hypotrichosis (MDWH). Cartilage-hair hypoplasia (CHH). Anauxetic dysplasia (AD). CHH-AD spectrum disorders are characterized by severe disproportionate (short-limb) short stature that is usually recognized in the newborn, and occasionally prenatally because of the short extremities. Other findings include joint hypermobility, fine silky hair, immunodeficiency, anemia, increased risk for malignancy, gastrointestinal dysfunction, and impaired spermatogenesis. The most severe phenotype, AD, has the most pronounced skeletal phenotype, may be associated with atlantoaxial subluxation in the newborn, and may include cognitive deficiency. The clinical manifestations of the CHH-AD spectrum disorders are variable, even within the same family.","alternate_symbols":["CHHV"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"22934317\",\"@Source\":\"PubMed\"},{\"$\":\"NBK100241\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"HMNDYT1","medgen_id":"C2750442","xrefs":["{\"db\":\"OMIM\",\"id\":\"613280\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"309854\"}","{\"db\":\"OMIM\",\"id\":\"613280\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMDPC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypermanganesemia+with+dystonia+polycythemia+and+cirrhosis/3580\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10706\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK100241\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613280\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hypermanganesemia with dystonia 1","id":"6768","public_definition":"The disorder dystonia/parkinsonism, hypermanganesemia, polycythemia, and chronic liver disease is characterized by the following: A movement disorder resulting from manganese accumulation in the basal ganglia. Whole-blood manganese concentrations that often exceed 2000 nmol/L (normal: \u003c320 nmol/L). Polycythemia. Hepatomegaly with variable hepatic fibrosis/cirrhosis. Neurologic findings can manifest: in childhood (ages 2-15 years) as four-limb dystonia, leading to a characteristic high-stepping gait (\"cock-walk gait\"), dysarthria, fine tremor, and bradykinesia or on occasion spastic paraplegia; or in adulthood as parkinsonism (shuffling gait, rigidity, bradykinesia, hypomimia, and monotone speech) unresponsive to L-dopa treatment. Hepatic failure, secondary complications of cirrhosis, and the neurologic disorder shorten life expectancy.","alternate_symbols":["HMDPC"],"alternate_names":["Dystonia/Parkinsonism, Hypermanganesemia, Polycythemia, and Chronic Liver Disease","Hepatic Cirrhosis, Dystonia, Polycythemia and Hypermanganesemia","Hypermanganesemia with dystonia"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23193613\",\"@Source\":\"PubMed\"},{\"$\":\"NBK114459\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"LGMDR12","medgen_id":"C1969785","xrefs":["{\"db\":\"OMIM\",\"id\":\"611307\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"206549\"}","{\"db\":\"OMIM\",\"id\":\"608662.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12\"}","{\"db\":\"OMIM\",\"id\":\"608662.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12\"}","{\"db\":\"OMIM\",\"id\":\"608662.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12\"}","{\"db\":\"OMIM\",\"id\":\"608662.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12\"}","{\"db\":\"OMIM\",\"id\":\"608662.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12\"}","{\"db\":\"OMIM\",\"id\":\"608662.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12\"}","{\"db\":\"OMIM\",\"id\":\"611307\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12\"}","{\"db\":\"OMIM\",\"id\":\"611307\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LGMD2L\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Muscular+dystrophy%2C+limb-girdle%2C+type+2l/8929\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK114459\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"611307\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Limb-girdle muscular dystrophy, type 2L","id":"2991","public_definition":"The spectrum of ANO5 muscle disease is a continuum that ranges from asymptomatic hyperCKemia and exercise-induced myalgia to proximal and/or distal muscle weakness. The most typical presentation is limb-girdle muscular dystrophy type 2L (LGMD2L) with late-onset proximal lower-limb weakness in the fourth or fifth decade (range 15-70 years). Less common is Miyoshi-like disease (Miyoshi muscular dystrophy 3) with early-adult-onset calf distal myopathy (around age 20 years). Incidental hyperCKemia may be present even earlier. Initial symptoms are walking difficulties, reduced sports performance, and difficulties in standing on toes as well as nonspecific exercise myalgia and/or burning sensation in the calf muscles. Muscle weakness and atrophy are frequently asymmetric. Cardiac findings can include cardiomyopathy and arrhythmias and/or left ventricular dysfunction. Bulbar or respiratory symptoms have not been reported. Females have milder disease manifestations than males. Disease progression is slow in both the LGMD and distal forms; ambulation is preserved until very late in the disease course. Life span is normal.","alternate_symbols":["LGMD2L"],"alternate_names":["MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23236639\",\"@Source\":\"PubMed\"},{\"$\":\"NBK114805\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"HBLRR","medgen_id":"C0220991","xrefs":["{\"db\":\"OMIM\",\"id\":\"237450\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3111\"}","{\"db\":\"OMIM\",\"id\":\"604843.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERBILIRUBINEMIA, ROTOR TYPE, DIGENIC\"}","{\"db\":\"OMIM\",\"id\":\"604843.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERBILIRUBINEMIA, ROTOR TYPE, DIGENIC\"}","{\"db\":\"OMIM\",\"id\":\"604843.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERBILIRUBINEMIA, ROTOR TYPE, DIGENIC\"}","{\"db\":\"OMIM\",\"id\":\"605495.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERBILIRUBINEMIA, ROTOR TYPE, DIGENIC\"}","{\"db\":\"OMIM\",\"id\":\"605495.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERBILIRUBINEMIA, ROTOR TYPE, DIGENIC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Rotor+syndrome/6364\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"rotor-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"218\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"32891000\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK114805\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"237450\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Rotor syndrome","id":"5279","public_definition":"Rotor syndrome is characterized by mild conjugated and unconjugated hyperbilirubinemia that usually begins shortly after birth or in childhood. Jaundice may be intermittent. Conjunctival icterus may be the only clinical manifestation.","alternate_symbols":[],"alternate_names":["HYPERBILIRUBINEMIA, ROTOR TYPE, DIGENIC"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23285490\",\"@Source\":\"PubMed\"},{\"$\":\"NBK115333\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"GSD4","medgen_id":"C0017923","xrefs":["{\"db\":\"OMIM\",\"id\":\"232500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"308621\"}","{\"db\":\"Orphanet\",\"id\":\"308638\"}","{\"db\":\"Orphanet\",\"id\":\"308684\"}","{\"db\":\"Orphanet\",\"id\":\"308712\"}","{\"db\":\"Orphanet\",\"id\":\"367\"}","{\"db\":\"OMIM\",\"id\":\"232500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GBE1 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"232500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GLYCOGENOSIS IV\"}","{\"db\":\"OMIM\",\"id\":\"232500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GSD IV\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Glycogen+Storage+Disease+Type+4/3124\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"11179002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK115333\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"232500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Glycogen storage disease, type IV","id":"5200","public_definition":"The clinical manifestations of glycogen storage disease type IV (GSD IV) discussed in this entry span a continuum of different subtypes with variable ages of onset, severity, and clinical features. Clinical findings vary extensively both within and between families. The fatal perinatal neuromuscular subtype presents in utero with fetal akinesia deformation sequence, including decreased fetal movements, polyhydramnios, and fetal hydrops. Death usually occurs in the neonatal period. The congenital neuromuscular subtype presents in the newborn period with profound hypotonia, respiratory distress, and dilated cardiomyopathy. Death usually occurs in early infancy. Infants with the classic (progressive) hepatic subtype may appear normal at birth, but rapidly develop failure to thrive; hepatomegaly, liver dysfunction, and progressive liver cirrhosis; hypotonia; and cardiomyopathy. Without liver transplantation, death from liver failure usually occurs by age five years. Children with the non-progressive hepatic subtype tend to present with hepatomegaly, liver dysfunction, myopathy, and hypotonia; however, they are likely to survive without progression of the liver disease and may not show cardiac, skeletal muscle, or neurologic involvement. The childhood neuromuscular subtype is rare and the course is variable, ranging from onset in the second decade with a mild disease course to a more severe, progressive course resulting in death in the third decade.","alternate_symbols":[],"alternate_names":["Adult Polyglucosan Body Disease","GBE1 DEFICIENCY","GLYCOGENOSIS IV","GSD IV"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23946964\",\"@Source\":\"PubMed\"},{\"$\":\"NBK153723\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"MCKD1","medgen_id":"C1868139","xrefs":["{\"db\":\"OMIM\",\"id\":\"174000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"34149\"}","{\"db\":\"Orphanet\",\"id\":\"88949\"}","{\"db\":\"OMIM\",\"id\":\"174000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ADMCKD1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7002\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ADMCKD1\"}","{\"db\":\"OMIM\",\"id\":\"174000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MCKD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7002\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MCKD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Medullary+cystic+kidney+disease+1/4549\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK153723\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"174000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7002\",\"ref_field\":\"symbol\"}"],"name":"Medullary cystic kidney disease 1","id":"2836","public_definition":"Autosomal dominant tubulointerstitial kidney disease, MUC1-related (ADTKD-MUC1) was previously known as medullary cystic kidney disease type 1. It is characterized by slowly progressive tubulointerstitial disease that leads to end-stage renal disease (ESRD) and the need for dialysis or kidney transplantation. ESRD typically occurs in adulthood but is extremely variable, occurring at any age between 20 and 70 years. There are no other systemic manifestations.","alternate_symbols":["ADMCKD1","MCKD"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"NPHP9","medgen_id":"C3151188","xrefs":["{\"db\":\"OMIM\",\"id\":\"613824\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"655\"}","{\"db\":\"GeneTests\",\"id\":\"315147\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nephronophthisis+9/8985\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613824\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Nephronophthisis 9","id":"9716","public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"NPHP18","medgen_id":"C3890591","xrefs":["{\"db\":\"OMIM\",\"id\":\"615862\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"655\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615862\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Nephronophthisis 18","id":"21233","public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"NPHP11","medgen_id":"C3150796","xrefs":["{\"db\":\"OMIM\",\"id\":\"613550\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"84081\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nephronophthisis+11/8979\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613550\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Nephronophthisis 11","id":"9715","public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","alternate_symbols":["TMEM67"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"NPHP16","medgen_id":"C3809320","xrefs":["{\"db\":\"OMIM\",\"id\":\"615382\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"655\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615382\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Nephronophthisis 16","id":"18247","public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"NPHPL1","medgen_id":"C3150419","xrefs":["{\"db\":\"OMIM\",\"id\":\"613159\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"655\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nephronophthisis-like+nephropathy+1/8986\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613159\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Nephronophthisis-like nephropathy 1","id":"9598","public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"NPHP7","medgen_id":"C1969092","xrefs":["{\"db\":\"OMIM\",\"id\":\"611498\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"655\"}","{\"db\":\"GeneTests\",\"id\":\"315139\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nephronophthisis+7/8983\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"611498\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Nephronophthisis 7","id":"5621","public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"NPHP4","medgen_id":"C1847013","xrefs":["{\"db\":\"OMIM\",\"id\":\"606966\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"655\"}","{\"db\":\"OMIM\",\"id\":\"606966\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEPHRONOPHTHISIS 4, JUVENILE\"}","{\"db\":\"GeneTests\",\"id\":\"203272\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nephronophthisis+4/8982\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"606966\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Nephronophthisis 4","id":"3029","public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","alternate_symbols":[],"alternate_names":["NEPHRONOPHTHISIS 4, JUVENILE"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27929632\",\"@Source\":\"PubMed\"},{\"$\":\"NBK401562\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C3281138","xrefs":["{\"db\":\"OMIM\",\"id\":\"614527\",\"type\":\"MIM\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK401562\",\"ref_field\":\"public_definition\"}"],"name":"Chromosome 17q12 deletion syndrome","id":"16859","public_definition":"The 17q12 recurrent deletion syndrome is characterized by variable combinations of the three following findings: structural or functional abnormalities of the kidney and urinary tract, maturity-onset diabetes of the young type 5 (MODY5), and neurodevelopmental or neuropsychiatric disorders (e.g., developmental delay, intellectual disability, autism spectrum disorder, schizophrenia, anxiety, and bipolar disorder). Using a method of data analysis that avoids ascertainment bias, the authors determined that multicystic kidneys and other structural renal anomalies occur in 80% to 85% of affected individuals, MODY5 in approximately 40%, and some degree of developmental delay or learning disability in approximately 50%. MODY5 is most often diagnosed before age 25 years (range: age 10-50 years).","alternate_symbols":[],"alternate_names":["17q12 Microdeletion Syndrome","17q12 Recurrent Microdeletion Syndrome"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"28448108\",\"@Source\":\"PubMed\"},{\"$\":\"NBK426063\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"MRD31","medgen_id":"C4015357","xrefs":["{\"db\":\"OMIM\",\"id\":\"616158\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"438213\"}","{\"db\":\"Orphanet\",\"id\":\"438216\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK426063\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616158\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Mental retardation, autosomal dominant 31","id":"32585","public_definition":"PURA-related neurodevelopmental disorders include PURA syndrome, caused by a heterozygous pathogenic sequence variant in PURA, and 5q31.3 deletion syndrome, caused by a genomic 5q31.3 deletion encompassing all or part of PURA.PURA-related neurodevelopmental disorders are characterized by moderate to severe neurodevelopmental delay with absence of speech in most and lack of independent ambulation in many. Early-onset problems can include hypotonia, hypothermia, hypersomnolence, feeding difficulties, excessive hiccups, recurrent central and obstructive apneas, epileptic seizures, abnormal nonepileptic movements (dystonia, dyskinesia, and dysconjugate eye movements), and abnormal vision. Congenital heart defects, urogenital malformations, skeletal abnormalities, and endocrine disorders occur, but are less common.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"28541650\",\"@Source\":\"PubMed\"},{\"$\":\"NBK431123\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"HMNDYT2","medgen_id":"C4310765","xrefs":["{\"db\":\"OMIM\",\"id\":\"617013\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"521406\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK431123\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"617013\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Hypermanganesemia with dystonia 2","id":"35747","public_definition":"SLC39A14 deficiency is characterized by evidence between ages six months and three years of delay or loss of motor developmental milestones (e.g., delayed walking, gait disturbance). Early in the disease course, children show axial hypotonia followed by dystonia, spasticity, dysarthria, bulbar dysfunction, and signs of parkinsonism including bradykinesia, hypomimia, and tremor. By the end of the first decade they develop severe, generalized, pharmaco-resistant dystonia, limb contractures, and scoliosis, and lose independent ambulation. Cognitive impairment appears to be less prominent than motor disability. Some affected children have succumbed in their first decade due to secondary complications such as respiratory infections.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"28837307\",\"@Source\":\"PubMed\"},{\"$\":\"NBK447920\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"PTLS","medgen_id":"C2931246","xrefs":["{\"db\":\"Gene\",\"id\":\"100038247\"}","{\"db\":\"OMIM\",\"id\":\"610883\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1713\"}","{\"db\":\"OMIM\",\"id\":\"610883\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHROMOSOME 17p11.2 DUPLICATION SYNDROME\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Potocki-Lupski+syndrome/5903\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Potocki-Lupski syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Chromosome+17%2C+Trisomy+17p11+2/1476\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5319\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK447920\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"610883\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10145\",\"ref_field\":\"symbol\"}"],"name":"Chromosome 17, trisomy 17p11 2","id":"8007","public_definition":"Potocki-Lupski syndrome (PTLS) is characterized by cognitive, behavioral, and medical manifestations. Cognitively, most individuals present with developmental delay, later meeting criteria for moderate intellectual disability. Behaviorally, issues with attention, hyperactivity, withdrawal, and anxiety may be seen. Some individuals meet criteria for autism spectrum disorder. Medically, hypotonia, oropharyngeal dysphagia leading to failure to thrive, congenital heart disease, hypoglycemia associated with growth hormone deficiency, and mildly dysmorphic facial features are observed. Medical manifestations typically lead to identification of PTLS in infancy; however, those with only behavioral and cognitive manifestations may be identified in later childhood.","alternate_symbols":[],"alternate_names":["CHROMOSOME 17p11.2 DUPLICATION SYNDROME","Potocki-Lupski syndrome"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"30973693\",\"@Source\":\"PubMed\"},{\"$\":\"NBK540017\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"COGIS","medgen_id":"C4479654","xrefs":["{\"db\":\"OMIM\",\"id\":\"617561\",\"type\":\"MIM\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK540017\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"617561\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Cohen-Gibson syndrome","id":"37914","public_definition":"EED-related overgrowth is characterized by fetal or early childhood overgrowth (tall stature, macrocephaly, large hands and feet, and advanced bone age) and intellectual disability that ranges from mild to severe. To date, EED overgrowth has been reported in eight individuals.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31021590\",\"@Source\":\"PubMed\"},{\"$\":\"NBK540448\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"SKDEAS","medgen_id":"C4539927","xrefs":["{\"db\":\"OMIM\",\"id\":\"617616\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"513456\"}","{\"db\":\"OMIM\",\"id\":\"617616\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INTELLECTUAL DISABILITY WITH SEIZURES, ABNORMAL GAIT, AND DISTINCTIVE FACIAL FEATURES\"}","{\"db\":\"OMIM\",\"id\":\"617424.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617424.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617424.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617424.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617424.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617424.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617616\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK540448\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"617616\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"SKRABAN-DEARDORFF SYNDROME","id":"37989","public_definition":"WDR26-related intellectual disability (ID) is characterized by developmental delay / intellectual disability, characteristic facial features, hypotonia, epilepsy, and infant feeding difficulties. To date 15 individuals, ages 24 months to 34 years, have been reported. Developmental delay is present in all individuals and ranges from mild to severe. All individuals have delayed speech. Although some begin to develop speech in the second year, others have remained nonverbal. Seizures, present in all affected individuals reported to date, can be febrile or non-febrile (tonic-clonic, absence, rolandic seizures); most seizures are self limited or respond well to standard treatment. Affected individuals are generally described as happy and socially engaging; several have stereotypies / autistic features (repetitive or rocking behavior, abnormal hand movements or posturing, and at times self-stimulation).","alternate_symbols":[],"alternate_names":["INTELLECTUAL DISABILITY WITH SEIZURES, ABNORMAL GAIT, AND DISTINCTIVE FACIAL FEATURES"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31070877\",\"@Source\":\"PubMed\"},{\"$\":\"NBK540959\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"DYTOABG","medgen_id":"C4310634","xrefs":["{\"db\":\"OMIM\",\"id\":\"617282\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"508093\"}","{\"db\":\"OMIM\",\"id\":\"617282\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 29, CHILDHOOD-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"617282\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DYT29\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK540959\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"617282\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Dystonia, childhood-onset, with optic atrophy and basal ganglia abnormalities","id":"36792","public_definition":"MECR-related neurologic disorder is characterized by a progressive childhood-onset movement disorder and optic atrophy; intellect is often  but not always  preserved. The movement disorder typically presents between ages one and 6.5 years and is mainly dystonia that can be accompanied by chorea and/or ataxia. Over time some affected individuals require assistive devices for mobility. Speech fluency and intelligibility are progressively impaired due to dysarthria. Optic atrophy typically develops between ages four and 12 years and manifests as reduced visual acuity, which can include functional blindness (also known as legal blindness) in adulthood. Because only 13 affected individuals are known to the authors, and because nearly half of them were diagnosed retrospectively as adults, the natural history of disease progression and other aspects of the phenotype have not yet been completely defined.","alternate_symbols":["DYT29"],"alternate_names":["DYSTONIA 29, CHILDHOOD-ONSET"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31194315\",\"@Source\":\"PubMed\"},{\"$\":\"NBK542334\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"CCHLND","medgen_id":"C3280965","xrefs":["{\"db\":\"OMIM\",\"id\":\"614482\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"300313\"}","{\"db\":\"Genetic Alliance\",\"id\":\"CONGENITAL+CATARACTS%2C+HEARING+LOSS%2C+AND+NEURODEGENERATION/8048\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK542334\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614482\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Congenital cataracts, hearing loss, and neurodegeneration","id":"16826","public_definition":"Huppke-Brendel syndrome (HBS) is characterized by bilateral congenital cataracts, sensorineural hearing loss, and severe developmental delay. To date, six individuals with HBS have been reported in the literature. All presented in infancy with axial hypotonia; motor delay was apparent in the first few months of life with lack of head control and paucity of limb movement. Seizures have been reported infrequently. In all individuals described to date serum copper and ceruloplasmin levels were very low or undetectable. Brain MRI examination showed hypomyelination, cerebellar hypoplasia mainly affecting the vermis, and wide subarachnoid spaces. None of the individuals reported to date were able to sit or walk independently. All affected individuals died between age ten months and six years.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31194316\",\"@Source\":\"PubMed\"},{\"$\":\"NBK542336\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"BRMUTD","medgen_id":"C4478940","xrefs":["{\"db\":\"OMIM\",\"id\":\"613735\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"401986\"}","{\"db\":\"OMIM\",\"id\":\"600727.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BRAIN MALFORMATIONS WITH OR WITHOUT URINARY TRACT DEFECTS\"}","{\"db\":\"OMIM\",\"id\":\"613735\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BRAIN MALFORMATIONS WITH OR WITHOUT URINARY TRACT DEFECTS\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK542336\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613735\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Brain malformations and urinary tract defects","id":"15751","public_definition":"For the purposes of this chapter, NFIA-related disorder is defined as heterozygous inactivation or disruption of only NFIA without involvement of adjacent or surrounding genes. NFIA-related disorder comprises central nervous system abnormalities (most commonly abnormalities of the corpus callosum) with or without urinary tract defects, such as unilateral or bilateral vesicoureteral reflux and hydronephrosis. Additional features include macrocephaly, seizures, developmental delay and/or cognitive impairment, nonspecific dysmorphic features, ventriculomegaly, and hypotonia, which can exacerbate motor delay and feeding issues in infancy. Rarer features may include strabismus, cutis marmorata, or craniosynostosis of the metopic, lambdoid, or sagittal suture.","alternate_symbols":[],"alternate_names":["BRAIN MALFORMATIONS WITH OR WITHOUT URINARY TRACT DEFECTS"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31219693\",\"@Source\":\"PubMed\"},{\"$\":\"NBK542806\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"ECHS1D","medgen_id":"C4225391","xrefs":["{\"db\":\"OMIM\",\"id\":\"616277\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"255241\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK542806\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616277\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Mitochondrial short-chain enoyl-coa hydratase 1 deficiency","id":"33046","public_definition":"Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency (ECHS1D) represents a clinical spectrum in which several phenotypes have been described: The most common phenotype presents in the neonatal period with severe encephalopathy and lactic acidosis and later manifests Leigh-like signs and symptoms. Those with presentation in the neonatal period typically have severe hypotonia, encephalopathy, or neonatal seizures within the first few days of life. Signs and symptoms typically progress quickly and the affected individual ultimately succumbs to central apnea or arrhythmia. A second group of affected individuals present in infancy with developmental regression resulting in severe developmental delay. A third group of affected individuals have normal development with isolated paroxysmal dystonia that may be exacerbated by illness or exertion. Across all three groups, T2 hyperintensity in the basal ganglia is very common, and may affect any part of the basal ganglia.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31219694\",\"@Source\":\"PubMed\"},{\"$\":\"NBK542807\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"NDHMSR","medgen_id":"C4693325","xrefs":["{\"db\":\"OMIM\",\"id\":\"617820\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"617820\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK542807\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"617820\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"NEURODEVELOPMENTAL DISORDER WITH OR WITHOUT HYPERKINETIC MOVEMENTS AND SEIZURES, AUTOSOMAL RECESSIVE","id":"38494","public_definition":"GRIN1-related neurodevelopmental disorder (GRIN1-NDD) is characterized by mild to profound developmental delay / intellectual disability (DD/ID) in all affected individuals. Other common manifestations are epilepsy, muscular hypotonia, movement disorders, spasticity, feeding difficulties, and behavior problems. To date, 72 individuals with GRIN1-NDD have been reported.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31294938\",\"@Source\":\"PubMed\"},{\"$\":\"NBK543515\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"SCA38","medgen_id":"C4518337","xrefs":["{\"db\":\"OMIM\",\"id\":\"615957\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"423296\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK543515\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615957\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Spinocerebellar ataxia 38","id":"31817","public_definition":"Spinocerebellar ataxia type 38 (SCA38) is characterized as a pure cerebellar ataxia with symptoms typically manifesting in the fourth decade of life. The most common presenting features are nystagmus and slowly progressive gait ataxia. As the disease progresses, cerebellar symptoms (limb ataxia, dysarthria, dysphagia, diplopia on the horizontal line) may emerge, and affected individuals may experience sensory loss. In the later stages of the condition, ophthalmoparesis followed by ophthalmoplegia may occur. Features that distinguish SCA38 from other spinocerebellar ataxias include pes cavus without paresis, hyposmia, hearing loss, and anxiety disorder. Dementia and extrapyramidal signs are not common features of SCA38. Brain imaging typically demonstrates cerebellar atrophy mainly affecting the vermis without atrophy of the cerebral cortex and a normal appearance of the brain stem. With disease progression, nerve conduction velocities and electromyography demonstrate a sensory and motor axonal polyneuropathy in all four extremities. Life span is apparently not decreased.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31393689\",\"@Source\":\"PubMed\"},{\"$\":\"NBK544951\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"VAIHS","medgen_id":"C3887654","xrefs":["{\"db\":\"OMIM\",\"id\":\"615688\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"404553\"}","{\"db\":\"OMIM\",\"id\":\"615688\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"615688\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DADA2\"}","{\"db\":\"OMIM\",\"id\":\"615688\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PAN\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7360\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PAN\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK544951\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615688\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Polyarteritis nodosa, childhoood-onset","id":"6159","public_definition":"Adenosine deaminase 2 deficiency (DADA2) is a complex systemic autoinflammatory disorder in which vasculopathy/vasculitis, dysregulated immune function, and/or hematologic abnormalities may predominate. Inflammatory features include intermittent fevers, rash (often livedo racemosa/reticularis), and musculoskeletal involvement (myalgia/arthralgia, arthritis, myositis). Vasculitis, which usually begins before age ten years, may manifest as early-onset ischemic (lacunar) and/or hemorrhagic strokes, or as cutaneous or systemic polyarteritis nodosa. Hypertension and hepatosplenomegaly are often found. More severe involvement may lead to progressive central neurologic deficits (dysarthria, ataxia, cranial nerve palsies, cognitive impairment) or to ischemic injury to the kidney, intestine, and/or digits. Dysregulation of immune function can lead to immunodeficiency or autoimmunity of varying severity; lymphadenopathy may be present and some affected individuals have had lymphoproliferative disease. Hematologic disorders may begin early in life or in late adulthood, and can include lymphopenia, neutropenia, pure red cell aplasia, thrombocytopenia, or pancytopenia. Of note, both interfamilial and intrafamilial phenotypic variability (e.g., in age of onset, frequency and severity of manifestations) can be observed; also, individuals with biallelic ADA2 pathogenic variants may remain asymptomatic until adulthood or may never develop clinical manifestations of DADA2.","alternate_symbols":["DADA2","PAN"],"alternate_names":["VASCULITIS, AUTOINFLAMMATION, IMMUNODEFICIENCY, AND HEMATOLOGIC DEFECTS SYNDROME"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"ES, 2012\",\"@Type\":\"practice guideline\",\"ID\":[{\"$\":\"22962670\",\"@Source\":\"PubMed\"},{\"$\":\"3431581\",\"@Source\":\"pmc\"}]}}","keywords":[],"medgen_id":"C1704429","xrefs":["{\"db\":\"OMIM\",\"id\":\"604091\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"425\"}","{\"db\":\"OMIM\",\"id\":\"604091\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HDL CHOLESTEROL, LOW SERUM\"}","{\"db\":\"OMIM\",\"id\":\"604091\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOALPHALIPOPROTEINEMIA, PRIMARY, 1\"}","{\"db\":\"OMIM\",\"id\":\"604091\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FHA\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2872\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FHA\"}","{\"db\":\"OMIM\",\"id\":\"604091\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FHD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2872\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FHD\"}","{\"db\":\"OMIM\",\"id\":\"604091\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HDLC\"}","{\"db\":\"OMIM\",\"id\":\"604091\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HDLD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2872\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HDLD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypoalphalipoproteinemia%2C+primary/3628\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"15346004\",\"ref_field\":\"name\"}"],"name":"Familial hypoalphalipoproteinemia","id":"5299","alternate_symbols":["FHA","FHD","HDLC","HDLD"],"alternate_names":["HDL CHOLESTEROL, LOW SERUM","HYPOALPHALIPOPROTEINEMIA, PRIMARY, 1","Hypoalphalipoproteinemia, primary"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301434\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1257\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Brandi et al., 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11739416\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ATA, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19469690\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21863057\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Int'l RET Mutation Consortium, 1996\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"8918855\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ES, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24893135\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NANETS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3419007\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","keywords":["Hereditary cancer syndrome","Neoplasm"],"symbol":"MEN2A","medgen_id":"C0025268","xrefs":["{\"db\":\"MeSH\",\"id\":\"D018813\"}","{\"db\":\"OMIM\",\"id\":\"171400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"247698\"}","{\"db\":\"Orphanet\",\"id\":\"653\"}","{\"db\":\"OMIM\",\"id\":\"164761.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0024\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0025\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0033\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0040\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0047\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"164761.0049\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"OMIM\",\"id\":\"171400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Multiple+endocrine+neoplasia+type+2A/4956\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"61808009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1257\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"171400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Multiple endocrine neoplasia, type 2a","id":"9534","public_definition":"Multiple endocrine neoplasia type 2 (MEN 2) includes the following phenotypes: MEN 2A, FMTC (familial medullary thyroid carcinoma, which may be a variant of MEN 2A), and MEN 2B. All three phenotypes involve high risk for development of medullary carcinoma of the thyroid (MTC); MEN 2A and MEN 2B involve an increased risk for pheochromocytoma; MEN 2A involves an increased risk for parathyroid adenoma or hyperplasia. Additional features in MEN 2B include mucosal neuromas of the lips and tongue, distinctive facies with enlarged lips, ganglioneuromatosis of the gastrointestinal tract, and a marfanoid habitus. MTC typically occurs in early childhood in MEN 2B, early adulthood in MEN 2A, and middle age in FMTC.","alternate_symbols":["RET"],"alternate_names":["MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"Decipher\",\"@Type\":\"review\",\"URL\":{\"$\":\"https://decipher.sanger.ac.uk/syndrome/2\"}},{\"@Abbrev\":\"ESHG/ASHG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25782669\",\"@Source\":\"PubMed\"}}]}","keywords":[],"medgen_id":"C0010314","xrefs":["{\"db\":\"OMIM\",\"id\":\"123450\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"281\"}","{\"db\":\"Decipher\",\"id\":\"2\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cri du Chat Syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"5p+partial+monosomy+syndrome/7619\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"70173007\",\"ref_field\":\"name\"}"],"name":"5p partial monosomy syndrome","id":"1689","alternate_symbols":[],"alternate_names":["Cri du Chat Syndrome"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"CPIC, 2011\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3098761\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"PLoS Currents, 2011\",\"@Type\":\"review\",\"URL\":{\"$\":\"http://currents.plos.org/genomictests/article/thiopurine-methyltransferase-tpmt-xv5k9xg3o4yu-8\"}},{\"@Abbrev\":\"CPIC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3604643\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"NACB, 2010\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"National Academy of Clinical Biochemistry, Clinical practice considerations. In: Laboratory medicine practice guidelines: guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice, 2010\"},\"URL\":{\"$\":\"https://www.guideline.gov/content.aspx?id=15664\"}}]}","keywords":[],"medgen_id":"CN971394","xrefs":["{\"db\":\"PharmGKB\",\"id\":\"PA356\",\"ref_field\":\"public_definition\"}"],"name":"Thiopurine response","id":"17938","public_definition":"The thiopurines include azathioprine (a pro-drug for mercaptopurine), mercaptopurine and thioguanine.  They are used to treat a variety of immunological disorders such as rheumatoid arthritis, non- Hodgkin lymphoma and ulcerative colitis. Both mercaptopurine and thioguanine can exert cytotoxic effects through the formation of thioguanine nucleotides (TGNs), active metabolites that incorporate into DNA. Mercaptopurine and thioguanine are directly inactivated by thiopurine S-methyltransferase (TPMT). Individuals with two nonfunctional TPMT alleles are at 100% risk of potentially fatal myelosuppression, due to an increased buildup of toxic TGNs. Alternative agents or a drastically reduced dose are recommended for patients with this genotype. Patients heterozygous for a nonfunctional TPMT allele are at increased risk of myelosuppression, and reduced dosing is recommended for these individuals. These dosing guidelines have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and are available on the PharmGKB website (http://www.pharmgkb.org/gene/PA356)","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"DrugResponse"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2011\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"20482602\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"PD","medgen_id":"C3160718","xrefs":["{\"db\":\"OMIM\",\"id\":\"168600\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"300144.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, AGE OF ONSET, MODIFIER\"}","{\"db\":\"OMIM\",\"id\":\"157140.0021\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"601517.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"603680.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"606463.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"606463.0048\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"607047.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+Disease/5603\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Parkinson's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"49049000\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Parkinson's disease\"}","{\"db\":\"OMIM\",\"id\":\"168600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PARK\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"parkinson-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"168600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Parkinson disease, late-onset","id":"3762","public_definition":"Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.Often the first symptom of Parkinson disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.Parkinson disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgment and memory.Generally, Parkinson disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson disease.","alternate_symbols":["PARK"],"alternate_names":["PARKINSON DISEASE, AGE OF ONSET, MODIFIER","PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO","Parkinson's disease"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301587\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1414\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2011\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"20482602\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"DYT11","medgen_id":"C1834570","xrefs":["{\"db\":\"OMIM\",\"id\":\"159900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"36899\"}","{\"db\":\"OMIM\",\"id\":\"159900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"OMIM\",\"id\":\"604149.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA 11, MYOCLONIC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dystonia+11/2408\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7139\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"439732004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1414\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"159900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7139\",\"ref_field\":\"symbol\"}"],"name":"Myoclonic dystonia","id":"3138","public_definition":"SGCE myoclonus-dystonia (SGCE-M-D) is a movement disorder characterized by a combination of rapid, brief muscle contractions (myoclonus) and/or sustained twisting and repetitive movements that result in abnormal postures (dystonia). The myoclonic jerks typical of SGCE-M-D most often affect the neck, trunk, and upper limbs with less common involvement of the legs. Approximately 50% of affected individuals have additional focal or segmental dystonia, presenting as cervical dystonia and/or writer's cramp. Non-motor features may include alcohol abuse, obsessive-compulsive disorder (OCD), and anxiety disorders. Symptom onset is usually in the first decade of life and almost always by age 20, but ranges from age six months to 80 years. Most affected adults report a dramatic reduction in myoclonus in response to alcohol ingestion. SGCE-M-D is compatible with an active life of normal span.","alternate_symbols":[],"alternate_names":["DYSTONIA 11, MYOCLONIC","Myoclonus-Dystonia"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301681\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1508\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2011\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"20482602\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"DRD","medgen_id":"C1851920","xrefs":["{\"db\":\"OMIM\",\"id\":\"128230\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98808\"}","{\"db\":\"OMIM\",\"id\":\"128230\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"OMIM\",\"id\":\"600225.0021\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA, DOPA-RESPONSIVE\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9817\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia\"}","{\"db\":\"OMIM\",\"id\":\"128230\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DYT5\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9817\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DYT5\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dystonia+5%2C+Dopa-Responsive+Type/2419\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9817\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1508\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"128230\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9817\",\"ref_field\":\"symbol\"}"],"name":"Dystonia 5, Dopa-responsive type","id":"1573","public_definition":"GTP cyclohydrolase 1-deficient dopa-responsive dystonia (GTPCH1-deficient DRD) is characterized by childhood-onset dystonia and a dramatic and sustained response to low doses of oral administration of levodopa. This disorder typically presents with gait disturbance caused by foot dystonia, later development of parkinsonism, and diurnal fluctuation of symptoms (aggravation of symptoms toward the evening and alleviation of symptoms in the morning after sleep). Initial symptoms are often gait difficulties attributable to flexion-inversion (equinovarus posture) of the foot. Occasionally, initial symptoms are arm dystonia, postural tremor of the hand, or slowness of movements. Brisk deep-tendon reflexes in the legs, ankle clonus, and/or the striatal toe (dystonic extension of the big toe) are present in many affected individuals. In general, gradual progression to generalized dystonia is observed. Intellectual, cerebellar, sensory, and autonomic disturbances generally do not occur.","alternate_symbols":["DYT5"],"alternate_names":["DYSTONIA, DOPA-RESPONSIVE","GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301303\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1124\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"AAP, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20876176\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"NS2","medgen_id":"C1854469","xrefs":["{\"db\":\"OMIM\",\"id\":\"605275\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"648\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Noonan+syndrome+2/5261\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10698\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1124\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"605275\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10698\",\"ref_field\":\"symbol\"}"],"name":"Noonan syndrome 2","id":"5653","public_definition":"Noonan syndrome (NS) is characterized by characteristic facies, short stature, congenital heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, varied coagulation defects, lymphatic dysplasias, and ocular abnormalities. Although birth length is usually normal, final adult height approaches the lower limit of normal. Congenital heart disease occurs in 50%-80% of individuals. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or develop in infancy or childhood. Other structural defects include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Up to one fourth of affected individuals have mild intellectual disability, and language impairments in general are more common in NS than in the general population.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301609\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1436\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"AAN, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25313375\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"EDMD","medgen_id":"C0410189","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS310300\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"261\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"emery-dreifuss-muscular-dystrophy\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6329\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"111508004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1436\",\"ref_field\":\"public_definition\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6329\",\"ref_field\":\"symbol\"}"],"name":"Emery-Dreifuss muscular dystrophy","id":"9490","public_definition":"Emery-Dreifuss muscular dystrophy (EDMD) is characterized by the clinical triad of: joint contractures that begin in early childhood; slowly progressive muscle weakness and wasting initially in a humero-peroneal distribution that later extends to the scapular and pelvic girdle muscles; and cardiac involvement that may manifest as palpitations, presyncope and syncope, poor exercise tolerance, and congestive heart failure along with variable cardiac rhythm disturbances. Age of onset, severity, and progression of muscle and cardiac involvement demonstrate both inter- and intrafamilial variability. Clinical variability ranges from early onset with severe presentation in childhood to late onset with slow progression in adulthood. In general, joint contractures appear during the first two decades, followed by muscle weakness and wasting. Cardiac involvement usually occurs after the second decade and respiratory function may be impaired in some individuals.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301609\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1436\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"XMPMA","medgen_id":"C2678055","xrefs":["{\"db\":\"OMIM\",\"id\":\"300696\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"178461\"}","{\"db\":\"Genetic Alliance\",\"id\":\"X-linked+myopathy+with+postural+muscle+atrophy/9517\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1436\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300696\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Myopathy with postural muscle atrophy, X-linked","id":"3423","public_definition":"Emery-Dreifuss muscular dystrophy (EDMD) is characterized by the clinical triad of: joint contractures that begin in early childhood; slowly progressive muscle weakness and wasting initially in a humero-peroneal distribution that later extends to the scapular and pelvic girdle muscles; and cardiac involvement that may manifest as palpitations, presyncope and syncope, poor exercise tolerance, and congestive heart failure along with variable cardiac rhythm disturbances. Age of onset, severity, and progression of muscle and cardiac involvement demonstrate both inter- and intrafamilial variability. Clinical variability ranges from early onset with severe presentation in childhood to late onset with slow progression in adulthood. In general, joint contractures appear during the first two decades, followed by muscle weakness and wasting. Cardiac involvement usually occurs after the second decade and respiratory function may be impaired in some individuals.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301680\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1507\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"CSTLO","medgen_id":"C0587248","xrefs":["{\"db\":\"OMIM\",\"id\":\"218040\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3071\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Costello+Syndrome/1942\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"costello-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1550\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"309776008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1507\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"218040\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Costello syndrome","id":"4860","public_definition":"While the majority of individuals with Costello syndrome share characteristic findings affecting multiple organ systems, the phenotypic spectrum is wide, ranging from a milder or attenuated phenotype to a severe phenotype with early lethal complications. Costello syndrome is typically characterized by failure to thrive in infancy as a result of severe postnatal feeding difficulties; short stature; developmental delay or intellectual disability; coarse facial features (full lips, large mouth, full nasal tip); curly or sparse, fine hair; loose, soft skin with deep palmar and plantar creases; papillomata of the face and perianal region; diffuse hypotonia and joint laxity with ulnar deviation of the wrists and fingers; tight Achilles tendons; and cardiac involvement including: cardiac hypertrophy (usually typical hypertrophic cardiomyopathy), congenital heart defect (usually valvar pulmonic stenosis), and arrhythmia (usually supraventricular tachycardia, especially chaotic atrial rhythm/multifocal atrial tachycardia or ectopic atrial tachycardia). Relative or absolute macrocephaly is typical, and postnatal cerebellar overgrowth can result in the development of a Chiari I malformation with associated anomalies including hydrocephalus or syringomyelia. Individuals with Costello syndrome have an approximately 15% lifetime risk for malignant tumors including rhabdomyosarcoma and neuroblastoma in young children and transitional cell carcinoma of the bladder in adolescents and young adults.","alternate_symbols":["CS"],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS/MDS-ES, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23279440\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"PARK7","medgen_id":"C1853445","xrefs":["{\"db\":\"OMIM\",\"id\":\"606324\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2828\"}","{\"db\":\"OMIM\",\"id\":\"602533.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"602533.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"602533.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"602533.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"602533.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"602533.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"606324\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+7/9090\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"parkinson-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"606324\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Parkinson disease 7","id":"3764","public_definition":"Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.Often the first symptom of Parkinson disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.Parkinson disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgment and memory.Generally, Parkinson disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson disease.","alternate_symbols":[],"alternate_names":["PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS/MDS-ES, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23279440\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"PARK15","medgen_id":"C1850100","xrefs":["{\"db\":\"OMIM\",\"id\":\"260300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"171695\"}","{\"db\":\"OMIM\",\"id\":\"605648.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"605648.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"605648.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"605648.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"260300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"260300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSONIAN-PYRAMIDAL SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"260300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PKPS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+15/9083\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"parkinson-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"260300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Parkinson disease 15","id":"3273","public_definition":"Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.Often the first symptom of Parkinson disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.Parkinson disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgment and memory.Generally, Parkinson disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson disease.","alternate_symbols":["PKPS"],"alternate_names":["PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE","PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE EARLY-ONSET","PARKINSONIAN-PYRAMIDAL SYNDROME"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS/MDS-ES, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23279440\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"PARK14","medgen_id":"C2751842","xrefs":["{\"db\":\"OMIM\",\"id\":\"612953\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"199351\"}","{\"db\":\"OMIM\",\"id\":\"612953\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA-PARKINSONISM, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"612953\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+14/9082\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"parkinson-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612953\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Parkinson disease 14","id":"6750","public_definition":"Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.Often the first symptom of Parkinson disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.Parkinson disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgment and memory.Generally, Parkinson disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson disease.","alternate_symbols":[],"alternate_names":["DYSTONIA-PARKINSONISM, ADULT-ONSET","PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS/MDS-ES, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23279440\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"PD","medgen_id":"C0030567","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS168600\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"319705\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+Disease/5603\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"49049000\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"168600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Parkinson disease","id":"33364","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301432\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1255\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS/ENS, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24418350\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"SACS","medgen_id":"C1849140","xrefs":["{\"db\":\"OMIM\",\"id\":\"270550\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98\"}","{\"db\":\"OMIM\",\"id\":\"270550\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC ATAXIA 6, AUTOSOMAL RECESSIVE\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1255\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ARSACS\"}","{\"db\":\"OMIM\",\"id\":\"270550\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ARSACS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4910\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ARSACS\"}","{\"db\":\"OMIM\",\"id\":\"270550\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SPAX6\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spastic+ataxia+Charlevoix-Saguenay+type/6671\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4910\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1255\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"270550\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4910\",\"ref_field\":\"symbol\"}"],"name":"Spastic ataxia Charlevoix-Saguenay type","id":"5931","public_definition":"ARSACS (autosomal recessive spastic ataxia of Charlevoix-Saguenay) is characterized in individuals born in Quebec Province by early-onset (age 12-18 months) difficulty in walking and gait unsteadiness. In individuals with ARSACS born outside the Province of Quebec, onset is often delayed until later childhood and even adulthood. Ataxia, dysarthria, spasticity, extensor plantar reflexes, distal muscle wasting, a distal sensorimotor neuropathy predominant in the legs, and horizontal gaze-evoked nystagmus constitute the most frequent progressive neurologic signs. Increased demarcation of the retinal nerve fibers located near the vessels close to the optic disc (formerly designated as yellow streaks of hypermyelinated fibers) is very common in individuals with ARSACS who originate from Quebec but may be absent in non-Quebec-born individuals. Individuals with ARSACS born in the Province of Quebec become wheelchair bound at the average age of 41 years; cognitive skills are preserved in the long term as individuals remain able to perform daily living tasks late into adulthood. Death commonly occurs in the sixth decade.","alternate_symbols":["ARSACS","SPAX6"],"alternate_names":["SPASTIC ATAXIA 6, AUTOSOMAL RECESSIVE"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"ACMG/NSGC, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25394175\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29215836\",\"@Source\":\"PubMed\"},{\"$\":\"NBK469816\",\"@Source\":\"BookShelf\"}]}]}","keywords":["Hereditary cancer syndrome","Neoplasm"],"symbol":"RTPS1","medgen_id":"C1836327","xrefs":["{\"db\":\"OMIM\",\"id\":\"609322\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"231108\"}","{\"db\":\"Orphanet\",\"id\":\"69077\"}","{\"db\":\"Orphanet\",\"id\":\"99966\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Rhabdoid+tumor+predisposition+syndrome+1/9251\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK469816\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"609322\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Rhabdoid tumor predisposition syndrome 1","id":"5873","public_definition":"Rhabdoid tumor predisposition syndrome (RTPS) is characterized by a markedly increased risk of developing rhabdoid tumors  rare and highly aggressive malignant tumors occurring predominantly in infants and children younger than age three years. Rhabdoid tumors can occur in almost any anatomic location, commonly in the central nervous system (i.e., atypical teratoid/rhabdoid tumor [AT/RT]); more than 50% occur in the cerebellum. Other common locations include extracranial extrarenal malignant rhabdoid tumors (e.g., rhabdoid tumors of the head and neck, paravertebral muscles, liver, bladder, mediastinum, retroperitoneum, pelvis, and heart) (eMRT), rhabdoid tumor of the kidney (RTK), and possibly small-cell carcinoma of the ovary (hypercalcemic type). Individuals with RTPS typically present before age 12 months with synchronous tumors that exhibit aggressive clinical behavior.","alternate_symbols":[],"alternate_names":["Familial Posterior Fossa Brain Tumor of Infancy"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"Int'l SCC for CMD, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21078917\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301468\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1291\",\"@Source\":\"BookShelf\"}]}]}","keywords":[],"symbol":"MDDGB6","medgen_id":"C1837229","xrefs":["{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98894\"}","{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, LARGE-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, TYPE 1D\"}","{\"db\":\"OMIM\",\"id\":\"603590.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 6\"}","{\"db\":\"OMIM\",\"id\":\"603590.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 6\"}","{\"db\":\"OMIM\",\"id\":\"603590.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 6\"}","{\"db\":\"OMIM\",\"id\":\"603590.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 6\"}","{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 6\"}","{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MDC1D\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+muscular+dystrophy-dystroglycanopathy+with+mental+retardation%2C+type+B6/8075\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608840\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Congenital muscular dystrophy-dystroglycanopathy with mental retardation, type B6","id":"2985","alternate_symbols":["MDC1D"],"alternate_names":["MUSCULAR DYSTROPHY, CONGENITAL, LARGE-RELATED","MUSCULAR DYSTROPHY, CONGENITAL, TYPE 1D","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH MENTAL RETARDATION), TYPE B, 6"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301434\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1257\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Brandi et al., 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11739416\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15604628\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"MEN2","medgen_id":"C4048306","xrefs":["{\"db\":\"Orphanet\",\"id\":\"653\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000021494\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260603\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000325033\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501433\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501488\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508573\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509383\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509879\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520186\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521505\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522280\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522559\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528040\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528367\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528651\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528909\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528911\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528912\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528913\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552183\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552245\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553206\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Multiple+endocrine+neoplasia%2C+type+2/4957\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3830\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"61808009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1257\",\"ref_field\":\"public_definition\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3830\",\"ref_field\":\"symbol\"}"],"name":"Multiple endocrine neoplasia, type 2","disease_mechanism":"gain of function","id":"14899","disease_mechanism_id":"274","public_definition":"Multiple endocrine neoplasia type 2 (MEN 2) includes the following phenotypes: MEN 2A, FMTC (familial medullary thyroid carcinoma, which may be a variant of MEN 2A), and MEN 2B. All three phenotypes involve high risk for development of medullary carcinoma of the thyroid (MTC); MEN 2A and MEN 2B involve an increased risk for pheochromocytoma; MEN 2A involves an increased risk for parathyroid adenoma or hyperplasia. Additional features in MEN 2B include mucosal neuromas of the lips and tongue, distinctive facies with enlarged lips, ganglioneuromatosis of the gastrointestinal tract, and a marfanoid habitus. MTC typically occurs in early childhood in MEN 2B, early adulthood in MEN 2A, and middle age in FMTC.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301327\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1148\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"THPH1","medgen_id":"C3160733","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004936\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004936\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Blood clot in vein\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THROMBOPHILIA DUE TO FACTOR 2 DEFECT\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thrombophilia/7086\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Thrombophilia\"}","{\"db\":\"SNOMED CT\",\"id\":\"234467004\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Thrombophilia\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"VENOUS THROMBOEMBOLISM\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500305\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"F2\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000025288\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000174333\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000246334\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000321099\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000326436\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331922\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331933\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332126\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332129\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502122\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502510\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503192\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505605\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507481\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509249\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511144\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520021\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520078\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521336\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521660\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522333\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530205\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530208\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530629\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531243\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552060\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556387\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004936\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"188050\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Venous thrombosis","disease_mechanism":"gain of function","id":"24727","disease_mechanism_id":"274","alternate_symbols":["F2"],"alternate_names":["Blood clot in vein","Prothrombin-Related Thrombophilia (Factor II)","THROMBOPHILIA DUE TO FACTOR 2 DEFECT","Thrombophilia","Thrombosis susceptibility","VENOUS THROMBOEMBOLISM"],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000525921\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000323271\"}]}"],"type":"Finding"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301540\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1366\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"TD2","medgen_id":"C1300257","xrefs":["{\"db\":\"OMIM\",\"id\":\"187601\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2655\"}","{\"db\":\"Orphanet\",\"id\":\"93274\"}","{\"db\":\"OMIM\",\"id\":\"187601\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"THANATOPHORIC DYSPLASIA WITH STRAIGHT FEMURS AND CLOVERLEAF SKULL\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226127\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226129\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327663\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000333529\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505530\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508854\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508990\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515562\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522269\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522270\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530324\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568358\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thanatophoric+dysplasia+type+2/7052\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"389158007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1366\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"187601\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1402\",\"ref_field\":\"symbol\"}"],"name":"Thanatophoric dysplasia, type 2","disease_mechanism":"gain of function","id":"4255","disease_mechanism_id":"274","public_definition":"Thanatophoric dysplasia (TD) is a short-limb dwarfism syndrome that is usually lethal in the perinatal period. TD is divided into type I, characterized by micromelia with bowed femurs and, uncommonly, the presence of cloverleaf skull deformity (Kleeblattschdel) of varying severity; and type II, characterized by micromelia with straight femurs and uniform presence of moderate-to-severe cloverleaf skull deformity. Other features common to type I and type II include: short ribs, narrow thorax, macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most affected infants die of respiratory insufficiency shortly after birth. Rare long-term survivors have been reported.","alternate_symbols":[],"alternate_names":["THANATOPHORIC DYSPLASIA WITH STRAIGHT FEMURS AND CLOVERLEAF SKULL","Thanatophoric Dysplasia"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301540\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1366\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"TD1","medgen_id":"C1868678","xrefs":["{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1860\"}","{\"db\":\"Orphanet\",\"id\":\"2655\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, SAN DIEGO TYPE\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, SAN DIEGO TYPE\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1366\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Thanatophoric Dysplasia\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TD\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226129\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327662\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327663\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327813\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000333529\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508438\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508854\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508990\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510735\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512698\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514902\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515562\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518899\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522269\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522270\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530324\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568358\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Thanatophoric+dysplasia+type+1/7051\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9295\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1366\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"187600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Thanatophoric dysplasia type 1","disease_mechanism":"gain of function","id":"4254","disease_mechanism_id":"274","public_definition":"Thanatophoric dysplasia (TD) is a short-limb dwarfism syndrome that is usually lethal in the perinatal period. TD is divided into type I, characterized by micromelia with bowed femurs and, uncommonly, the presence of cloverleaf skull deformity (Kleeblattschdel) of varying severity; and type II, characterized by micromelia with straight femurs and uniform presence of moderate-to-severe cloverleaf skull deformity. Other features common to type I and type II include: short ribs, narrow thorax, macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most affected infants die of respiratory insufficiency shortly after birth. Rare long-term survivors have been reported.","alternate_symbols":["TD"],"alternate_names":["LETHAL SHORT-LIMBED PLATYSPONDYLIC DWARFISM, SAN DIEGO TYPE","PLATYSPONDYLIC LETHAL SKELETAL DYSPLASIA, SAN DIEGO TYPE","Thanatophoric Dysplasia"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0020608","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000668\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"PS106600\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"99798\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000668\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Failure of development of between one and six teeth\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000668\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypodontia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000668\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Missing between one and six teeth\"}","{\"db\":\"OMIM\",\"id\":\"106600\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TOOTH AGENESIS, FAMILIAL\"}","{\"db\":\"OMIM\",\"id\":\"PS106600\",\"type\":\"Phenotypic series\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Tooth agenesis, selective\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000324344\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Tooth+agenesis%2C+selective%2C+1/9411\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"64969001\",\"ref_field\":\"name\"}"],"name":"Partial congenital absence of teeth","disease_mechanism":"loss of function","id":"33410","disease_mechanism_id":"273","alternate_symbols":[],"alternate_names":["Failure of development of between one and six teeth","Hypodontia","Missing between one and six teeth","TOOTH AGENESIS, FAMILIAL","Tooth agenesis, selective"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0175778","xrefs":["{\"db\":\"Orphanet\",\"id\":\"503\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508858\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522269\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522270\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Larsen+syndrome/4093\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"larsen-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6860\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"63387002\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"larsen-syndrome\",\"ref_field\":\"public_definition\"}"],"name":"Larsen syndrome","disease_mechanism":"loss of function","id":"14587","disease_mechanism_id":"273","public_definition":"Larsen syndrome is a disorder that affects the development of bones throughout the body. The signs and symptoms of Larsen syndrome vary widely even within the same family. Affected individuals are usually born with inward- and upward-turning feet (clubfeet) and dislocations of the hips, knees, and elbows. They generally have small extra bones in their wrists and ankles that are visible on x-ray images. The tips of their fingers, especially the thumbs, are typically blunt and square-shaped (spatulate).People with Larsen syndrome may also have an unusually large range of joint movement (hypermobility) and short stature. They can also have abnormal curvature of the spine (kyphosis or scoliosis) that may compress the spinal cord and lead to weakness of the limbs.Characteristic facial features include a prominent forehead (frontal bossing), flattening of the bridge of the nose and of the middle of the face (midface hypoplasia), and wide-set eyes (ocular hypertelorism). Some people with Larsen syndrome have an opening in the roof of the mouth (a cleft palate) or hearing loss caused by malformations in the tiny bones in the ears (ossicles). Some affected individuals experience respiratory problems as a result of weakness of the airways that can lead to partial closing, short pauses in breathing (apnea), and frequent respiratory infections. People with Larsen syndrome can survive into adulthood and intelligence is unaffected.","alternate_symbols":[],"alternate_names":[],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C0342471","xrefs":["{\"db\":\"MeSH\",\"id\":\"C579862\"}","{\"db\":\"OMIM\",\"id\":\"201810\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90791\"}","{\"db\":\"OMIM\",\"id\":\"201810\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"613890.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320609\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HSD3B2\"}","{\"db\":\"OMIM\",\"id\":\"201810\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HSDB\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320609\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500409\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503060\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508723\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000555663\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"3-Beta-Hydroxysteroid+Dehydrogenase+Deficiency/30\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"54470008\",\"ref_field\":\"name\"}"],"name":"3 beta-Hydroxysteroid dehydrogenase deficiency","disease_mechanism":"loss of function","id":"10967","disease_mechanism_id":"273","alternate_symbols":["HSD3B2","HSDB"],"alternate_names":["ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 3-BETA-HYDROXYSTEROID DEHYDROGENASE 2 DEFICIENCY"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"symbol":"ARCL2B","medgen_id":"C2751987","xrefs":["{\"db\":\"OMIM\",\"id\":\"612940\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"612940\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA WITH PROGEROID FEATURES\"}","{\"db\":\"OMIM\",\"id\":\"179035.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB\"}","{\"db\":\"OMIM\",\"id\":\"179035.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB\"}","{\"db\":\"OMIM\",\"id\":\"179035.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB\"}","{\"db\":\"OMIM\",\"id\":\"179035.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB\"}","{\"db\":\"OMIM\",\"id\":\"179035.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB\"}","{\"db\":\"OMIM\",\"id\":\"179035.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB\"}","{\"db\":\"OMIM\",\"id\":\"179035.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB\"}","{\"db\":\"OMIM\",\"id\":\"179035.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB\"}","{\"db\":\"OMIM\",\"id\":\"612940\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331788\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000510761\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553576\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561718\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Autosomal+recessive+cutis+laxa+type+2B/7790\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612940\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"Autosomal recessive cutis laxa type 2B","disease_mechanism":"loss of function","id":"6726","disease_mechanism_id":"273","alternate_symbols":[],"alternate_names":["CUTIS LAXA WITH PROGEROID FEATURES","CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IIB"],"attribute_content":[],"type":"Disease"}
{"keywords":[],"medgen_id":"C1536500","xrefs":["{\"db\":\"OMIM\",\"id\":\"203750\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"134\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"872\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Beta ketothiolase deficiency\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521369\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552246\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Deficiency+of+acetyl-CoA+acetyltransferase/8198\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"124258007\",\"ref_field\":\"name\"}"],"name":"Deficiency of acetyl-CoA acetyltransferase","disease_mechanism":"loss of function","id":"280","disease_mechanism_id":"273","alternate_symbols":[],"alternate_names":["Beta ketothiolase deficiency"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301505\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1330\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"TES, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"18782869\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111049\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"AAP, 2011\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21187304\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23519317\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESHG/ASHG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25782669\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"PWS","medgen_id":"C0032897","xrefs":["{\"db\":\"OMIM\",\"id\":\"176270\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"739\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000166462\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000202255\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000274682\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320921\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501126\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501985\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502292\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502862\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503131\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508986\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509082\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509337\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509731\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514010\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515779\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515780\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519582\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520019\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520411\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521642\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521657\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525860\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525867\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529012\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529077\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531722\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552178\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556577\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556611\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558215\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558519\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558935\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568371\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508917\",\"ref_field\":\"mode_of_inheritance\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Prader-Willi+syndrome/5912\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"prader-willi-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"89392001\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1330\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"176270\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5575\",\"ref_field\":\"symbol\"}"],"name":"Prader-Willi syndrome","disease_mechanism":"loss of function","id":"3526","disease_mechanism_id":"273","mode_of_inheritance":"Microdletion","public_definition":"Prader-Willi syndrome (PWS) is characterized by severe hypotonia and feeding difficulties in early infancy, followed in later infancy or early childhood by excessive eating and gradual development of morbid obesity (unless eating is externally controlled). Motor milestones and language development are delayed. All individuals have some degree of cognitive impairment. A distinctive behavioral phenotype (with temper tantrums, stubbornness, manipulative behavior, and obsessive-compulsive characteristics) is common. Hypogonadism is present in both males and females and manifests as genital hypoplasia, incomplete pubertal development, and, in most, infertility. Short stature is common (if not treated with growth hormone); characteristic facial features, strabismus, and scoliosis are often present.","alternate_symbols":[],"alternate_names":[],"attribute_content":["{\"Attribute\":{\"$\":\"Microdeletion\",\"@Type\":\"disease mechanism\"},\"XRef\":{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000508917\"}}"],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}}}","keywords":[],"medgen_id":"C2750405","xrefs":["{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000309827\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551656\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552477\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568144\",\"ref_field\":\"disease_mechanism\"}"],"name":"Malignant rhabdoid tumor, somatic","disease_mechanism":"loss of function","id":"9191","disease_mechanism_id":"273","alternate_symbols":[],"alternate_names":["Atypical teratoid/rhabdoid tumor","Rhabdoid tumor"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301390\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1211\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EGAPP, 2009\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"2743612\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ASCRS, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11598466\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15604628\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AMA/NCHPEG, 2012\",\"@Type\":\"Suggested Reading\",\"URL\":{\"$\":\"http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf\"}},{\"@Abbrev\":\"MSTF, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25070057\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24493721\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CAPS, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3585492\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"MSTF, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25003300\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ASCO/ESMO, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25452455\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24310308\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Mork et al., 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25711197\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Dutch SCG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23535968\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACG, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25645574\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Mallorca group, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23408351\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]},{\"@Abbrev\":\"SGO, 2014\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Society of Gynecologic Oncology (SGO) Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer\"},\"URL\":{\"$\":\"https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer\"}}]}","keywords":[],"symbol":"HNPCC","medgen_id":"C1333990","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS120435\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"144\"}","{\"db\":\"SNOMED CT\",\"id\":\"315058005\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hereditary nonpolyposis colon cancer\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000316595\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000321105\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000322202\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000324168\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000325623\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332519\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500363\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512403\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512828\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515534\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515773\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515774\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515821\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518997\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518998\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518999\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519000\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519150\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519254\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519255\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520026\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520030\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520080\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520392\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520393\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520394\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520865\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520867\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520868\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520869\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520870\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520871\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520872\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522224\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522225\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522278\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522559\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527981\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527983\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527984\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528529\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528534\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528915\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528930\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529017\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530028\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530202\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551450\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551459\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551461\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551463\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551464\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552183\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552184\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552245\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552440\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558503\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558908\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561860\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562151\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568362\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568365\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"GeneTests\",\"id\":\"2622\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+Non-Polyposis+Colorectal+Cancer+%28HNPCC%29/3371\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9905\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1211\",\"ref_field\":\"public_definition\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9905\",\"ref_field\":\"symbol\"}"],"name":"Lynch syndrome","disease_mechanism":"loss of function","id":"14688","disease_mechanism_id":"273","public_definition":"Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, stomach, ovary, small bowel, hepatobiliary tract, urinary tract, brain, and skin. In individuals with Lynch syndrome the following lifetime risks for cancer are seen: CRC: 52%-82% (mean age at diagnosis 44-61 years). Endometrial cancer in females: 25%-60% (mean age at diagnosis 48-62 years). Gastric cancer: 6%-13% (mean age at diagnosis 56 years). Ovarian cancer: 4%-12% (mean age at diagnosis 42.5 years; ~30% are diagnosed \u003c age 40 years). The risk for other Lynch syndrome-related cancers is lower, though substantially increased over general population rates.","alternate_symbols":[],"alternate_names":["Hereditary nonpolyposis colon cancer"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301528\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1354\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"symbol":"MCLDS","medgen_id":"C0398568","xrefs":["{\"db\":\"OMIM\",\"id\":\"300842\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"59306\"}","{\"db\":\"OMIM\",\"id\":\"300842\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MCLEOD PHENOTYPE\"}","{\"db\":\"OMIM\",\"id\":\"300842\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROACANTHOCYTOSIS, MCLEOD TYPE\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500117\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507942\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509072\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509191\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509486\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511451\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519366\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519384\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528288\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"McLeod+neuroacanthocytosis+syndrome/8791\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10731\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1354\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300842\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"name":"McLeod neuroacanthocytosis syndrome","disease_mechanism":"loss of function","id":"10628","disease_mechanism_id":"273","public_definition":"McLeod neuroacanthocytosis syndrome (designated as MLS throughout this review) is a multisystem disorder with central nervous system (CNS), neuromuscular, cardiovascular, and hematologic manifestations in males. CNS manifestations are a neurodegenerative basal ganglia disease including (1) movement disorders, (2) cognitive alterations, and (3) psychiatric symptoms. Neuromuscular manifestations include a (mostly subclinical) sensorimotor axonopathy and muscle weakness or atrophy of different degrees. Cardiac manifestations include dilated cardiomyopathy, atrial fibrillation, and tachyarrhythmia. Hematologically, MLS is defined as a specific blood group phenotype (named after the first proband, Hugh McLeod) that results from absent expression of the Kx erythrocyte antigen and weakened expression of Kell blood group antigens. The hematologic manifestations are red blood cell acanthocytosis and compensated hemolysis. Allo-antibodies in the Kell and Kx blood group system can cause strong reactions to transfusions of incompatible blood and severe anemia in affected male newborns of Kell-negative mothers. Females heterozygous for XK pathogenic variants have mosaicism for the Kell and Kx blood group antigens but usually lack CNS and neuromuscular manifestations; however, some heterozygous females may develop clinical manifestations including chorea or late-onset cognitive decline.","alternate_symbols":[],"alternate_names":["MCLEOD PHENOTYPE","NEUROACANTHOCYTOSIS, MCLEOD TYPE"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301691\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1518\",\"@Source\":\"BookShelf\"}]}}","keywords":[],"medgen_id":"C0016952","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004919\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"352\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004919\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Galactose intolerance\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Galactosemia/2973\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"190745006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1518\",\"ref_field\":\"public_definition\"}"],"name":"Galactosemia","disease_mechanism":"loss of function","id":"16954","disease_mechanism_id":"273","mode_of_inheritance":"homozygous or compound heterozygous pathogenic variants in GALT","public_definition":"The term \"galactosemia\" refers to disorders of galactose metabolism that include classic galactosemia, clinical variant galactosemia, and biochemical variant galactosemia. This GeneReview focuses on: Classic galactosemia, which can result in life-threatening complications including feeding problems, failure to thrive, hepatocellular damage, bleeding, and E. coli sepsis in untreated infants. If a lactose-restricted diet is provided during the first ten days of life, the neonatal signs usually quickly resolve and the complications of liver failure, sepsis, and neonatal death are prevented; however, despite adequate treatment from an early age, children with classic galactosemia remain at increased risk for developmental delays, speech problems (termed childhood apraxia of speech and dysarthria), and abnormalities of motor function. Almost all females with classic galactosemia manifest premature ovarian insufficiency (POI). Clinical variant galactosemia, which can result in life-threatening complications including feeding problems, failure to thrive, hepatocellular damage including cirrhosis, and bleeding in untreated infants. This is exemplified by the disease that occurs in African Americans and native Africans in South Africa. Persons with clinical variant galactosemia may be missed with newborn screening (NBS) as the hypergalactosemia is not as marked as in classic galactosemia and breath testing is normal. If a lactose-restricted diet is provided during the first ten days of life, the severe acute neonatal complications are usually prevented. African Americans with clinical variant galactosemia and adequate early treatment do not appear to be at risk for long-term complications including POI.","alternate_symbols":[],"alternate_names":["Galactose intolerance"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301323\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1144\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111049\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"Eurogentest, 2008\",\"@Type\":\"Translational/Evidence-based\",\"URL\":{\"$\":\"http://www.eurogentest.org/web/files/public/unit3/ClinicalUtilityGeneCards/Indication%20criteria%20-%20AS.pdf\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23519317\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESHG/ASHG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25782669\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"27467454\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"AS","medgen_id":"C0162635","xrefs":["{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"72\"}","{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HAPPY PUPPET SYNDROME\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226643\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260593\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320687\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327662\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331025\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331374\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501273\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501274\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501275\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501276\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502292\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503131\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507771\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508896\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508937\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509438\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515563\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515566\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519582\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520979\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520995\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520996\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520998\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521642\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522320\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525860\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525867\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000527540\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529013\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529077\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530022\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530102\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530238\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531722\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551668\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552178\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552326\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552341\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556577\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556612\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558215\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558216\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558805\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558906\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568371\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501320\",\"ref_field\":\"mode_of_inheritance\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Angelman+Syndrome/452\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"angelman-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5810\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"76880004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1144\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"105830\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5810\",\"ref_field\":\"symbol\"}"],"name":"Angelman syndrome","disease_mechanism":"loss of function","id":"404","disease_mechanism_id":"273","mode_of_inheritance":"AS is caused by disruption of maternally imprinted UBE3A located within the 15q11.2-q13 Angelman syndrome/Prader-Willi syndrome (AS/PWS) region.","public_definition":"Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs, and a unique behavior with an inappropriate happy demeanor that includes frequent laughing, smiling, and excitability. Microcephaly and seizures are also common. Developmental delays are first noted at around age six months; however, the unique clinical features of AS do not become manifest until after age one year, and it can take several years before the correct clinical diagnosis is obvious.","alternate_symbols":[],"alternate_names":["Angelman syndrome-like","HAPPY PUPPET SYNDROME"],"attribute_content":["{\"Attribute\":{\"$\":\"imprinting disorder\",\"@Type\":\"mode of inheritance\"},\"XRef\":{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260593\"}}"],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22797890\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301558\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1384\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110344\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111012\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2005\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110946\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111547\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21540884\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23519317\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EMQN, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25227148\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23765048\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"FXS","medgen_id":"C0016667","xrefs":["{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"449291\"}","{\"db\":\"Orphanet\",\"id\":\"908\"}","{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRAGILE X MENTAL RETARDATION SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH marXq28\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000264966\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552393\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552933\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553203\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556541\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558826\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000560955\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561923\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568236\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568277\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fragile+X+Syndrome/2906\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6464\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"613003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1384\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6464\",\"ref_field\":\"symbol\"}"],"name":"Fragile X syndrome","disease_mechanism":"loss of function","id":"1302","disease_mechanism_id":"273","public_definition":"FMR1-related disorders include fragile X syndrome, fragile X-associated tremor/ataxia syndrome (FXTAS), and FMR1-related primary ovarian insufficiency (POI). Fragile X syndrome occurs in individuals with an FMR1 full mutation or other loss-of-function variant and is nearly always characterized by moderate intellectual disability in affected males and mild intellectual disability in affected females. Because FMR1 pathogenic variants are complex alterations involving non-classic gene-disrupting alterations (trinucleotide repeat expansion) and abnormal gene methylation, affected individuals occasionally have an atypical presentation with an IQ above 70, the traditional demarcation denoting intellectual disability (previously referred to as mental retardation). Males with an FMR1 full mutation accompanied by aberrant methylation may have a characteristic appearance (large head, long face, prominent forehead and chin, protruding ears), connective tissue findings (joint laxity), and large testes after puberty. Behavioral abnormalities, sometimes including autism spectrum disorder, are common. FXTAS occurs in males (and some females) who have an FMR1 premutation and is characterized by late-onset, progressive cerebellar ataxia and intention tremor. FMR1-related POI (age at cessation of menses \u003c40 years) occurs in approximately 20% of females who have an FMR1 premutation.","alternate_symbols":[],"alternate_names":["FRAGILE X MENTAL RETARDATION SYNDROME","Fragile X syndrome, type A","MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH marXq28"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Abbrev\":\"NSGC, 2011\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21618060\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"18197059\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2005\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16301868\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19915395\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AAP, 2011\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21788214\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACOG, 2007\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"17197615\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACOG, 2007\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"18055749\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"23334531\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ISPD, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22275335\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESHG/ASHG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25782669\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"27467454\",\"@Source\":\"PubMed\"}}]}","keywords":[],"symbol":"DS","medgen_id":"C0013080","xrefs":["{\"db\":\"OMIM\",\"id\":\"190685\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"870\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508914\",\"ref_field\":\"mode_of_inheritance\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Down+Syndrome/2327\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"41040004\",\"ref_field\":\"name\"}"],"name":"Complete trisomy 21 syndrome","disease_mechanism":"Meiosis non dynjunction","id":"1116","mode_of_inheritance":"Chromosomal","alternate_symbols":[],"alternate_names":["Down syndrome","T21"],"attribute_content":[],"type":"Disease"}
{"content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","keywords":[],"medgen_id":"C0002986","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"name":"Fabry disease","disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","id":"1790","public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% -Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% -Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","alternate_symbols":[],"alternate_names":["Angiokeratoma corporis diffusum","Fabry syndrome","Fabry's disease"],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000327665\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520062\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556725\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000503671\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522329\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000337467\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000519384\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520061\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528288\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000519366\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"}]}"],"type":"Disease"}
